Hemodynamic and metabolic actions of Adiponectin in muscle by Bussey, CT
 
 
 
 
HEMODYNAMIC AND 
METABOLIC ACTIONS OF 
ADIPONECTIN IN MUSCLE 
 
 
 
 
 
Carol Bussey, BSc. 
 
 
 
 
 
 
Submitted in partial fulfilment of the requirements for the degree of  
Doctor of Philosophy. 
 
 
 
Menzies Research Institute 
UNIVERSITY OF TASMANIA 
HOBART 
 
 
July 2011 
 
ii 
TABLE OF CONTENTS 
 
DECLARATION OF ORIGINALITY         v 
AUTHORITY OF ACCESS          v 
STATEMENT OF ETHICAL CONDUCT        v 
ABSTRACT            vi 
ACKNOWLEDGEMENTS                     viii 
ABBREVIATIONS           ix 
PREFACE            xi 
Publications. ............................................................................................................. xi 
Oral presentations at scientific meetings.................................................................. xi 
Posters at scientific meetings. .................................................................................. xi 
 
 
 
CHAPTER 1 – INTRODUCTION....................................................................................... 1 
1.1 Overview ............................................................................................................. 1 
1.2 Type 2 Diabetes................................................................................................... 1 
1.3 Hemodynamic Actions of Insulin........................................................................ 2 
1.4 Microvascular Perfusion...................................................................................... 3 
1.5 Microvascular Perfusion in Insulin Resistance ................................................... 6 
1.6 Adiponectin and Insulin Resistance .................................................................... 9 
1.7 Adiponectin: Structure and Function ................................................................ 11 
1.8 Vascular Actions of Adiponectin ...................................................................... 15 
1.9 Do acute hemodynamic actions of adiponectin contribute to insulin sensitivity?17 
CHAPTER 2 – PREPARATION AND CHARACTERISATION OF RECOMBINANT 
ADIPONECTIN .................................................................................................... 18 
2.1 Introduction ..................................................................................................... 18 
2.2 Materials and Methods ................................................................................... 20 
2.2.1Adiponectin preparation...................................................................................................... 20 
2.2.1.1 Cloning the adiponectin gene..................................................................................... 20 
2.2.1.2 Protein expression...................................................................................................... 21 
2.2.1.3 Purification of native protein using Ni-NTA affinity resin ......................................... 22 
2.2.1.4 Concentration and dialysis of protein preparations using Vivaspin 20 units............. 23 
2.2.2 SDS-PAGE analysis........................................................................................................... 24 
2.2.2.1 SDS-PAGE under denaturing conditions ................................................................... 24 
2.2.2.2 SDS-PAGE under non-denaturing conditions ............................................................ 24 
2.2.2.3 Staining SDS-PAGE gels for total protein ................................................................. 24 
2.2.3 Western Blot Analysis ....................................................................................................... 25 
2.2.4 Preparation of mouse fat homogenate................................................................................ 25 
iii 
2.2.5 Quantification of adiponectin by ELISA ........................................................................... 25 
2.2.6 Determination of adiponectin-mediated eNOS phosphorylation in bovine aortic endothelial 
cells.................................................................................................................................. 26 
2.2.6.1 Bovine Aortic Endothelial Cell Isolation.................................................................... 26 
2.2.6.2 Determination of adiponectin-mediated eNOS activation.......................................... 26 
2.3 Results............................................................................................................... 28 
2.3.1 Analysis of the purity of the recombinant adiponectin preparation ................................... 28 
2.3.2 Native conformation of recombinant adiponectin.............................................................. 29 
2.3.3 Quantification of the recombinant adiponectin preparation............................................... 30 
2.3.4 Adiponectin-stimulated eNOS phosphorylation ................................................................ 31 
2.4 Discussion ......................................................................................................... 33 
CHAPTER 3 – ADIPONECTIN OPPOSES ENDOTHELIN-1-MEDIATED 
VASOCONSTRICTION IN THE PERFUSED RAT HINDLIMB.................................... 36 
3.1 Introduction ..................................................................................................... 36 
3.2 Materials and Methods ................................................................................... 39 
3.2.1 Animals .............................................................................................................................. 39 
3.2.2 Perfused rat hindlimb ......................................................................................................... 39 
3.2.2.1 Perfusion Buffer ......................................................................................................... 39 
3.2.2.2 Surgery ....................................................................................................................... 39 
3.2.2.3 Perfusion apparatus ................................................................................................... 41 
3.2.2.4 Perfusion protocols .................................................................................................... 42 
3.2.2.5 Measurement of glucose and lactate .......................................................................... 44 
3.2.2.6 Calculation of oxygen consumption ........................................................................... 44 
3.2.3 Statistics ............................................................................................................................. 45 
3.3 Results............................................................................................................... 46 
3.3.1 Hemodynamic and metabolic actions of adiponectin......................................................... 46 
3.3.2 Effect of adiponectin on the hemodynamic and metabolic effects of endothelin-1 ........... 47 
3.3.2.1 Adiponectin opposes vasoconstriction caused by low dose endothelin-1................... 47 
3.3.2.2 Adiponectin is ineffective against established endothelin-1-mediated vasoconstriction
.................................................................................................................................... 50 
3.3.2.3 Low-dose endothelin-1 vasoconstriction is reversible ............................................... 50 
3.3.2.4 Adiponectin is unable to oppose high dose endothelin-1 ........................................... 52 
3.3.3 Adiponectin does not effect the hemodynamic and metabolic actions of norepinephrine . 53 
3.4 Discussion ......................................................................................................... 54 
CHAPTER 4 – MODULATION OF ADIPONECTIN AND ENDOTHELIN-1 ACTION IN 
INSULIN RESISTANCE ......................................................................................... 59 
4.1 Introduction ..................................................................................................... 59 
4.2 Materials and Methods ................................................................................... 62 
4.2.1 Animals .............................................................................................................................. 62 
4.2.2 Perfused rat hindlimb ......................................................................................................... 62 
4.2.3 Biochemical Measurements ............................................................................................... 64 
4.2.4 Statistics ............................................................................................................................. 64 
4.3 Results............................................................................................................... 65 
4.3.1 Four week high-fat feeding causes insulin resistance ........................................................ 65 
iv 
4.3.1.1 High-fat feeding increases adiposity .......................................................................... 65 
4.3.1.2 High-fat feeding reduces insulin sensitivity................................................................ 66 
4.3.1.3 Plasma levels of ET-1 and adiponectin following high-fat feeding............................ 66 
4.3.2 Adiponectin is ineffective against ET-1 in insulin resistance ............................................ 67 
4.3.3 The response to ET-1 is reduced following high-fat feeding ............................................. 69 
4.3.4 Inhibition of nitric oxide synthase restores normal ET-1 response in high-fat fed rats...... 70 
4.3.4.1 Nitric oxide synthase inhibition with L-NAME........................................................... 70 
4.3.4.2 Specific inhibition of inducible nitric oxide synthase ................................................. 70 
4.4 Discussion ......................................................................................................... 73 
CHAPTER 5 – THE HEMODYNAMIC AND METABOLIC ACTIONS OF ADIPONECTIN IN 
VIVO.................................................................................................................... 80 
5.1 Introduction ..................................................................................................... 80 
5.2 Methods ............................................................................................................ 83 
5.2.1 Animals .............................................................................................................................. 83 
5.2.2 In vivo experiments............................................................................................................ 84 
5.2.2.1 Surgery ....................................................................................................................... 84 
5.2.2.2 Experimental procedures ........................................................................................... 84 
5.2.2.3 1-methylxanthine metabolism..................................................................................... 86 
5.2.2.4 Muscle glucose uptake................................................................................................ 87 
5.2.2.5 Rate of glucose turnover............................................................................................. 88 
5.2.3 Biochemical measurements................................................................................................ 88 
5.2.4 Data analysis ...................................................................................................................... 89 
5.2.5 Statistical analysis .............................................................................................................. 89 
5.3 Results............................................................................................................... 90 
5.3.1 Effect of high-dose adiponectin on in vivo hemodynamics and glucose homeostasis ....... 90 
5.3.1.1 Infusion of recombinant adiponectin raised circulating adiponectin......................... 90 
5.3.1.2 Effect of high-dose adiponectin on in vivo hemodynamics......................................... 91 
5.3.1.3 Effect of adiponectin on glucose homeostasis ............................................................ 93 
5.3.2 Effect of high-dose adiponectin in vivo in insulin resistance............................................. 95 
5.3.2.1 High-fat feeding induces insulin resistance................................................................ 96 
5.3.2.2 Effect of adiponectin on basal and insulin-mediated hemodynamics and metabolism 
in high-fat fed rats....................................................................................................... 96 
5.3.3 Pre-treatment and co-infusion of adiponectin during an insulin clamp revealed marked 
vehicle effects ................................................................................................................ 100 
5.3.4 Eliminating the vascular vehicle effects using a reduced dose did not expose adiponectin 
action ............................................................................................................................. 102 
5.3.4.1 Adiponectin does not alter hemodynamics in vivo ................................................... 102 
5.3.4.2 Adiponectin does not alter insulin sensitivity ........................................................... 104 
5.3.4.3 Adiponectin did not affect circulating levels of insulin or endothelin-1................... 105 
5.4 Discussion ....................................................................................................... 107 
CHAPTER 6 – DISCUSSION......................................................................................... 112 
 
 
 
REFERENCES                     114 
v 
DECLARATION OF ORIGINALITY 
 
This thesis contains no material which has been accepted for a degree or diploma by 
the University or any other institution, except by way of background information and 
duly acknowledged in the thesis, and to the best of the my knowledge and belief no 
material previously published or written by another person except where due 
acknowledgement is made in the text of the thesis, nor does the thesis contain any 
material that infringes copyright. 
 
 
 
Carol Bussey  
 
 
AUTHORITY OF ACCESS 
 
This thesis may be available for loan and limited copying in accordance with the 
Copyright Act 1968. 
 
 
 
Carol Bussey. 
 
 
STATEMENT OF ETHICAL CONDUCT 
 
The research associated with this thesis abides by the international and Australian 
codes on human and animal experimentation, the guidelines by the Australian 
Government's Office of the Gene Technology Regulator and the rulings of the 
Safety, Ethics and Institutional Biosafety Committees of the University. 
 
 
Carol Bussey. 
vi 
ABSTRACT 
 
Insulin resistance is characterised by an impaired ability of insulin to stimulate glucose 
uptake, especially into skeletal muscle. Insulin has hemodynamic actions, stimulating total 
blood flow as well as increasing microvascular perfusion. This stimulation of microvascular 
perfusion may account for up to half of insulin-mediated skeletal muscle glucose uptake and 
is impaired in insulin resistant states. Adiponectin exhibits a number of actions similar to 
insulin, including stimulation of glucose uptake in incubated muscle, and reduction of 
glucose release from hepatocytes. Recent studies have shown that adiponectin is also able to 
increase nitric oxide (NO) production by the endothelium and relax pre-constricted isolated 
aortic rings, suggesting that adiponectin may act as a vasodilator. It was hypothesised that 
adiponectin may have hemodynamic effects similar to insulin, which may be an important 
aspect of its insulin-sensitising ability by regulating access of insulin and glucose to 
myocytes. Therefore, there were three major aims of this thesis: i) to examine the acute 
vascular actions of adiponectin in a simplified but intact vascular system, the pump-perfused 
rat hindlimb; ii) to investigate whether acute adiponectin infusion alters hemodynamics or 
glucose homeostasis in the presence and absence of insulin in anaesthetised rats; and iii) to 
determine whether the vascular actions of adiponectin are altered in insulin resistance. 
  
The initial aim of the present study was to produce high purity, physiologically active 
recombinant adiponectin in sufficient quantity for use in perfused hindlimb and in vivo 
experiments. Full-length murine adiponectin was expressed in E. coli and purified by affinity 
chromatography. The adiponectin product was found to be present primarily as a trimer, 
similar to that reported in previous studies. 
 
The constant-flow pump-perfused rat hindlimb was used to evaluate the direct effects of 
adiponectin on the skeletal muscle vasculature. A physiological concentration of adiponectin 
(6.5µg.mL-1) alone had no observable vascular activity in this largely dilated system. 
Adiponectin pre-treatment and co-infusion inhibited the increase in perfusion pressure and 
associated metabolic stimulation caused by low-dose (1nM) endothelin-1 (ET-1), but not 
vasoconstriction caused by either high-dose (20nM) ET-1 or 50nM norepinephrine. This 
action of adiponectin was apparently independent of NO, suggesting a potential novel 
mechanism of adiponectin action. 
 
A high-fat fed rat model was used to determine whether the vascular actions of adiponectin 
are retained in insulin resistance. The ability of adiponectin to inhibit ET-1-mediated 
vasoconstriction was not apparent in animals fed a high-fat diet. However, the 
vasoconstrictor response to ET-1 (1 or 3nM) itself was found to be reduced following high-
fat feeding. The vasoconstrictor response was restored in the presence of the NO synthase 
(NOS) inhibitor NG-nitro-L-arginine methyl ester, indicating increased NO bioavailability 
during hindlimb perfusion in the insulin resistant rats. Use of a specific inhibitor of the 
inducible NOS (iNOS) isoform demonstrated that this increased NO was derived from 
induction of iNOS.  
 
Systemic vascular and metabolic actions of adiponectin were then examined in anaesthetised 
rats, alone and during a hyperinsulinemic euglycemic clamp. No differences were observed 
between vehicle and adiponectin (24 or 96μg.min-1.kg-1) treated rats in macrovascular 
parameters, microvascular perfusion or glucose metabolism. This finding was consistent 
whether the rats were fed normal chow or a high-fat diet to induce insulin resistance. 
 
This study has identified a novel vascular action of adiponectin to specifically oppose ET-1-
mediated vasoconstriction. This effect was not apparent in insulin resistance, possibly 
vii 
implicating loss of adiponectin activity in disease development. Additionally, the response to 
exogenous ET-1 was reduced in high-fat fed rats, due to upregulation of iNOS. The altered 
state of balance between ET-1 and NO in insulin resistance may have important implications 
for endothelial dysfunction. Meanwhile, no effect of acute adiponectin infusion, either 
hemodynamic or metabolic, was apparent in vivo. Whilst chronic hemodynamic actions of 
adiponectin may play a role in insulin sensitivity, they do not appear to be a major aspect of 
acute adiponectin action in vivo. 
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1 
CHAPTER 1 – INTRODUCTION 
 
 
1.1 Overview 
Type 2 diabetes is a major health concern worldwide. It is caused by an inability of 
the body to properly respond to insulin, primarily as a decreased stimulation of 
glucose uptake in skeletal muscle. Insulin also stimulates both total blood flow and 
microvascular perfusion. Insulin-mediated microvascular perfusion has been 
demonstrated to be a major factor, which along with a direct action on myocytes, is 
involved in insulin’s ability to stimulate skeletal muscle glucose uptake. This vascular 
action of insulin is impaired in insulin resistant states. The adipokine adiponectin has 
been shown to have both metabolic and vascular effects in vitro, and it has also been 
proposed to act as an insulin sensitiser. Therefore, it is hypothesised that adiponectin 
may have vascular activity, particularly to augment insulin-mediated microvascular 
perfusion, and may thus provide a novel therapeutic approach to treating insulin 
resistance.  
 
1.2 Type 2 Diabetes 
Diabetes mellitus is a disease of rapidly rising prevalence (Wild et al., 2004). This 
epidemic has enormous costs, in terms of both human suffering and economic burden, 
and is set to be one of the major contributors to global health costs this century (Wild 
et al., 2004; Dunstan et al., 2002). Diabetes is characterised by elevated blood 
glucose, which results in a range of complications including neural and renal damage 
and cardiovascular disease (Lloyd et al., 1996). More than 85% of diabetic cases are 
classified as type 2 (Kingwell et al., 2002), caused by an inability of the body to 
properly respond to insulin. 
 
Insulin is responsible for the regulation of key metabolic pathways in the liver, fat and 
muscle (Steinberg & Baron, 2002). Maintenance of glucose homeostasis, through the 
regulation of glucose release into and uptake from the blood, is a principal function of 
insulin. Skeletal muscle accounts for over 85% of insulin-mediated glucose uptake 
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(IMGU; DeFronzo et al., 1985). It has been estimated that a reduced capacity for 
glucose uptake in skeletal muscle accounts for approximately 80% of the defect in 
insulin action seen in type 2 diabetics (Bonadonna, 1993). Glucose uptake in response 
to insulin is facilitated by the glucose transporter GLUT-4, which is translocated to the 
plasma membrane following stimulation (Bonadonna, 1993). This has traditionally 
been considered to be the primary mechanism by which insulin acts to mediate 
glucose uptake in skeletal muscle. However, insulin also causes dilation of blood 
vessels, increasing access to myocytes for both glucose and itself (reviewed in Clark 
et al., 2003). Thus, in addition to increasing glucose transport across the cell 
membrane, insulin increases delivery of glucose to the cell. 
 
1.3 Hemodynamic Actions of Insulin 
Insulin is believed to cause vasodilation via a direct interaction with endothelial cells 
to produce nitric oxide (NO), the most potent known endogenous vasodilator (Figure 
1.1; Steinberg & Baron, 2002).  This occurs via a signalling cascade from the insulin 
receptor and insulin receptor substrate (IRS)-1, activating phosphatidylinositol 3-
kinase (PI3K) and Akt, resulting in phosphorylation of endothelial nitric oxide 
synthase (eNOS) on serine 1177 (Kim et al., 2001). Activated eNOS then catalyses 
the conversion of L-arginine to NO, which is released from the endothelium. The NO 
diffuses to nearby vascular smooth muscle cells (VSMCs), where it stimulates  
production of cyclic GMP, causing a reduction in intracellular Ca2+ and resulting in 
smooth muscle relaxation and vasodilation (Ignarro, 1990). Insulin-mediated 
stimulation of NO production has been demonstrated in vivo with a doubled 
production rate of the oxidative end-products nitrite and nitrate, accompanied by a 
proportional increase in leg blood flow (Baron & Clark, 1997; Steinberg et al., 1994). 
Meanwhile, inhibition of NOS prevents insulin-mediated vasodilation, indicating that 
this action is NO-dependent (Steinberg et al., 1994). Additionally, insulin is unable to 
elicit a vasodilatory response in the absence of a functional endothelium (Schroeder et 
al., 1999). However, a study by Miller et al. (2002) found that insulin-mediated 
vasodilation in isolated mesenteric arteries was endothelium-, but not NO-, dependent, 
and alternately suggested a cyclooxygenase (COX) dependent mechanism. The 
authors suggested that variable reports may be due to differences in the size and origin 
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of the vessel investigated. However, that study demonstrated that insulin may elicit 
vasodilation by multiple mechanisms. 
 
By stimulating vasodilation, insulin increases total blood flow (Laakso, 1990; Baron 
& Clark, 1997; Steinberg et al., 1994), with an observed increase in cardiac output 
preferentially distributed to skeletal muscle (Baron & Brechtel, 1993). Stimulation of 
leg blood flow in humans in response to insulin closely correlates to the increase in 
whole body glucose uptake (Laakso et al., 1992). Physically impeding rat muscle 
perfusion with microspheres does not affect basal glucose uptake, but markedly 
impairs insulin delivery to muscle and thus insulin-mediated Akt phosphorylation and 
glucose uptake (Vollus et al., 2007). Halseth et al. (1998) reported that glucose 
delivery is a limiting factor in IMGU. Indeed, it is estimated that vascular effects 
account for a significant proportion of IMGU in muscle, highlighting the importance 
of hemodynamic actions in insulin sensitivity (Baron & Clark, 1997). Additionally, 
insulin-stimulated blood flow is impaired in states of insulin resistance (Laakso et al., 
1992; Santuré et al., 2002; Wallis et al., 2002). Defects in both glucose transport into 
myocytes and delivery to muscle have been implicated in diet-induced insulin 
resistance (Halseth et al., 2000). Thus, increased blood flow may contribute to IMGU 
by enhancing delivery of both glucose and insulin to skeletal muscle, and impairments 
in this process may contribute to insulin resistance. However, the extent of increased 
total blood flow in response to insulin is insufficient to account for the large increase 
in muscle glucose uptake (Baron, 1994), and glucose uptake rises prior to any 
observable increase in total flow (Yki-Jarvinen, 1998). Furthermore, Bradley et al. 
(1999) reported that inhibition of NOS reduces glucose uptake but not total blood flow 
during exercise, indicating that NO augments glucose uptake independent of changes 
in total blood flow. Therefore, increases in total blood flow alone do not explain the 
NO-dependent effects of insulin to enhance muscle glucose uptake. 
 
1.4 Microvascular Perfusion 
A growing body of evidence demonstrates that insulin is able to increase 
microvascular perfusion within muscle, an effect termed capillary recruitment. Under 
basal conditions, only a proportion of all capillaries are perfused at any given time 
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(Sweeney & Sarelius, 1989), allowing microvascular perfusion to increase in times of 
increased metabolic demand, such as during exercise, hypoxia or in response to 
insulin (Clark et al., 2003). This results in greater exposure of the tissue to glucose, 
and thus an increase in glucose uptake. In addition, it is thought that insulin 
preferentially increases flow to nutritive vessels, those that supply nutrients to muscle 
cells, at the expense of flow to non-nutritive vessels (Baron & Clark, 1997).  
 
A basic premise underlying capillary recruitment is that there is a flow reserve under 
basal conditions, which can be redistributed when required. Much of the evidence for 
two functionally distinct flow routes comes from experiments using the isolated 
perfused rat hindlimb to study the effects of various vasoconstrictors. Some 
vasoconstrictors were found to enhance metabolism, including angiotensin II and 
vasopressin, while others, such as serotonin, inhibit it (reviewed in Clark et al., 1995). 
Thus, although both types of vasoconstrictor increase vascular resistance, they have 
opposing metabolic effects. However, the changes seen in both parameters can be 
blocked by vasodilators, indicating that the ability of these substances to modulate 
metabolism is primarily due to their effects on the vasculature.  
 
It was initially proposed that two parallel circulatory routes exist, one directly in 
contact with myocytes (nutritive) and another that is non-nutritive in terms of muscle, 
which passes through connective and adipose tissue within the muscle (reviewed in 
Clark et al., 2000). However, fluorescently labelled microspheres infused into 
perfused rat hindlimbs pre-constricted with either norepinephrine or serotonin were 
detected throughout muscle sections with either constrictor (Vincent et al., 2001b). 
Although norepinephrine and serotonin are thought to promote nutritive and non-
nutritive flow respectively, there was no difference in the broad-scale distribution of 
fluorescence, indicating that the two flow routes are not anatomically separated 
(Vincent et al., 2001b ). However, the low levels of microspheres assayed within the 
muscle prevented description of localised variations in vessel distribution, and indeed 
the authors suggest that nutritive and non-nutritive vessels may exist within and 
outside of individual muscle fibres, respectively (Vincent et al., 2001b). Additionally, 
physically impeding capillary blood flow impairs the metabolic actions of both type A 
and B constrictors (Vincent et al., 2001a). In another study, microspheres small 
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enough to pass through resistance arterioles but not capillaries, predominantly 
between 8-16μm, were infused into the perfused rat hindimb. Negligible amounts of 
these microspheres were able to pass through the capillary bed, discounting the 
suggestion of large vasculature shunts bypassing the muscle (Newman et al., 1996). It 
has alternatively been suggested that the flow routes may derive from two co-localised 
capillary populations; the nutritive vessels slightly narrower and longer than the non-
nutritive (Harrison et al., 1990). The difference in diameter between these capillaries 
is suggested to be as little as 2μm, but even this small difference would significantly 
affect the rate of blood flow and thus the opportunity for nutritive exchange (Potter & 
Groom, 1983). These data suggest that the two flow routes may not be anatomically 
separated. However, regardless of the anatomical source of the differences, it is the 
non-nutritive system that is thought to contain the flow reserve. 
 
One way microvascular perfusion can be assessed is by measuring the conversion of 
1-methylxanthine (1-MX) to 1-methylurate by xanthine oxidase, an enzyme 
concentrated in the endothelium of capillaries. To do this, exogenous 1-MX is added 
to the system, which was found to have no vasoactivity itself (Rattigan et al., 1997a; 
Rattigan et al., 1997b). Use of this technique in the perfused hindlimb demonstrated 
that there is a positive correlation between conversion of 1-MX and measures of 
metabolism for a wide variety of vasoconstrictors. For example, disappearance of 1-
MX decreases during serotonin infusion (non-nutritive flow), coinciding with 
increased pressure and decreased metabolism (Rattigan et al., 1997a). This was taken 
to indicate that the technique was measuring a change in the number of nutritive 
vessels exposed to the 1-MX. The same technique was then utilised in vivo, where 
physiological doses of insulin increased 1-MX metabolism by 50% with concomitant 
increases in blood flow and hindleg glucose uptake (HGU), indicating that insulin 
may act to favour nutritive flow (Rattigan et al., 1997b). It has been shown that 
increased 1-MX metabolism is not simply a result of an increase in total flow, as 
infusion of epinephrine causes an increase in flow without an associated increase in 1-
MX metabolism (microvascular perfusion; Rattigan et al., 1997b). A physical measure 
of the microvasculature, by the use of contrast-enhanced ultrasound, has also been 
used to analyse microvascular perfusion. This method uses albumin or phospholipid 
microbubbles as an exclusively intravascular contrast agent to enhance the ultrasound 
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image and allow microvascular blood volume (MBV) to be determined. Physiological 
doses of insulin in vivo were shown to cause MBV to double using this method 
(Dawson et al., 2002). Data obtained using these two approaches have been found to 
correlate well (Vincent et al., 2002). Taken together, these two lines of evidence 
indicate that insulin mediates changes in muscle microvascular perfusion consistent 
with capillary recruitment. 
 
Like glucose uptake, capillary recruitment in response to insulin precedes changes in 
total blood flow (Vincent et al., 2002), and in fact occurs before an increase in glucose 
uptake can be observed (Vincent et al., 2004). As the microvasculature is recruited in 
vivo within 5-10 minutes of commencement of an insulin infusion (Vincent et al., 
2004), this is likely to be one of the earliest actions of insulin. Capillary recruitment 
also occurs at lower insulin doses than those required to induce an increase total flow 
(Zhang et al., 2004). Increased microvascular perfusion in response to insulin has also 
been demonstrated in the human forearm, with an associated stimulation of glucose 
uptake, in the absence of any change in total blood flow (Coggins et al., 2001).  
Exercise-mediated microvascular perfusion is similarly out of proportion with the 
increase in total blood flow, suggesting that capillary recruitment is a distinct and 
separate event (Womack et al., 2009). As previously stated, insulin-mediated 
increases in total flow have been found to correlate with whole body glucose uptake 
(Laakso et al., 1992). However, this increased total flow does not correlate with 
increases in hindleg glucose uptake (HGU), a better measure of uptake into skeletal 
muscle (Rattigan et al., 1999; Clerk et al., 2002). Microvascular perfusion, on the 
other hand, correlates strongly with HGU, and is in fact estimated to account for up to 
50% of IMGU in vivo (Rattigan et al., 1999; Clerk et al., 2002; Vincent et al., 2003). 
Thus, via this vascular action, insulin is able to enhance perfusion of muscle 
independently of changes in total flow, an effect which may be extremely important in 
the maintenance of glucose homeostasis. 
 
1.5 Microvascular Perfusion in Insulin Resistance 
Insulin-mediated capillary recruitment is impaired in several models of insulin 
resistance. These include acute infusion of -methylserotonin (Rattigan et al., 1999), 
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tumour necrosis factor- (TNF-; Youd et al., 2000) or lipids (Clerk et al., 2002) in 
anaesthetised rats. These interventions have been found to block the hemodynamic 
actions of insulin, including 1-MX metabolism, at the same time as impairing IMGU 
by approximately 50%. However, neither serotonin or TNF- blocked IMGU in 
incubated muscle (Rattigan et al., 1993; Nolte, 1998), suggesting that, in these 
models, insulin resistance results largely from their actions on the vasculature. 
Capillary recruitment in response to insulin is absent in obese, insulin-resistant 
humans (Clerk et al., 2006; Keske et al., 2009; de Jongh, 2004), suggesting that loss 
of microvascular function is an early event on the path to diabetes. Furthermore, 
vascular insulin signalling via Akt, eNOS and NO is impaired in response to high-fat 
feeding prior to the development of insulin resistance in liver, muscle or adipose tissue 
(Kim et al., 2008). Insulin-mediated capillary recruitment and associated muscle 
glucose uptake is also impaired in rats fed a high-fat diet (St-Pierre et al., 2010), and 
in the Zucker obese diabetic rat (Clerk et al., 2007; Wallis et al., 2002). Additionally, 
in many cases, the defect appears to be limited to insulin signalling, as exercise-
mediated capillary recruitment is retained in insulin resistance (Zhang et al., 2003; 
Wheatley et al., 2004). However, Womack et al. (2009) recently reported that 
although microvascular perfusion in response to handgrip exercise is normal in the 
general diabetic population it is impaired in type 2 diabetics with microvascular 
complications, suggesting that the exercise response may also be impaired with 
greater disease progression. 
 
Insulin-mediated microvascular perfusion, along with increased total flow, is 
completely blocked by systemic inhibition of NOS, with an accompanying 40% 
impairment of IMGU (Vincent et al., 2003). Local administration of a NOS inhibitor 
into rat hindleg also blocked insulin-mediated capillary recruitment, but not that 
elicited by contraction (Bradley et al., 2007). These data indicates that insulin 
increases microvascular perfusion via a NO-dependent pathway and, in conjunction 
with previously described results, implicates endothelial dysfunction in the impaired 
vascular actions of insulin in states of insulin resistance. In addition to NO, insulin 
stimulates production of the vasoconstrictor endothelin-1 (ET-1; Juan et al., 2004; 
Yang & Li, 2008), providing tightly regulated hemodynamic control under normal 
conditions. Imbalance in these pathways resulting in preferential vasoconstriction is  
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present in endothelial dysfunction (Figure 1.1). Romanko et al. (2009) described 
superoxide-dependent impairment of NO-mediated dilation in the fructose-fed rat 
model of insulin resistance in the absence of obesity, suggesting endothelial 
dysfunction is a primary event in the development of metabolic syndrome pathologies. 
Endothelial dysfunction precedes the development of type 2 diabetes (Tooke & Goh, 
1998) and is believed to play an important role in the development of both 
microvascular (retinopathy, nephropathy, neuropathy) and macrovascular 
(atherosclerosis, coronary artery disease) complications of the disease  
(reviewed in Laight, 1999). Thus, impaired insulin-mediated capillary recruitment is 
potentially an important factor in the development of both diabetes and its 
complications. 
 
It has been demonstrated that the hemodynamic actions of insulin are very important 
in maintaining glucose homeostasis, and that these effects are impaired in states of 
insulin resistance. Consequently, methods of augmenting insulin-mediated capillary 
PP
Insulin
Insulin receptor
Vasoconstriction Vasodilation
Endothelium
INS
INS
RAS
RAF
MEK
MAPK
ET-1
P
PDK1
Akt
eNOS
NO
SHC
PI3-kSOS
IRS
GRB2
PIP2 PIP3
P
P
P
P P
P P
P P
P
PP
P
Diabetes, obesity, 
hypertension
PP
Compensatory  
hyperinsulinaemia Insulin 
receptor
Vasoconstriction
Vasodilation
Endothelial    
dysfunction
INS
INS
RAS
RAF
MEK
MAPK
ET-1
P
PDK1
Akt
eNOS
NO
SHC
PI3-kSOS
IRS
GRB
2
PIP2 PIP3
P
P
P
P P
P P
P P
P
PP
P
INS
INSINS
Insulin 
resistance
A B Glucotoxicity
Lipotoxicity
Inflammation
Figure 1.1: Insulin signalling and endothelial dysfunction. Taken from Ross et al. (Ross, 
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recruitment may provide a novel therapeutic approach to treating insulin resistance 
and diabetes. 
1.6 Adiponectin and Insulin Resistance 
Adiponectin is one of a variety of metabolically active proteins secreted by 
adipocytes, collectively termed adipokines (Scherer et al., 1995). It is the most 
abundant peptide hormone circulating in plasma, with concentrations of 
approximately 2-20μg/mL (Arita et al., 1999; Nakano et al., 1996). Circulating 
adiponectin levels do not normally exhibit large-scale variability over a 24hr period 
(English et al., 2003; Bertani et al., 2010). However, a postprandial increase in 
adiponectin has been described in obese subjects, which may provide a compensatory 
mechanism in insulin resistance (English et al., 2003). Although it is principally 
produced by adipose tissue, plasma levels of adiponectin decrease with increasing 
adiposity (Arita et al., 1999; Bruce et al., 2005; Kern et al., 2003), unlike other 
adipokines such as leptin, resistin and TNF-. Classically, it has been believed that 
adiponectin is exclusively expressed by adipocytes, but emerging evidence shows that 
it can be produced by other cells including hepatocytes and myocytes (Yoda-
Murakami et al., 2001; Liu et al., 2009a). The functional significance of such 
expression has so far been unclear, but Liu et al. (2009a) showed that increasing 
skeletal muscle adiponectin expression using rosiglitazone was accompanied by 
significant improvements in insulin sensitivity, in both cultured myocytes and high-
fat, high-sucrose fed rats. 
 
Plasma adiponectin concentrations are reduced in subjects with diabetes and insulin 
resistance (Weyer et al., 2001; Kern et al., 2003). Similarly, serum adiponectin is 
decreased in mouse models of type 2 diabetes (Yamauchi et al., 2001). Plasma 
adiponectin in humans negatively correlates with plasma glucose concentrations under 
fasting and hyperinsulinemic conditions, as well as basal and insulin-suppressed 
endogenous glucose production (Stefan et al., 2003). Indeed, Yamauchi et al. (2001) 
found that adiponectin levels in mice are more closely associated with insulin 
sensitivity than obesity. Low plasma concentrations of adiponectin are also associated 
with hypertension, independent of obesity and insulin sensitivity (Iwashima et al., 
2004), and are found in patients with coronary artery disease (Hotta et al., 2000; 
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Ouchi et al., 1999). Adiponectin is decreased in mice fed a high-fat diet, and may be 
reduced within three days of high-fat feeding (Yamauchi et al., 2001; Mullen et al., 
2009). Mutations in the adiponectin gene that reduce plasma levels are strongly 
associated with insulin resistance and obesity in humans (reviewed in Kadowaki & 
Yamauchi, 2005). Genetic deletion of adiponectin generally results in moderate 
insulin resistance, which is exacerbated by dietary challenge (Nawrocki et al., 2006; 
Kubota et al., 2002; Maeda et al., 2002a). However, Ma et al. (2002) did not observe 
insulin resistance in adiponectin knockout mice, even after 7 months of high-fat, high-
sucrose feeding. The discrepant responses may be due to compensatory mechanisms, 
such as increased leptin sensitivity in adiponectin knockout mice (Yano et al., 2008). 
Adiponectin knockouts have also been shown to exhibit pro-atherosclerotic changes 
(Kubota et al., 2002) and to develop hypertension following high-salt challenge 
(Ohashi et al., 2006). In many cases, these changes were corrected by adenoviral 
replenishment of adiponectin (Maeda et al., 2002a; Ohashi et al., 2006). 
 
Overexpression of adiponectin is protective against insulin resistance and 
atherosclerosis, and is able to offset the development of diet-induced obesity (Combs 
et al., 2004; Satoh et al., 2005; Shklyaev et al., 2003; Okamoto et al., 2002; Yamauchi 
et al., 2001; Yamauchi et al., 2003). Although most adipokines are pro-inflammatory 
and contribute to insulin resistance and endothelial dysfunction, adiponectin is anti-
inflammatory and confers protection against these states (Hattori et al., 2008; Yoda-
Murakami et al., 2001; reviewed in Lau et al., 2005). Interventions that improve 
insulin sensitivity, including caloric restriction, weight reduction following surgical 
intervention and exercise training, result in increased plasma adiponectin 
concentrations (Berg et al., 2001; Kondo et al., 2009; Yang et al., 2001; Kriketos, 
2004; Bluher, 2006). Adiponectin is also upregulated by the insulin sensitising drugs 
thiazolidinediones in genetic and diet-induced models of insulin resistance, in 
association with ameliorated hyperglycemia, insulin resistance and hypertension 
(Combs et al., 2002; Potenza et al., 2006; Yamauchi et al., 2001). Adiponectin 
administration causes weight loss in mice fed a high fat diet and ameliorates insulin 
resistance in mouse models of obesity and type 2 diabetes (Fruebis et al., 2001; 
Yamauchi et al., 2001). Collectively, these data indicate that adiponectin promotes 
insulin sensitivity. Therefore, a reduction in adiponectin, and thus its insulin 
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sensitising actions, may be an important link between the dual epidemics of obesity 
and diabetes. 
 
1.7 Adiponectin: Structure and Function 
Adiponectin was independently discovered and described by several groups and so 
was given a variety of names, including adipocyte complement-related protein of 
30kDa (Acrp30; Scherer et al., 1995), adipoQ (Hu et al., 1996), adipose most  
abundant gene transcript 1 (apM1; Maeda et al., 1996) and gelatine-binding protein of 
28kDa (GBP28; Nakano et al., 1996), although adiponectin is now the most widely 
accepted term. 
 
Adiponectin is a 244 amino acid protein in humans (247 amino acids in mice) of 
approximately 28kDa. It consists of an amino-terminal signal peptide, a short variable 
region that shows no homology to other known proteins, 22 collagenous repeats 
involved in triple helix formation, and a globular head at the carboxyl-terminus 
(Figure 1.2; Scherer et al., 1995; Nakano et al., 1996). The protein sequence is 
reasonably conserved, with 91% similarity between the rat and mouse sequences, and 
Figure 1.2: Domain structure of human adiponectin. Adapted from Whitehead et al. 
(Whitehead et al., 2006). 
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82% of the amino acids conserved between mice and humans (Nakano et al., 1996). 
The majority of these conserved regions occur within the C-terminal globular domain. 
The globular domain is made up predominantly of -sheets (Shapiro & Scherer, 
1998), which commonly self-associate, and so it is thought that this occurs and 
promotes the subsequent formation of the collagenous triple helix. Adiponectin 
peptides bind together via disulphide bonds and non-covalent linkages to produce a 
variety of homomultimers. The basic adiponectin unit in vivo is a trimer (low 
molecular weight; LMW). Hexamers (middle molecular weight; MMW) are then 
formed via the linking of two trimers by a disulphide bond between cysteine 36 
residues (cysteine 39 in the mouse sequence; Pajvani et al., 2003; Tsao et al., 2003). 
Association of a number of hexamers leads to the formation of high molecular weight 
(HMW) complexes consisting of up to 18 peptides (Scherer et al., 1995; Waki et al., 
2003). It has been demonstrated that adiponectin undergoes post-translational 
modification including hydroxylation and glycosylation (Wang et al., 2002; Wang et 
al., 2004), and this appears to be crucial in HMW complex formation (Wang et al., 
2006). This is supported by the fact that HMW species have not been observed in 
adiponectin expressed in bacteria, which do not carry out the post-translational 
modifications, and that replacement of certain amino acids involved in these 
modifications prevent both glycosylation and formation of HMW complexes (Waki et 
al., 2003). All of the multimeric forms are present in plasma, although the relative 
proportion of each can vary (Pajvani et al., 2003), and variation in the ratio of the 
different forms has been linked with insulin resistance (Pajvani et al., 2004). 
 
AdipoR1 and AdipoR2 are the first recognised adiponectin receptors, and may explain 
some of the biological actions of adiponectin (Yamauchi et al., 2003). AdipoR1 is 
most abundantly expressed in skeletal muscle, and binds most prominently to LMW 
multimers of adiponectin. Meanwhile, AdipoR2 is located primarily in liver and has a 
higher affinity for larger adiponectin multimers. Expression of both receptors is 
reduced in the leptin deficient mouse model of insulin resistance (Tsuchida et al., 
2004). Adiponectin has been shown to upregulate the AdipoR1 receptor, an effect that 
was absent in obese subjects and type 2 diabetics, and did not return with weight loss 
(McAinch et al., 2006). A third receptor, T-cadherin has been identified, which only 
showed affinity for hexameric and HMW adiponectin (Hug et al., 2004). T-cadherin is 
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expressed in endothelial and smooth muscle cells, although the functional relevance of 
its interaction with adiponectin is not yet clear (reviewed in Takeuchi et al., 2007). 
A number of studies have demonstrated that adiponectin is involved in glucose 
homeostasis. HMW adiponectin administration lowers circulating glucose levels in 
mice, and Combs et al. (2001) found this to be entirely attributable to a reduction in 
hepatic glucose production Adiponectin may indirectly improve glucose homeostasis, 
as it has been shown to stimulate secretion of insulin (Okamoto et al., 2008). 
However, adiponectin also has direct tissue effects. In cultured myocytes and isolated 
muscle, adiponectin stimulates glucose uptake, and causes a reduction in the 
triglyceride content of this tissue (Tomas et al., 2002; Yamauchi et al., 2002). Ceddia 
et al. (2005) reported that adiponectin stimulates translocation of GLUT-4 in cultured 
skeletal muscle cells, leading to increased glucose uptake and subsequently a 
reduction in glycogen synthesis. Adiponectin also stimulates phosphorylation and thus 
inhibition of acetyl coenzyme-A carboxylase (ACC), resulting in increased -
oxidation of fatty acids (Ceddia et al., 2005; Yamauchi et al., 2001; Wu et al., 2003). 
A number of studies have shown that adiponectin operates via activation of AMP-
activated protein kinase (AMPK; Ceddia et al., 2005; Tomas et al., 2002; Yamauchi et 
al., 2002; Satoh et al., 2005; Wu et al., 2003). Chen et al. (2005) found adiponectin-
mediated stimulation of AMPK is impaired in obese type 2 diabetics. Adiponectin 
stimulates AMPK phosphorylation via the adaptor protein containing pleckstrin 
homology domain, phosphotyrosine binding domain and leucine zipper motif 
(APPL1; Zhou et al., 2009), a protein involved in insulin signalling and required for 
GLUT-4 translocation (Saito et al., 2007). Recent evidence suggests a second 
adiponectin-activated pathway in myocytes, stimulating phospholipase C to increase 
intracellular calcium release, stimulate calmodulin-dependent protein kinase kinase 
(CAMKK) and secondarily phosphorylate AMPK (Zhou et al., 2009; Hattori et al., 
2008). It has been demonstrated that these actions are differentially regulated by the 
various adiponectin multimers, with the HMW forms found to be most active in liver 
whilst the trimer has primarily muscular effects (Waki et al., 2003). 
 
Increasing evidence suggests that the carboxyl-terminal globular domain of 
adiponectin may be formed as a proteolytic cleavage product from the full-length 
adiponectin protein. Low levels of globular adiponectin have been identified in human 
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and mouse plasma (Fruebis et al., 2001; Maeda et al., 2002a; Yamauchi et al., 2001). 
A potential mechanism for such a cleavage reaction, involving leukocyte elastase, has 
been described (Fruebis et al., 2001; Waki et al., 2005). This proteolysed form is 
unable to form multimers greater than a trimer because it lacks the cysteine residue 
required for disulphide bond formation (Waki et al., 2003). Similar to the full-length 
protein, globular adiponectin has been shown to stimulate AMPK activity, fatty acid 
oxidation, and improve both basal and insulin-stimulated glucose uptake in isolated 
human skeletal muscle (Bruce et al., 2005). These effects were significantly impaired 
in muscle from obese subjects (Bruce et al., 2005). However, compared to full-length 
adiponectin, globular adiponectin elicits more potent activation of AMPK in muscle 
cells (Tomas et al., 2002; Yamauchi et al., 2002), greater stimulation of glucose and 
free fatty acid removal from plasma, and an ability to reduce the body weight of mice 
fed a high fat diet not seen with full-length adiponectin (Fruebis et al., 2001). 
Additionally, the majority of studies reporting stimulation of muscle glucose uptake 
conducted their investigations using globular adiponectin (Bruce et al., 2005; Ceddia 
et al., 2005; Tomas et al., 2002; Wu et al., 2003). Therefore, it has been proposed that 
globular adiponectin may be the most potent adiponectin species in muscle.  
 
Overall, the metabolic actions of adiponectin are somewhat complex, but can be 
summarised as shown in Figure 1.3.  
Figure 1.3: Differential actions of adiponectin multimers. Adapted from Waki et al. 
(Waki et al., 2003). 
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1.8 Vascular Actions of Adiponectin 
A growing body of evidence indicates that in addition to its direct insulin-sensitising 
effects, adiponectin is active in the vasculature. Decreased levels of adiponectin are 
associated with hypertension (Iwashima et al., 2004) and coronary artery disease 
(Ouchi et al., 1999), as well as atherosclerosis and vascular dysfunction (reviewed in 
Goldstein & Scalia, 2004). Hypoadiponectinemia is strongly associated with impaired 
vasoreactivity in hypertensive patients (Ouchi et al., 2003). As stated above, 
adiponectin confers protection against inflammation and endothelial dysfunction 
(reviewed in Lau et al., 2005). Adiponectin is cardioprotective, reducing cell death 
and oxidative stress associated with myocardial ischemia/reperfusion injury (Tao et 
al., 2007). These effects have been demonstrated to occur via stimulation of AMPK, 
Akt and NO production (Gonon et al., 2008). Adiponectin suppresses smooth muscle 
cell proliferation (Wang et al., 2005) and inhibits monocyte adhesion to cultured 
endothelial cells (Ouchi et al., 1999; Ouchi et al., 2001), revealing anti-atherosclerotic 
properties. Indeed, Yamauchi et al. (2003) found that overexpression of globular 
adiponectin protects against the formation of atherosclerotic lesions in the 
apolipoprotein E-deficient mouse. Adiponectin also stimulates angiogenesis, via a 
mechanism involving AMPK, PI3K and Akt (Ouchi et al., 2004). Increases in 
adiponectin due to caloric restriction are associated with improved revascularisation of 
ischemic rat hindlimb, via an AMPK and eNOS dependent pathway (Kondo et al., 
2009). Another study demonstrated adiponectin-stimulated revascularisation in 
ischemic muscle via a PI3K, Akt and COX2 dependent mechanism (Ohashi et al., 
2009). This action was found to be occurring via adiponectin interacting with 
calreticulin and its adaptor protein CD91, rather than the previously described 
adiponectin receptors (Ohashi et al., 2009). This novel receptor pathway involves non-
classical ligand binding, so may require the high adiponectin concentrations that occur 
in vivo. The authors found that the effects of adiponectin on eNOS and COX2 are 
additive, and vascular endothelial cell function depends on the products of both 
reactions (Ohashi et al., 2009). 
 
A role for adiponectin in hemodynamic regulation has previously been suggested by a 
correlation between increased adiponectin in liver cirrhosis and increased blood flow 
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and vascular resistance (Tietge et al., 2004). Plasma adiponectin in type 2 diabetics 
also correlates with insulin-stimulated NOS activity and whole body glucose uptake 
(Kashyap et al., 2010 ). Low levels of plasma adiponectin in humans are associated 
with impaired endothelium-dependent vasodilation, independent of type 2 diabetes 
(Tan et al., 2004). Similarly, endothelium-dependent vasodilation is impaired in 
adiponectin knock-out mice (Ouchi et al., 2003). Several groups have demonstrated 
increased production of the vasodilator NO by endothelial cells in response to both 
globular and full-length mammalian adiponectin (Chen et al., 2003; Hattori et al., 
2003; Xi et al., 2005). This adiponectin-stimulated NO production is mediated by 
activation of PI3K and AMPK, leading to induction of eNOS phosphorylation and 
eNOS- heat shock protein 90 (HSP90)-Akt complex formation (Chen et al., 2003; Xi 
et al., 2005). Interestingly, chemical activation of AMPK has previously been found to 
cause microvascular recruitment (Bradley et al., 2010). Indeed, Cheng et al. (2007) 
described APPL1 and AMPK dependent adiponectin-meditated vasorelaxation in 
mesenteric arteries from lean heterozygous leptin deficient mice. This effect was 
endothelium-dependent and abolished by NOS inhibition, emphasising the likely 
importance of NO in adiponectin-induced vasodilation (Cheng et al., 2007). 
Additionally, adiponectin-meditated vasorelaxation was significantly reduced in 
arteries from homozygous leptin deficient diabetic mice, and the authors suggest that 
reduced function of adiponectin and/or APPL1 may contribute to endothelial 
dysfunction (Cheng et al., 2007). Xi et al., 2005) have also demonstrated NO- and 
endothelium-dependent relaxation of pre-constricted isolated aortic rings in response 
to globular adiponectin. Furthermore, Fesus et al. (2007) found that human 
recombinant adiponectin blunted serotonin-mediated vasoconstriction in isolated 
aortic rings and mesenteric arteries, an effect which was endothelium-independent in 
contrast to previous studies. These observations suggest that in addition to direct 
affects on skeletal myocyte glucose uptake, adiponectin may enhance glucose delivery 
by stimulating vasodilation. 
 
As described above, NO-dependent vasodilator activity of insulin is a major aspect of 
its ability to stimulate glucose uptake. Thus, any similar responses adiponectin elicits 
may make important contributions to both its insulin sensitivity and cardiovascular 
benefits.  
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1.9 Do acute hemodynamic actions of adiponectin contribute to 
insulin sensitivity? 
Hemodynamic regulation is a major aspect of insulin action. These effects are 
impaired in insulin resistance, and alternative methods of stimulating it may be 
therapeutically beneficial in insulin resistance and type 2 diabetes. Adiponectin shows 
potential to have similar vascular actions to insulin, which may improve glucose 
homeostasis by regulating access of insulin and glucose to myocytes. However, the 
effects of adiponectin have not been examined in an intact vascular system, and so the 
physiological significance of such effects remains unclear. Therefore the overall aim 
of this thesis was to determine whether adiponectin acts in the vasculature acutely to 
improve insulin sensitivity. 
 
This principal aim was addressed via four major research aims:  
i) to produce physiologically active recombinant adiponectin; 
ii) to examine the acute vascular actions of adiponectin in a simplified but intact 
vascular system, the pump-perfused rat hindlimb;  
iii) to investigate whether acute adiponectin infusion alters hemodynamics and/or 
glucose homeostasis in the presence and absence of insulin in anaesthetised 
rats; 
iv) to determine whether the acute vascular actions of adiponectin are altered in 
insulin resistance. 
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CHAPTER 2 – PREPARATION AND CHARACTERISATION 
OF RECOMBINANT ADIPONECTIN 
 
 
2.1 Introduction 
 
In order to undertake investigations into the physiological actions of adiponectin, a 
supply of adiponectin was first required. While recombinant adiponectin is 
commercially available, the cost of the large amounts required for perfused rat 
hindlimb and in vivo experiments is prohibitive, with micrograms required to maintain 
physiologically relevant (μg.mL-1) doses throughout the experiments (Fesus et al., 
2007; Cheng et al., 2007). Recombinant protein expression in E. coli is a widely used 
method of producing large quantities of a desired protein (Kou et al., 2007; Galluccio 
et al., 2007). Although mammalian and bacterially produced proteins can vary in their 
actions, much lower protein yields are achieved with mammalian cells. Thus bacterial 
expression was considered the most appropriate system to produce the required 
amounts of adiponectin. 
 
Adiponectin circulates as low molecular weight (LMW), mid molecular weight 
(MMW) and high molecular weight (HMW) multimers (Shklyaev et al., 2003). A 
number of studies have identified differences in the biological actions of the various 
adiponectin multimeric forms (reviewed in Whitehead et al., 2006). LMW adiponectin 
acts predominantly via AdipoR1 receptors in skeletal muscle while larger adiponectin 
multimers have a higher affinity for the AdipoR2 receptors located primarily in liver 
(for review see Kadowaki & Yamauchi, 2005). Therefore, the large multimeric 
complexes formed by mammalian-produced adiponectin have well described hepatic 
actions but low potency in muscle (Tsao et al., 2003; Waki et al., 2003). Conversely, 
LMW and globular adiponectin have been found to have greater action on muscle 
(Yamauchi et al., 2001; Yamauchi et al., 2002; Fruebis et al., 2001; Tomas et al., 
2002; Waki et al., 2003). The present study focused on the effects of adiponectin in 
skeletal muscle, and the bulk of evidence suggests this is primarily a target of LMW 
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adiponectin. Therefore, bacterially expressed LMW and globular adiponectin were 
selected for use in the current investigations. 
 
The aim of this group of experiments was to produce purified recombinant 
adiponectin, with four major requirements, i) accuracy of sequence and structure, ii) 
adequate yield, iii) sufficient purity, and iv) biological activity. This required cloning 
the adiponectin gene sequence, protein expression in E. coli, purification of the 
recombinant protein and quantification of the protein product. The protein product 
was then quantified and characterised via SDS-PAGE and Western Blot for purity and 
multimerisation status. The recombinant adiponectin was shown to stimulate 
phosphorylation of eNOS in isolated endothelial cells, indicating that it is biologically 
active. 
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2.2 Materials and Methods 
 
2.2.1Adiponectin preparation 
2.2.1.1 Cloning the adiponectin gene 
The full-length and globular adiponectin sequences were cloned separately for 
bacterial expression. Total RNA was extracted from differentiated 3T3-L1 adipocytes 
using the TRI Reagent® method (Sigma, St Louis, MO, USA). Approximately 1ng of 
total RNA was reverse transcribed using SuperScript™ III RNase H- Reverse 
Transcriptase (Invitrogen, Carlsbad, CA, USA). The mouse full-length adiponectin 
cDNA excluding the N-terminal signal sequence (718bp; Gen bank accession number  
NM_009605) was amplified, using the 5’-CACCAGTCATGCCGAAGATGA-3’ sense and 
5’-ATGGGTAGTTGCAGTCAGTTGG-3’ antisense primers. Platinum® Pfx polymerase 
(Invitrogen, Carlsbad, CA, USA) was used to produce a blunt-ended PCR product. 
This sequence was incorporated into the pET100/D-TOPO bacterial expression vector 
(Figure 2.1; Invitrogen, Carlsbad, CA, USA).This vector includes a polyhistidine tag, 
allowing simple purification of the protein using a metal chelating resin. This tag is 
situated on the N-terminus, which is imperative since the C-terminal end of 
adiponectin is highly conserved and thought to mediate many of the protein’s 
important actions (Fruebis et al., 2001), so any modification to this region was likely 
to affect the function of the protein. The sequence for the globular domain of 
adiponectin, corresponding to amino acids 110-248 of murine adiponectin (483bp) 
was amplified from the previously prepared adiponectin plasmid using 5’-
GGGGACAAGTTTGTACAAAAAAGCAGGCTCAGCCGCTTATATGTATCGCT-3’ sense and 
5’-GGGGACCACTTTGTACAAGAAAGCTGGGTTTGCAGTCAGTTGGTATCATGG-3’ 
antisense primers, including the attB sequence for insertion into the pEXP1-DEST 
expression vector (Invitrogen, Carlsbad, CA, USA).This vector has similar features 
and an identical N-terminal tag to the pET100/D-TOPO vector. 
 
The pET/D/Acrp plasmid was transformed into OneShot® TOP10 Chemically 
Competent E. coli (Invitrogen, Carlsbad, CA, USA) for proliferation and purified 
using the Wizard ®Plus SV Minipreps DNA Purification System (Promega, Madison, 
WI, USA). Plasmid fidelity and orientation was confirmed by i) size analysis via  
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electrophoresis following linearisation with the HindIII restriction enzyme, ii) PCR 
amplification of the regions overlapping each insertion site, and iii) sequencing using 
the CEQ™ DTCS-Quick Start Kit (Beckman Coulter, Fullerton, CA, USA) according 
to the manufacturer’s instructions, except that the amount of glycogen added with the 
stop solution was halved, as it had previously been determined in this laboratory that 
lower levels improve the efficiency of sequencing.  
 
2.2.1.2 Protein expression 
Expression of the adiponectin gene from the pET/D/Acrp plasmid occurs via a T7 
promoter, under the control of the lac operon, which permits efficient expression of 
the target gene in E. coli. The lac repressor, coded for by the lac ORF, binds to the lac 
operon controlling the T7 promoter and inhibits basal expression of the recombinant 
Figure 2.1: Vector map of pET100/D-TOPO. Inset shows the transcription initiation 
elements, N-terminal tag and gene insertion site (Invitrogen, Carlsbad, CA, USA). 
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protein. When isopropyl -D-thiogalactopyranoside (IPTG) is added to the bacterial 
culture it competes with the lac repressor, removing it from the lacO site and allowing 
transcription to proceed. The BL21(DE3) E. coli strain carries the DE3 bacteriophage 
lambda (DE3) lysogen and is specifically designed for expression of genes regulated 
by the T7 promoter. The DE3 lysogen contains the gene for T7 RNA polymerase, 
under the control of the lacUV5 promoter, which operates as described above. The 
promoters for T7 RNA polymerase do not naturally occur in E. coli and the enzyme is 
highly specific (Studier & Moffatt, 1986), so the polymerase will only transcribe 
introduced T7-regulated genes. Proteases that break down heterologous proteins are 
absent from B strains of E. coli such as BL21(DE3) (Grodberg & Dunn, 1988), 
ensuring that neither the T7 RNA polymerase nor the target protein are proteolysed. 
Thus, when IPTG is added to cultures of this bacterium T7 RNA polymerase is 
produced and repression of the target gene is removed, providing a dual control 
mechanism to ensure strict control of protein expression. 
 
BL21(DE3) E. coli (Invitrogen, Carlsbad, CA, USA) were made chemically 
competent using CaCl2 in order to facilitate uptake of DNA. The plasmid sample was 
added to competent cells and gently stirred using a pipette tip to limit cell lysis. 
Transformed bacteria were aliquoted and stored at -80°C in 15% glycerol. 
Transformed bacteria were grown up to log phase (0.5-0.8 OD) before IPTG was 
added to a final concentration of 6.7mM to induce protein expression. The amount of 
IPTG was increased from the 1mM suggested by the manufacturer following variable 
results in pilot expression experiments. Bacteria were grown for a further 3hs, which 
produced optimal adiponectin expression, before the cells were harvested. A vehicle 
preparation was produced using untransformed BL21(DE3) E. coli and without the 
addition of IPTG, whilst all other processes remained the same. 
 
2.2.1.3 Purification of native protein using Ni-NTA affinity resin 
Metal chelate affinity chromatography is a common method of protein purification, 
using a substrate such as Ni-NTA resin, composed of Ni2+ ions bound to 
nitrilotriacetic acid (for review see Gaberc-Porekar & Menart, 2005). The imidazole 
rings of closely associated histidine residues bind to the nickel ions and consequently 
proteins that contain them are immobilised in the resin. Often, as in this study, a 
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polyhistidine tag is introduced to a target protein by recombination with a vector that 
contains the corresponding nucleotide sequence. As it is uncommon to find stretches 
of several neighbouring histidine residues in naturally occurring proteins, this 
technique is reasonably selective. 
 
Recombinant adiponectin was purified under native conditions using the Ni-NTA 
Purification System from Invitrogen (Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Briefly, the bacteria were lysed by a combination of 
lysozyme and a series of rapid sonicate-freeze-thaw cycles. The bacterial lysate was 
bound to the Ni-NTA resin for 1hr with gentle agitation. Unbound protein was 
removed by a series of washes in low ionic strength imidazole buffer. The 
recombinant protein was eluted in 15mL of 250mM imidazole and stored at 4°C. 
 
2.2.1.4 Concentration and dialysis of protein preparations using Vivaspin 20 units 
After purification using a Ni-NTA column, the recombinant protein is present in a 
high concentration imidazole buffer. Imidazole and chemicals containing an imidazole 
ring have been found to have numerous effects in vivo; including inhibition of 
mitogen-activated protein kinases, resulting in the reduced production of pro-
inflammatory cytokines such as interleukin 1 and TNF- (English & Cobb, 2002), and 
activation of some phosphodiesterases (Gaillard, 1970). As these molecules exhibit 
vasoactivity, the presence of imidazole could affect the outcomes of the current 
studies. Thus it was necessary to remove the imidazole from the recombinant 
adiponectin. 
 
Samples were concentrated and dialysed with phosphate buffered saline (0.14M NaCl, 
2.5mM KCl, 1.5mM KH2PO4, 10mM Na2HPO4; pH 7.4) using Vivaspin 20 
ultrafiltration units (Sartorius, Goettingen, Germany). Total protein content was 
assessed using the Lowry method (Lowry et al., 1951; DC Protein Assay, Bio-Rad, 
Hercules, CA, USA). Adiponectin preparations were stored at 4°C for up to 30 days. 
 
24 
2.2.2 SDS-PAGE analysis 
2.2.2.1 SDS-PAGE under denaturing conditions 
Protein samples were analysed via denaturing SDS-PAGE using the XCell 
SureLock™ Mini-Cell and NuPAGE® Novex Pre-Cast 1.0 mm, 10 well, 10% Bis-Tris 
Gels (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. 
NuPAGE® Antioxidant was used to prevent proteins reoxidising during 
electrophoresis. Samples were combined with an equal volume of 2x SDS-PAGE 
Sample Buffer (0.125M Tris-HCl pH 6.8, 20% glycerol, 4% -mercaptoethanol, 
0.2%Bromophenol Blue, 4% SDS). Samples were heated at 90°C for 5-10 minutes to 
denature the protein, immediately before being loaded onto a SDS-PAGE gel. Each 
gel was loaded with 5μL of the SeeBlue® Plus2 Pre-Stained Standard (Invitrogen, 
Carlsbad, CA, USA) and 20μL of each sample to be analysed. The gels were 
electrophoresed at 200 volts for 45-60 minutes at room temperature. 
 
2.2.2.2 SDS-PAGE under non-denaturing conditions 
In order to examine the native conformation of the recombinant adiponectin, samples 
were analysed via non-denaturing SDS-PAGE using 3-8% Tris-Acetate NuPAGE® 
gels (Invitrogen, Carlsbad, CA, USA). Samples were prepared in buffer containing no 
-mercaptoethanol (LDS Sample Buffer; Invitrogen, Carlsbad, CA, USA) and were 
not heated, as these treatments break disulphide bonds between cysteine residues and 
non-covalent bonds between protein subunits, respectively. Prepared samples (20μL) 
were loaded onto a gel, along with 5μL of the SeeBlue® Plus2 Pre-Stained Standard. 
The buffer chambers were filled with Tris-glycine Native Running Buffer (Invitrogen, 
Carlsbad, CA, USA) with no added antioxidant, and the gel was electrophoresed at 
150 volts for 1-2hrs.  
 
2.2.2.3 Staining SDS-PAGE gels for total protein 
SDS-PAGE gels were soaked in Gel Staining Solution (0.1% coomassie blue, 25% 
methanol, 10% acetic acid) overnight to stain for protein. The gels were then soaked 
in Gel Destaining Solution (20% methanol, 10% acetic acid) for 4-8hrs until 
satisfactory destaining was achieved. 
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2.2.3 Western Blot Analysis 
Following separation via non-denaturing SDS-PAGE, proteins were transferred to 
nitrocellulose membranes at 30 volts for 1hr at room temperature. The membranes 
were washed in TBS (0.02MTris base, 0.137MNaCl; pH 7.6), then incubated in 
Blocking Buffer (5% non-fat milk powder in TBS/T) for 1hr at room temperature.  
Immunoblotting was conducted with either a specific anti-adiponectin antibody 
(AB3269P; Chemicon, Temecula, CA, USA) or the Anti-Xpress™ antibody, which 
recognises an epitope in the N-terminal tag (Invitrogen, Carlsbad, CA, USA). The 
membrane was placed into a solution of either antibody at a dilution of 1:5000 in 
Blocking Buffer and tumbled at 4°C overnight. The membrane was washed three 
times in TBS/T (0.1% Tween 20 in TBS); before being tumbled for 1hr at room 
temperature with an appropriate secondary antibody linked to horseradish peroxidise 
(Cell Signalling, Danvers, MA, USA). The membrane was again washed in TBS/T, 
before immunoreactive proteins were visualised using the SuperSignal® West Pico 
Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL, USA). 
Chemiluminescence was detected by exposure to the blot and subsequent development 
of autoradiography film (Amersham (GE Healthcare)). 
 
2.2.4 Preparation of mouse fat homogenate 
Mouse fat homogenate was obtained as source of mammalian adiponectin for 
comparison with the bacterially expressed recombinant adiponectin produced in this 
study. The epididymal fat pads from five male mice were pooled and ground to a 
powder under liquid nitrogen. Six millilitres of Sample Buffer (0.02M Tris base pH 
7.5, 0.2M potassium fluoride, 0.02M EDTA) containing 50μL of Protease Inhibitor 
Cocktail (Sigma, St Louis, MO, USA) was added to approximately 1g of tissue in a 
chilled tube. The sample was homogenised using an ultraturrax, before being 
centrifuged at 13,000g for 10min at 4°C in a microcentrifuge. The infranatant was 
carefully collected, as adipocytes produce a top layer of fat from this process. This 
sample was aliquoted and frozen in liquid nitrogen, before being stored at -80°C. 
 
2.2.5 Quantification of adiponectin by ELISA 
Adiponectin concentrations were assayed using the Adiponectin ELISA kit from 
Phoenix Pharmaceuticals (Burlingame, CA, USA), according to the manufacturer’s 
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instructions. This assay was specifically chosen as it reacts with both mouse and rat 
adiponectin, and so would detect both the recombinant mouse adiponectin and 
adiponectin endogenous to the rats studied. Samples were serially diluted until they 
were within the range of the standard curve. 
 
2.2.6 Determination of adiponectin-mediated eNOS phosphorylation in bovine 
aortic endothelial cells 
2.2.6.1 Bovine Aortic Endothelial Cell Isolation 
Bovine aortic endothelial cells (BAECs) were isolated from thoracic aortae excised 
from one year old calves. Aortae were placed in sterile HEPES Buffered Hanks 
Balanced Salt Solution (HBSS; in mM: 136.9 NaCl, 0.33 Na2HPO4, 0.44 KH2PO4, 
5.37 KCl, 4.16 NaHCO3, 5.55 D-glucose, 0.027 Phenol Red, 20.0 HEPES, 1.26 CaCl2, 
0.81 MgSO4) and transported to the laboratory within 1hr of excision. The fatty 
adventia was removed from each section. The lumen was exposed and rinsed 
thoroughly with HBSS to remove adherent blood or gut bacteria. The endothelial layer 
was gently collected into HBSS containing 10μg.mL-1 gentamicin and 2.5μg.mL-1 
amphotericin (both Sigma, St Louis, MO, USA) and kept on ice. The cells were 
washed in HBSS, and suspended in 0.1% Collagenase II (Worthington, Lakewood, 
NJ, USA) in HBSS. The suspension was incubated at 37°C for 15min with trituration, 
before digestion was neutralised by the addition of Foetal Calf Serum (FCS; JRH 
Biosciences, Lenexa, KS, USA). The cells were collected by centrifugation at 300g 
and resuspended in sterile low glucose Dulbecco’s Modified Eagles Medium (DMEM; 
pH 7.4; GIBCO, Invitrogen, Carlsbad, CA, USA) supplemented with 44mM NaHCO3, 
10mL.L-1 penicillin/streptomycin solution (JRH Biosciences, Lenexa, KS, USA), 
4mM L-glutamine (Sigma, St Louis, MO, USA) and 10% FCS. BAECs were 
incubated in a humidified, 5% CO2 atmosphere at 37°C and passaged every 2-4 days. 
Cells were not passaged more than five times, as after this the morphology and thus 
possibly the phenotype of the cells is altered by the culturing process. 
 
2.2.6.2 Determination of adiponectin-mediated eNOS activation 
Cells were serum starved for 2hr in Krebs Buffer (120mM NaCl, 4.7mM KCl, 1.2mM 
KH2PO4, 2.4mM MgSO4, 25mM NaHCO3, 1.25mM CaCl2). The cells were then 
incubated for 15min with adiponectin (0-10μg.mL-1) diluted in Krebs. The buffer was 
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aspirated and the cells resuspended in Solubilising Buffer (0.12mM Tris-HCl, 4% w/v 
SDS, 20% glycerol, 10% -mercaptoethanol, Bromophenol Blue, pH 6.8) with 
thorough trituration. Samples were subjected to non-denaturing SDS-PAGE and 
Western Blotting as described in Sections 2.2.2 and 2.2.3, except that electrophoretic 
transfer to nitrocellulose was conducted at 30 volts at 4°C overnight. Membranes were 
immunoblotted using antibodies for total or serine 1177 phosphorylated eNOS (BD 
Transduction Laboratories, Franklin Lakes, NJ, USA) diluted in 5% BSA in TBS/T. 
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2.3 Results 
 
2.3.1 Analysis of the purity of the recombinant adiponectin preparation 
To verify the purity of the adiponectin, a SDS-PAGE was conducted on fractions 
eluted from a Ni-NTA column and stained for total protein. A distinct band was 
apparent in each of the fractions at 29.4kDa, the expected size of adiponectin, whilst 
the remainder of the gel was essentially free from protein (Figure 2.2). Coomassie 
blue stained SDS-PAGE of globular adiponectin similarly showed enrichment of a 
band at 20.7kDa, the predicted size of the recombinant protein, following purification 
(data not shown). This indicated that recombinant adiponectin had been purified from 
the bacterial lysate. Yield was highest in the initial fraction and rapidly reduced with 
increasing elution volume. All experimental adiponectin preparations were prepared 
from 12-15mL elution volumes. 
 
 
Figure 2.2: De-naturing SDS-PAGE of purified adiponectin fractions stained for total 
protein. Lanes 1-4 show samples of consecutive 1mL fractions eluted from a Ni-NTA 
column. Predicted size of the monomeric recombinant protein was 29.4kDa. 
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Both the full-length and globular proteins were confirmed as recombinant adiponectin 
through immunoreactivity with both the anti-Xpress antibody, which detects the N-
terminal tag, and with the specific anti-adiponectin antibody. Meanwhile, no 
immunoreactive bands were detected in vehicle preparations (Figure 2.3B), indicating 
that they were free from recombinant protein as expected. 
 
2.3.2 Native conformation of recombinant adiponectin 
The distribution of the multimeric forms of recombinant adiponectin was evaluated 
via non-denaturing, non-reducing SDS-PAGE and Western blotting (Figure 2.3). The 
bacterially produced full-length adiponectin was present substantially at an apparent 
weight of approximately 70kDa, the reported weight of the trimer (Figure 2.3A). 
Small amounts of immunoreactive protein was also observed between 
approximately115-150kDa, consistent with mid molecular weight adiponectin species, 
which have previously been reported in bacterially expressed adiponectin (Figure 
 
Figure 2.3: Native conformation of recombinant adiponectin preparations. Non-reducing, 
non-denaturing Western Blot analysis of (A) full-length recombinant adiponectin, (B) recombinant 
globular adiponectin (Lane 1) and vehicle (Lane 2), and (C) mammalian adiponectin. A and C 
were conducted using the anti-adiponectin antibody, whilst B was prepared using the anti-Xpress 
antibody. 
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2.3A; Waki et al., 2003; Yamauchi et al., 2002; Tsao et al., 2002). The apparent 
weight of trimeric adiponectin has previously been reported to be lower than its true 
molecular weight, as the quarternary structure of the non-denatured protein affects the 
way it travels through the gel (Waki et al., 2003). Native recombinant globular 
adiponectin appeared as a single band at approximately 60kDa, consistent with a 
trimer, but lacked higher molecular weight multimers as expected (Figure 2.3B; Waki 
et al., 2003; Pajvani et al., 2003). No high molecular weight species, expected in the 
range >300kDa (Waki et al., 2003), were detected in the recombinant adiponectin, 
although they were detectable in mammalian adiponectin analysed using the same 
method (Figure 2.3C). Comparison of the bacterially expressed recombinant 
adiponectin and endogenous mammalian adiponectin shows the shift from high 
molecular weight to low molecular weight adiponectin that occurs in bacterial 
expression systems (Figure 3.3A and C). The mammalian trimer has a greater 
apparent size than its bacterial counterpart, possibly due to post-translational 
modifications such as glycosylation, that are not present in bacterial proteins, 
impeding the progression of the protein through the gel (Figure 2.3; Wang et al., 
2002). Also characterised was the breakdown of the recombinant adiponectin into 
apparent trimer, dimer and monomer species following reduction, heating and 
combined treatment respectively, to ensure that the recombinant protein was forming 
as expected (data not shown; Waki et al., 2003).  
 
2.3.3 Quantification of the recombinant adiponectin preparation 
Quantification of adiponectin by ELISA confirmed that adiponectin was present at 
high levels in the recombinant protein preparations, with an average content of 
1.7±0.4mg.mL-1 adiponectin (Figure 2.4A). The increase in adiponectin content was 
reflected by increased total protein content (Figure 2.4B). Meanwhile, adiponectin 
detected in vehicle preparations was negligible, at 12.2±3.2ng.mL-1 two orders of 
magnitude lower than that seen in the adiponectin samples (Figure 2.4A). However, 
the difference in total protein levels was much smaller, with vehicle preparations 
containing approximately a fifth the total protein observed in the adiponectin samples. 
This suggests that bacterial proteins are present, and are potentially also contaminating 
the adiponectin preparations despite not being apparent in the SDS-PAGE analysis. 
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Comparison of the measured adiponectin and total protein content of the recombinant 
adiponectin and vehicle preparations would suggest that essentially all of the protein 
present in the adiponectin samples is adiponectin. This would in turn suggest that the 
vehicle contains a level of protein contamination that is not present in the adiponectin 
preparation, and thus may not be a genuine control. However, due to the extremely 
high levels of adiponectin present in the purified recombinant protein preparations, the 
samples had to be highly diluted to reach the range of the ELISA standard curve. 
Thus, there was a substantial degree of calculation required to achieve an estimate of 
the original adiponectin concentration. In addition, information regarding the affinity 
of this assay for the various adiponectin multimers is not available from the 
manufacturer. As the recombinant adiponectin consists primarily of LMW adiponectin 
multimers, whilst polyclonal antibodies directed against mammalian adiponectin were 
used in the assay, potential differential reactivity to the different adiponectin 
multimers may also affect the resulting values. Whilst these data clearly show 
significant enrichment of adiponectin in the recombinant protein samples, the absolute 
values may not provide an entirely accurate assessment of the exact adiponectin 
concentrations. 
 
2.3.4 Adiponectin-stimulated eNOS phosphorylation 
As the adiponectin produced for this study had not been used previously, it was 
deemed necessary to ensure that the recombinant adiponectin was biologically active. 
Adiponectin has previously been found to stimulate phosphorylation of eNOS in 
Figure 2.4: Quantification of adiponectin and total protein content of recombinant 
protein preparations. (A) Adiponectin content as determined by ELISA (n=5). (B) Total 
protein content as assayed using the Lowry method (n=9-11).  
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endothelial cells in vitro (Chen et al., 2003; Xi et al., 2005). Thus, the extent of eNOS 
phosphorylation in response to the recombinant adiponectin was examined as an 
assessment of the bioactivity of the recombinant adiponectin produced in this study. 
Adiponectin dose-dependently increased phosphorylation of eNOS on serine 1177 in 
BAECs (Figure 2.5). This indicates that the recombinant adiponectin elicits biological 
activity similar to that reported in the literature. 
 
 
Figure 2.5: Phosphorylation of eNOS in response to adiponectin. Bovine aortic 
endothelial cells were treated with the indicated dose of adiponectin for 15min, before being 
immunoblot assayed for total and phosphorylated eNOS. 
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2.4 Discussion 
 
The aim of this series of experiments was to produce purified, biologically active 
recombinant adiponectin. Murine full-length adiponectin was expressed in E. coli and 
purified by affinity chromatography. The preparation consisted of a single protein of 
the expected size of approximately 30kDa, as assessed by coomassie blue stained 
SDS-PAGE, indicating a relatively pure preparation. Under non-denaturing 
conditions, the full-length adiponectin preparation was shown to consist primarily of 
protein of approximately 70kDa, corresponding to a trimer, with small amounts of 
protein around 115-150kDa thought to represent mid-molecular weight multimers. 
Globular adiponectin was also produced, and identified as a single band at 
approximately 60kDa, consistent with a trimer, when immunoblotted under non-
denaturing conditions. The purification procedure produced solutions sufficiently 
concentrated for physiological perfused rat hindlimb and in vivo experiments, 
containing approximately 1.7mg.mL-1 adiponectin. The full-length adiponectin was 
found to be biologically active, stimulating phosphorylation of eNOS in cultured 
endothelial cells. The protein profiles and biological activity shown here are similar to 
those reported in previous studies, indicating the protein produced was recombinant 
adiponectin. 
 
The adiponectin produced in this study was expressed in bacteria, a system in which 
post-translational modifications are limited. Consequently, multimerisation of this 
adiponectin species is typically limited to LMW species. As described above and in 
Chapter 1, HMW adiponectin is likely to have a different range of actions to the LMW 
form. There is evidence that post-translational modifications may have additional 
roles unrelated to multimerisation, including a study using adiponectin containing a 
mutation of the cysteine residue required for disulphide bond formation. That protein 
more potently stimulated phosphorylation of AMPK and ACC in cultured myocytes 
than the wild-type recombinant protein expressed in bacteria, despite also being 
limited to a trimer (Waki et al., 2003). Thus, the findings of investigations using the 
current adiponectin preparation can not be extrapolated to other forms of adiponectin. 
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It might be argued that the presence of a modified N-terminus could affect activity. 
However, preliminary experiments in cultured bovine aortic endothelial cells 
demonstrated dose-dependent stimulation of eNOS phosphorylation by the full-length 
adiponectin preparation, similar to that previously described (Hattori et al., 2003; 
Cheng et al., 2007). These positive results suggest that the tag was not significantly 
affecting the activity of the protein. Additionally, recombinant adiponectin with a 
similar attached N-terminal histidine tag was used in a study by Yamauchi et al. 
(2001), where adiponectin was found to ameliorate insulin resistance. These data 
suggest that removal of the tag is not required.  
 
The recombinant adiponectin was cloned from murine cells, although it is intended for 
physiological experiments in rats. However, adiponectin protein sequences are highly 
conserved between species; the rat and mouse proteins are 91% conserved, and there 
is 83% similarity between mouse and human adiponectin (Nakano et al., 1996). Most 
of the variation is within the N-terminal variable region, with the active globular 
domain and cysteine residues crucial for multimer formation particularly conserved 
(Tsao et al., 2003). Many other studies have used divergent adiponectin preparations 
and test systems. Tomas et al. (2002) similarly used mouse adiponectin in isolated rat 
muscles to show increased fat oxidation and glucose uptake. In their study on 
adiponectin-mediated diminution of serotonin constriction, Fesus et al. (2007) used 
recombinant human adiponectin in rat aortic rings. Due to the high level of 
conservation of adiponectin proteins, the use of adiponectin from a different species 
should not affect experimental outcomes. 
 
Any number of bacterial contaminants could potentially have persisted throughout the 
purification process. The discrepancy between the adiponectin and total protein 
estimates potentially suggests the presence of contaminating bacterial proteins. 
Proteins rich in histidine residues are particularly likely to be present in the final 
elution from the affinity column. Non-protein contaminants, including the endotoxin 
lipopolysaccharide, may also be present in the purified protein preparations. The 
presence of any bacterial contaminants may affect the results of physiological 
investigations. However, use of the vehicle control preparation should account for 
effects of the preparations that are not specific to adiponectin. 
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The aim of this series of experiments was to produce purified, biologically active 
recombinant adiponectin. The data shown here demonstrates that the adiponectin 
produced is of sufficient purity, quantity and structural integrity. The recombinant 
adiponectin displayed biological activity, to stimulate phosphorylation of eNOS, 
similar to previous reports. Thus it was concluded that these recombinant adiponectin 
preparations were suitable for use in physiological experiments.  
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CHAPTER 3 – ADIPONECTIN OPPOSES ENDOTHELIN-1-
MEDIATED VASOCONSTRICTION IN THE 
PERFUSED RAT HINDLIMB. 
 
 
3.1 Introduction 
 
Previous studies in cultured cells and isolated vessels suggest that adiponectin is 
vasoactive. However, there has been little information as to whether this translates to 
any effects in an intact vascular system. The constant-flow pump-perfused rat 
hindlimb has been widely used to investigate skeletal muscle blood flow. This 
preparation consists of 95% skeletal muscle (Ruderman et al., 1971), a tissue which 
accounts for over 85% of insulin-mediated glucose uptake (DeFronzo et al., 1985). 
The perfused hindlimb also has the benefit of being devoid of circulating endogenous 
vasoactive factors and neural input, thus allowing experimental conditions to be 
tightly controlled. Therefore, the preparation allows for the acute examination of the 
direct effects of a physiological concentration of adiponectin, rather than augmenting 
endogenous levels. However, the perfused rat hindlimb is largely dilated under basal 
conditions, due its denervated state and the absence of endogenous regulatory factors. 
This means that dilatory responses are generally not apparent under basal conditions. 
For instance, insulin infusion alone causes no change in perfusion pressure in this 
system, despite its well described vasodilator actions in vivo (Clark et al., 2003). The 
only reported hemodynamic effects of insulin in this preparation to date have been its 
ability to block endothelin-1 (ET-1)-mediated vasoconstriction (Kolka et al., 2005) 
and a mild vasodilator response against norepinephrine (NE; Kolka et al., 2005; 
Rattigan et al., 1995). Thus, in this system, adiponectin-mediated vasodilation may 
only be detectable in the presence of vasoconstriction. Insulin-mediated vasodilation 
in the perfused hindlimb is primarily detectable during vasoconstriction due to ET-1, 
and the hemodynamic actions of adiponectin are hypothesised to be similar to those of 
insulin. Therefore, it is most likely that adiponectin-mediated vasodilation will be 
observed in the presence of ET-1-mediated vasoconstriction. 
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The endothelin family consists of three 21 amino acid peptides, with ET-1 considered 
the main isoform involved in the cardiovascular system (Plusczyk et al., 2001; Levin, 
1995). ET-1 is one of the most potent known vasoconstrictors, with a slow developing 
but sustained effect (Yanagisawa et al., 1988). ET-1 is secreted abluminally by 
endothelial cells (Yoshimoto et al., 1991) and elicits vasoconstriction predominantly 
via type A endothelin (ETA) receptors situated on vascular smooth muscle cells 
(D'Orléans-Juste et al., 1993; Maguire & Davenport, 1995). Circulating levels of ET-1 
are increased in obese and type 2 diabetic subjects (Cardillo et al., 2002; Ferri et al., 
1995; Takahashi et al., 1990), and elevated plasma ET-1 is implicated in the 
development of hypertension and cardiovascular disease (Rich & McLaughlin, 2003; 
Shichiri et al., 1990). It has been proposed that chronically elevated ET-1 leads to 
desensitisation of the insulin signalling pathway (Ishibashi et al., 2001), and Wilkes et 
al. (2003) found that both acute and chronic infusion of ET-1 results in 
hyperinsulinemia and insulin resistance in vivo. Increased ET-1 in obesity and type 2 
diabetes contributes to the endothelial dysfunction seen in these states, as defined by a 
reduced endothelium-dependent vasodilator response (Mather et al., 2002). Inhibition 
of ET-1 activity via blockade of type A endothelin (ETA) receptors restored NO-
mediated endothelial function in apolipoprotein E-deficient mice (Barton et al., 1998). 
ET-1 has also been shown to block the hemodynamic actions of insulin in vivo, along 
with the associated insulin-mediated glucose uptake (Ross et al., 2007). Additionally, 
Shemyakin et al. (2010) have recently suggested that ET-1 may impair glucose uptake 
via a direct action on skeletal muscle cells. This bulk of evidence illustrates the 
multitude of detrimental effects resulting from uncontrolled ET-1 activity. 
 
Adiponectin has been demonstrated to suppress ET-1-induced cellular hypertrophy in 
cultured cardiomyocytes (Fujioka et al., 2006). I hypothesised that adiponectin may 
similarly be able to inhibit vasoconstriction caused by ET-1, via a NO-dependent 
vasodilator activity. Therefore, the aim of this study was to investigate the vascular 
actions of adiponectin in a perfused muscle system. After determining the effect of 
adiponectin alone on the vasculature, I investigated its effects on ET-1-mediated 
vasoconstriction. In the perfused hindlimb, at low doses ET-1 stimulates metabolism 
(Type A vasoconstriction) while high doses lead to metabolic inhibition (Type B 
vasoconstriction; Kolka et al., 2005). These two different types of vasoconstriction are 
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thought to be the result of constriction occurring at different locations in the vascular 
tree, and thus affecting the extent of skeletal muscle perfusion (for review see Clark et 
al., 1995). I then examined the action of adiponectin against low dose NE, a 
vasoconstrictor with similar dose-dependent metabolic actions to ET-1 in the perfused 
hindlimb (Dora et al., 1992; Kolka et al., 2005), to assess the specificity of any 
vascular action of adiponectin. I found that adiponectin specifically inhibits ET-1-
mediated vasoconstriction by an apparently NO-independent mechanism. 
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3.2 Materials and Methods 
 
3.2.1 Animals 
All experiments were approved by the University of Tasmania Animal Ethics 
Committee and were performed in accordance with the guidelines set out under the 
NHMRC Code of Practice for the care and use of animals for scientific purposes 
seventh edition (2004). Male Hooded Wistar Rats (n=105) were housed at 21±1°C 
under a 12h light/dark cycle. Rats were provided with rat chow (Gibson’s, Hobart, 
TAS, Australia), containing 21.4% protein, 4.6% lipid, 68% carbohydrate and 6% 
crude fibre by weight, with added vitamins and minerals, and water ad libitum. 
 
3.2.2 Perfused rat hindlimb 
3.2.2.1 Perfusion Buffer 
Krebs-Henseleit bicarbonate buffer (118mM NaCl, 4.7mM KCl, 1.2mM KH2PO4, 
1.2mM MgSO4, 25mM NaHCO3) was supplemented with 8.3mM glucose and 4% 
(w/v) bovine serum albumin. This was passed through a 0.45μm filter under pressure 
and stored at -20°C for up to six months. Before use, the buffer was equilibrated at 
32°C and gassed with 95% O2: 5% CO2 for 30min before the addition of 2.54mM 
CaCl2, to avoid precipitation of calcium salts. 
 
3.2.2.2 Surgery 
Surgery was conducted on male 180-200g rats to isolate blood flow to a single 
hindlimb (Figure 3.1).  The surgical procedures were essentially as described 
previously (Ruderman et al., 1971), with additional details as outlined elsewhere 
(Colquhoun et al., 1988).  
 
Animals were anaesthetised with an intraperitoneal injection of pentobarbital sodium 
(50mg.kg-1 body weight; Ilium Veterinary Laboratories, Smithfield, NSW, Australia) 
and allowed to freely breathe room air. String ligatures were positioned around the 
tarsus of the experimental leg and the base of the tail to restrict blood flow. A ventral 
incision was made along the midline, through the skin and body wall. The inferior and  
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superior epigastric arteries were ligated to allow removal of the body wall and greater 
access to the body cavity. The superficial epigastric artery of the experimental leg was 
ligated adjacent to the femoral vessels to restrict flow to the skin of the hindlimb. The 
testes were tied off and removed, and a single ligature was placed around the bladder 
and seminal vesicles and the seminal vesicles were removed. Two ties were placed 
around the lower descending colon approximately 1cm apart, and the colon was cut 
between these ties. A further tie was placed around the duodenum and the superior 
mesenteric artery just below the stomach, and the gastrointestinal tract was removed. 
The connective tissue was gently separated, allowing the ureter, internal spermatic 
vessels and iliolumbar vessels on both sides to be tied off together. The common iliac 
artery supplying the contra-lateral hindlimb was also ligated, as only one hindlimb 
was perfused. 
 
Figure 3.1: Perfused rat hindlimb surgery. Surgery details are given in section 3.2.2.2. 
Depicted is the ventral view of the rat, showing vessel ligation and cannulation performed to 
isolate blood flow to a single hindlimb (Adapted from Ross, 1972 and Greene, 1968). 
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The inferior vena cava and descending aorta were separated and two silk threads were 
loosely positioned around each one between the origins of the renal and iliolumbar 
vessels. Heparin (200IU in 200μL) was injected into the vena cava above the renal 
vessel. The vena cava was ligated below the renal vessel and an 18G, 1¼ inch Surflo® 
cannula (Terumo, Elkton, MD, USA) was inserted and secured in place with the lower 
tie. The aorta was cannulated in the same manner, using a small cut with fine scissors 
and a needle threader to facilitate insertion of a 20G, 1¼ inch Surflo® cannula 
(Terumo, Elkton, MD, USA). The cannulae were connected to the perfusion line to 
provide perfusion buffer to the hindlimb. Once the hindlimb was connected to the 
perfusion network, the animal was sacrificed with an intracardiac overdose of 
pentobarbital sodium. Denervation occurs through loss of central nervous system 
function following sacrifice. A further string ligature was positioned around the 
abdomen at approximately the level of the L3 vertebra to impede extraneous flow. The 
entire procedure was completed within 30min, with care taken to ensure perfusion of 
the experimental hindlimb was interrupted for no more than 2min.  
 
3.2.2.3 Perfusion apparatus 
Hindlimbs were perfused in a non-recirculating manner with perfusion buffer, using a 
Masterflex® peristaltic pump (Cole-Parmer, Vernon Hills, IL, USA) to ensure a 
constant flow rate of 5mL.min-1. The perfusate was gassed with 95% O2: 5% CO2 in a 
silastic tube oxygenator. Experiments were conducted at 32°C in a temperature 
controlled cabinet, with the buffer temperature maintained by passage through a 
water-jacketed heat exchange coil. Test substances were infused into a small 
magnetically stirred bubble trap located in the arterial perfusion line via a 
programmable syringe pump (World Precision Instruments, Sarasota, FL, USA). 
Perfusion pressure was constantly monitored via a pressure transducer located in the 
arterial line. Venous effluent oxygen content was measured using a 0.5mL flow-
through Clark-type oxygen electrode assembly, also maintained at 32°C. The venous 
effluent was periodically sampled and the remainder discarded. Perfusion pressure and 
oxygen content was continually recorded using WinDaq data acquisition software 
(Dataq Instruments, Akron, OH, USA). This apparatus is depicted in Figure 3.2. 
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3.2.2.4 Perfusion protocols 
The hindlimb was allowed to equilibrate for 30-40min in order to reach a steady-state 
before any experimental protocols were commenced. Venous effluent was sampled for 
glucose and lactate determinations every five minutes. All test substances were  
dissolved in 0.9% NaCl before infusion. Insulin (Humulin R; Eli Lilly, Indianapolis, 
IN, USA) was diluted 1:200 in saline and infused at 25μL.min-1, to provide 15nM to 
the hindlimb. ET-1 (Calbiochem, San Diego, CA, USA) was dissolved in acetic acid 
and made up to volume in saline. NE (Arterenol) was obtained from Sigma-Aldrich 
(St. Louis, MO, USA). Vasoconstrictors were infused at 25μL.min-1, 1/200th of the 
pump flow rate, providing final concentrations of 1nM or 20nM ET-1 and 50nM NE. 
Adiponectin solutions were diluted to 0.65mg.mL-1 in saline and infused at 50μL.min-
1, equivalent to 1/100th of the pump flow rate, to give a final concentration of 
6.5μg.mL-1. This dose was selected to mimic normal circulating levels of adiponectin 
in rats, approximately 6μg.mL-1 under normal conditions (Satoh et al., 2005).  
Globular adiponectin was diluted to 0.46mg.mL-1 in saline and infused in the same 
way as the full-length form to provide an equimolar final concentration. The vehicle 
 
Figure 3.2: Apparatus for the non-recirculating constant flow, pump-perfused rat 
hindlimb. The apparatus is described in section 3.2.2.3. (Taken from Kolka, 2006). 
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solutions were diluted to the same extent as the adiponectin solutions, so that the 
amount of contaminants, but not total protein content, remained consistent. Individual 
protocols are shown in Figure 3.3.  
 
Figure 3.3: Perfusion protocols. Horizontal bars represent infusion of test substances;  
designates collection of venous effluent samples for determination of glucose and lactate; 
ET-1: endothelin-1; NE: norepinephrine. 
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3.2.2.5 Measurement of glucose and lactate 
Glucose and lactate determinations were made using a glucose analyser (Model 2300 
Stat Plus, Yellow Springs Instruments), and hindlimb uptake or release data 
respectively were derived from the product of flow, arterio-venous (A-V) 
concentration difference and perfused muscle mass.  
 
3.2.2.6 Calculation of oxygen consumption 
The oxygen electrode was calibrated with air and oxygen, and the oxygen content of 
the arterial perfusion buffer was measured before and after each experiment.  
 
Muscle oxygen consumption was calculated using the Fick principle: 
 
VO2 =  x (PaO2 – PvO2) x (flow/1000) x 60 
muscle weight (g) 
 
* Where  = calculated from the Bunsen coefficient 
  =  / (22.4 x 760) 
    = 0.0230mL.L-1 / (22.4mM x 760mmHg) 
    = 1.351μmol.L-1.mmHg 
 ( = the volume (mL) of oxygen dissolved per mL of plasma at 0°C and 
 760mmHg.  is 0.0230 in plasma at 32°C.) 
 
* Where PaO2 = arterial PO2 using the arterial oxygen measurement and the air and 
oxygen calibrations from the oxygen electrode, and using their known PO2. 
 
 PaO2 =     Art – cal Air      x (PO2 at 100% - PO2 in Air) + PO2 in Air 
   cal 100%O2 - cal Air 
 
 where: Art = electrode arterial measurement 
  cal Air = electrode air calibration 
  cal 100%O2 = electrode oxygen calibration 
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  PO2 at 100% = 760mmHg – 36mmHg (H2O vapour pressure at 32°C, 
      due to the use of a wet oxygen electrode) 
             = 724mmHg 
  PO2 in Air = 154mmHg 
 
* Where PvO2 = venous PO2 calculated the same as the PaO2, however the value for 
Art was replaced by the value measured in the venous effluent. 
 
* Where flow = perfusion flow rate in mL.min-1 
 
* Where muscle weight = total perfused muscle mass, which has previously been 
determined to be 8.3% of the body weight for a single perfused hindlimb (Richter et 
al., 1982). 
 
3.2.3 Statistics 
Two-way repeated measures ANOVA was performed using SigmaStat (SPSS Science, 
Chicago, IL, USA). Reversal of ET-1 effects (section 3.3.2.3) was assessed using a 
one way ANOVA. Differences between conditions were assessed using the Student-
Neuman-Keuls post hoc test. Significance was assumed at the level of p<0.05. Data 
are presented as means ± standard error; if error bars are not visible, they are within 
the symbol. 
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3.3 Results 
 
3.3.1 Hemodynamic and metabolic actions of full-length adiponectin  
Under basal conditions at a flow rate of 5mL.min-1, average measurements were 
perfusion pressure: 28.7±3.3mmHg, oxygen uptake: 10.6±1.2μmol.g-1.h-1, glucose 
uptake: 9.0±1.0μmol.g-1.h-1, and lactate release: 20.6±2.4μmol.g-1.h-1 (n=74). Infusion 
of full-length adiponectin alone did not elicit any change in perfusion pressure, 
indicating that full-length adiponectin does not have any hemodynamic effects under 
basal conditions, in the absence of endogenous vasoconstriction (Figure 3.4A). Full-
length adiponectin caused a significant stimulation of hindlimb glucose uptake 
(p<0.05), although this effect was much smaller than that seen with insulin 
(adiponectin 1.58±0.21 vs. insulin 2.47±0.12 fold increase from basal; p<0.01; Figure 
3.4C). Glucose uptake levels returned to basal within 5min of the full-length 
adiponectin infusion ceasing, indicating that this is a relatively rapid and reversible  
Figure 3.4. Effect of adiponectin or insulin on (A) perfusion pressure, (B) oxygen uptake, (C) 
glucose uptake and (D) lactate release. Substances were infused at the times indicated according to 
Figure 3.3A. Data are normalised to t=0min according to Figure 3.3A. * Significantly different 
from saline (p<0.05; n=9-10 except insulin n=3). 
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effect (data not shown). Despite the observed increase in glucose uptake during full-
length adiponectin infusion, there was no concomitant increase in lactate release, 
unlike that seen with insulin treatment, suggesting that the transported glucose is 
either oxidised or stored as glycogen (Figure 3.4D). Additionally, no significant 
adiponectin-induced change in oxygen consumption was seen under basal conditions 
(Figure 3.4B). 
 
3.3.2 Effect of adiponectin on the hemodynamic and metabolic effects of 
endothelin-1 
3.3.2.1 Adiponectin opposes vasoconstriction caused by low dose endothelin-1 
Low-dose ET-1 (1nM) significantly increased perfusion pressure within 10min of 
administration, with an increase of 29.3±4.4mmHg following a 40min infusion 
(p<0.001; Figure 3.5A). The increased perfusion pressure was accompanied by the 
enhanced metabolism typical of Type A vasoconstrictors (Clark et al., 1995), 
indicated by increases in oxygen consumption (1.3±0.2μmol.g-1.h-1), glucose uptake 
 
Figure 3.5: Effect of adiponectin on ET-1-mediated changes in (A) perfusion pressure, (B) 
oxygen uptake, (C) glucose uptake and (D) lactate release. Substances were infused at the 
times indicated according to Figure 3.3B. Data are normalised to t=0min. * Significantly 
different from all other groups and # significantly different from ET-1 alone (p<0.05; n=8-
10).  
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(7.4±0.9μmol.g-1.h-1), and lactate release (15.8±2.7μmol.g-1.h-1) after 40min, similar to 
the effects that have previously been reported (Kolka et al., 2005). Pre-treatment and 
co-infusion with physiological levels of full-length adiponectin led to a significant 
attenuation of ET-1-mediated vasoconstriction from 15min after ET-1 infusion 
commenced until the end of the protocol (Figure 3.5A). Perfusion pressure was 
increased only by 14.3±2.1mmHg representing a 51% reduction compared to ET-1 
alone (p<0.001). In conjunction, the associated metabolic stimulation was also 
diminished, with the increases in oxygen consumption, glucose uptake and lactate 
release blunted by 44% (0.7±0.1μmol.g-1.h-1), 57% (3.2±0.6μmol.g-1.h-1) and 36% 
(10.0±1.9μmol.g-1.h-1) respectively (Figure 3.5). The attenuated response to ET-1 was 
maintained after adiponectin co-infusion ceased, and indeed the differences between 
the two groups continued to increase for the duration of the experiment, indicating that 
the vascular actions of adiponectin are not rapidly reversible. A vehicle preparation, 
isolated by the same process used for adiponectin, but from untransformed bacteria, 
had no effect on the any of the actions of ET-1 measured (Figure 3.6) indicating that 
the observed effects were specific to adiponectin and not the result of nonspecific 
contaminants. 
  
The effect of a preparation of the truncated, globular form of adiponectin on ET-1-
mediated vasoconstriction was evaluated to determine whether globular adiponectin 
acts more potently than the full-length trimer in the skeletal muscle vasculature. ET-1-
mediated perfusion pressure development was reduced by 49% by pre-treatment and 
co-infusion of globular adiponectin (11.2±1.7mmHg vs. 21.7±1.0mmHg with ET-1 
alone; Figure 3.7A). Similarly, globular adiponectin decreased ET-1-stimulated 
oxygen consumption by 58% (0.6±0.4μmol.g-1.h-1 vs. 1.6±0.1μmol.g-1.h-1 with ET-1 
alone; Figure 3.7B). ET-1-mediated lactate release was abolished by infusion of 
globular adiponectin, with lactate maintained at basal levels over 40min of ET-1 
infusion (2.2±0.9μmol.g-1.h-1 vs. 13.1±0.3μmol.g-1.h-1 with ET-1 alone; p<0.001). 
Globular adiponectin did not affect the glucose uptake stimulated by ET-1 
(8.1±3.6μmol.g-1.h-1 vs. 9.7±3.2μmol.g-1.h-1 with ET-1 alone at t=50min; NS). The 
lack of an inhibitory effect of globular adiponectin on ET-1-mediated glucose uptake 
may be due to confounding with an effect of globular adiponectin itself on glucose 
uptake. These data showed that the globular adiponectin was not markedly more  
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potent, but had similar vascular effects to the full-length protein, with both 
preparations approximately halving the ET-1 response. Therefore, globular and LMW 
Figure 3.7: Effect of 4.6μg.mL-1 globular adiponectin on ET-1-mediated changes in (A) 
perfusion pressure and (B) oxygen uptake at t=50min. Substances were infused at the times 
indicated according to Figure 3.3B. Data are normalised to t=0min.  Glob: globular 
adiponectin. * Significantly different from all other groups and # significantly different from 
ET-1 alone (p<0.05; n=3 except saline n=10).  
Figure 3.6: Effect of vehicle on ET-1-mediated changes in (A) perfusion pressure, (B) 
oxygen uptake, (C) glucose uptake at t=50min and (D) lactate release at t=50min. Substances 
were infused at the times indicated according to Figure 3.3B. Data are normalised to t=0min. 
Veh: Vehicle. * Significantly different from all other groups and # significantly different 
from ET-1 alone (p<0.05; n=8-10 except vehicle n=3).  
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adiponectin have comparable vascular activity. All further investigations were thus 
conducted using only the full-length adiponectin preparation. 
 
3.3.2.2 Adiponectin is ineffective against established endothelin-1-mediated 
vasoconstriction 
I next examined whether adiponectin was able to oppose established ET-1-mediated 
vasoconstriction. The previous experiments were repeated with the adiponectin 
infusion commencing 10min after commencement of ET-1 infusion. Once ET-1 
vasoconstriction had developed, a physiological dose of adiponectin was unable to 
attenuate the increase in perfusion pressure or the associated stimulation of oxygen 
uptake (Figure 3.8). Similarly, there was no significant difference in glucose uptake 
between rats treated with adiponectin and those without, with an increase of 
5.5±1.2μmol.g-1.h-1 following co-infusion compared to 4.8±0.8μmol.g-1.h-1 after 
40min of ET-1 alone (NS). Adiponectin did cause a small but significant diminution 
in lactate release by the end of the experiment, reducing it to 11.6±1.4μmol.g-1.h-1 
compared to 15.6±2.4μmol.g-1.h-1 after ET-1 infusion alone (p<0.05). 
 
3.3.2.3 Low-dose endothelin-1 vasoconstriction is reversible 
The inability of adiponectin to oppose ET-1-mediated vasoconstriction once it was 
established suggested that adiponectin was interfering in ET-1 signalling, and not 
directly binding ET-1. However, ET-1-mediated vasoconstriction is long-lasting, with 
one study showing that human forearm blood flow did not fully recover until 120min 
after cessation of a 60min infusion of ET-1 (Clarke et al., 1989). Therefore,  
Figure 3.8: Effect of adiponectin on ET-1-mediated changes in (A) perfusion pressure and 
(B) oxygen uptake at t=40min. Substances were infused at the times indicated according to 
Figure 3.3C. Data are normalised to t=0min. Ad: Adiponectin. * Significantly different from 
all other groups (p<0.05; n=7-10).  
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adiponectin-mediated reversal of ET-1 vasoconstriction may not be observable with 
the current 30min infusion. To address this, I determined the reversibility of ET-1-
mediated vasoconstriction in the perfused rat hindlimb. A 40min infusion of ET-1  
alone was undertaken as in the previous experiments, and at the end of this period the 
ET-1 infusion was stopped while monitoring continued for a further 20min. Twenty 
minutes after the ET-1 infusion was stopped, the perfusion pressure had decreased 
45% from the peak ET-1-mediated increase in perfusion pressure (change 
9.0±2.7mmHg at 60min vs. 16.3±1.1mmHg at 40min; p<0.05; Figure 3.9). There was 
also a trend for reduced lactate release 20min post ET-1 infusion, with a decrease of 
57% from the peak (change 6.0±1.7μmol.g-1.h-1 at 60min vs. 13.8±3.1μmol.g-1.h-1 at 
40min; p=0.074). However, 20min after the ET-1 infusion ceased, there was no 
apparent change in either oxygen uptake (change 0.8±0.3μmol.g-1.h-1 at 60min vs. 
0.9±0.3μmol.g-1.h-1 at 40min) or glucose uptake (change 3.5±3.1μmol.g-1.h-1 at 60min 
vs. 4.3±2.6mol.g-1.h-1 at 40min), indicating that these effects of ET-1 are more 
sustained. Whilst the effects of ET-1 are far more sustained than most other 
vasoconstrictors, many of which reverse within 5min of infusion withdrawal, ET-1-
mediated vasoconstriction is diminished 10-20min after it is removed. Thus, if 
adiponectin were effective at reducing established ET-1-mediated vasoconstriction, 
this should be observable within the 30min adiponectin infusion used in the present 
study. 
 
Figure 3.9: ET-1-induced perfusion pressure is rapidly reversed upon cessation of ET-1 
infusion. ET-1 was infused over the time indicated. (n=2).
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3.3.2.4 Adiponectin is unable to oppose high dose endothelin-1 
The biphasic dose-response to ET-1 that has previously been reported was again 
demonstrated (Kolka et al., 2005). However, the high ET-1 dose (10nM) used 
previously was not sufficient to produce net metabolic inhibition in any of the 
parameters measured at the lower flow rate used in the current study. Therefore, the 
ET-1 dose was increased to 20nM to produce a type B vasoconstrictor response. 
A 20nM ET-1 infusion elicited a marked increase in perfusion pressure of 
185.8±13.7mmHg (p<0.001; Figure 3.10A), but unlike the 1nM ET-1 response, the 
high dose caused a transient metabolic stimulation, before shifting towards an 
inhibition of metabolism. After a 40min infusion of high-dose ET-1, oxygen 
consumption was significantly inhibited compared to basal, with a net decrease in 
oxygen uptake of 2.9±0.7μmol.g-1.h-1 (p<0.001; Figure 3.10B). Glucose uptake and 
lactate release showed a similar trend, with significant (p<0.001) increases of 
10.6±0.8μmol.g-1.h-1 and 40.2±3.0μmol.g-1.h-1 respectively after 10min of ET-1 
infusion, and a return to near basal levels by 40min (Figure 3.10). Thus, high doses of 
ET-1 were again seen to display a Type B vasoconstrictor response with an overall 
 
Figure 3.10: Effect of adiponectin on high-dose ET-1-mediated changes in (A) perfusion 
pressure, (B) oxygen uptake, (C) glucose uptake and (D) lactate release. Substances were 
infused at the times indicated according to Figure 3.3B. Data are normalised to t=0min. * 
Significantly different from all other groups and # significantly different from ET-1 alone 
(p<0.05; n=6-10).  
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metabolic inhibition (Clark et al., 1995).  There was no overall significant difference 
in any of the parameters measured between rats treated with 20nM ET-1 alone or in 
conjunction with adiponectin. Therefore, physiological adiponectin was unable to 
overcome the effects of high-dose ET-1-mediated vasoconstriction (Figure 3.10).  
 
3.3.3 Adiponectin does not effect the hemodynamic and metabolic actions of 
norepinephrine 
Infusion of low dose NE caused rapid vasoconstriction, demonstrated by an increase 
in perfusion pressure of 13.0mmHg after 5min (p<0.001; Figure 3.11A). A low NE 
dose was used to stimulate Type A vasoconstriction (Clark et al., 1995), similar to that 
observed with low-dose ET-1. Enhanced metabolism was demonstrated by a 
significant increase in oxygen consumption of 1.7±0.2μmol.g-1.h-1 after 40min of 
treatment (p<0.001 vs. saline; Figure 3.11B). Glucose uptake and lactate release were 
similarly stimulated, with maximal increases of 5.8±0.9μmol.g-1.h-1 and 
8.2±1.4μmol.g-1.h-1 respectively after 5min of NE infusion (p<0.001 vs. saline). Pre-
treatment and co-infusion with adiponectin, using the same protocol as the original 
ET-1 experiments, had no effect on any measure of NE action under these conditions 
(Figure 3.11). 
 
 
Figure 3.11: Effect of adiponectin on NE-mediated changes in (A) perfusion pressure and 
(B) oxygen uptake. Substances were infused at the times indicated according to Figure 3.3D. 
Data are normalised to t=0min. * Significantly different from all other groups (p<0.05; n=8-
10).  
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3.4 Discussion 
 
This study demonstrated that adiponectin is vasoactive in an intact perfused muscle 
system, with the ability to restrict ET-1-mediated vasoconstriction. Adiponectin alone, 
however, had no observable hemodynamic actions in this system. Adiponectin was 
unable to overcome vasoconstriction due to ET-1 once it had developed, or that 
caused by high doses of ET-1. Additionally, under the same conditions, adiponectin 
infusion had no effect on NE-induced vasoconstriction, suggesting adiponectin does 
not act as a general vasodilator. 
 
The attenuation of ET-1 action by adiponectin observed in this study appears to be due 
to a specific action of adiponectin on ET-1-mediated vasoconstriction and its 
associated metabolic effects. Full-length LMW adiponectin and globular adiponectin 
were shown to have similar effects on ET-1 action. No hemodynamic changes were 
observed during the infusion of adiponectin alone, as is the case with insulin. 
Additionally, in both previous reports of insulin attenuating vasoconstriction it was 
found to be ineffective once vasoconstriction is established (Kolka et al., 2005; 
Rattigan et al., 1995). Thus, the effects of adiponectin reported here appear to be 
similar to those previously described for insulin, which does not have a general 
vasodilatory activity against all vasoconstrictors in the perfused rat hindlimb. Given 
the reported insulin sensitising effects of adiponectin, there is also potential for greater 
inhibition of ET-1 in the presence of insulin, and such a relationship warrants further 
investigation.  Adiponectin was unable to overcome vasoconstriction due to high-dose 
ET-1, potentially suggesting an adiponectin resistance situation in hypertensive 
patients where ET-1 levels are elevated. However, it is unknown whether in vivo ET-1 
reaches the levels I have used in the perfused hindlimb, with the doses used in this 
study several orders of magnitude higher than reported ET-1 plasma concentrations 
(Shichiri et al., 1990; Takahashi et al., 1990). However, the local nature of ET-1 
production means that the possibility of localised high concentrations cannot be 
excluded. 
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The inability of adiponectin to moderate the actions of ET-1 when introduced after 
vasoconstriction is established suggests that adiponectin may not, in fact, be acting as 
a NO-dependent vasodilator as hypothesised. Such a general vasodilatory action 
would be expected to reduce vasoconstriction regardless of prior pressure 
development, given that ET-1 vasoconstriction was reversible within the timeframe 
used. In contrast to adiponectin, SNP, a direct NO donor, is able to rapidly reduce 
perfusion pressure when administered during ET-1-mediated vasoconstriction (Kolka, 
2006). Chen et al. (2003) studied adiponectin-mediated NO production in endothelial 
cells and found that this effect was rapid, reaching its peak within a few minutes of 
exposure to adiponectin. This suggests that were adiponectin-mediated inhibition of 
ET-1 occurring via endothelial NO release, it would be a rapid effect and thus not 
require pre-treatment as demonstrated in the present study. The finding that 
adiponectin did not diminish NE-mediated vasoconstriction, while the endothelial 
NO-dependent dilators UTP and ATP both rapidly dilate against NE (Richards et al., 
1993), further points to a NO-independent process. In fact, there is a precedent for this 
in a recent study by Fesus et al. (2007), who reported adiponectin-mediated relaxation 
of de-endotheliated rat aortic rings pre-constricted with serotonin. Additionally, 
insulin has been shown to have dual actions, the well characterised NO-dependent 
effect, but also a direct effect on smooth muscle to reduce agonist-induced increases in 
intracellular calcium concentration ([Ca2+]i; Han et al., 1995). This further supports 
the possibility of a NO-independent mechanism of adiponectin action, as well as 
providing a potential explanation for the specific relationship both insulin and 
adiponectin have with ET-1. Adiponectin-mediated inhibition of ET-1-mediated 
vasoconstriction is maintained after adiponectin is removed from this constant flow-
through system, whilst the ET-1 supply remains. Additionally, adiponectin was unable 
to reverse ET-1-mediated vasoconstriction once it was established, although the 
vasoconstriction was demonstrated to be reversible. Therefore, attenuation of ET-1 
action by adiponectin is unlikely to be due to either direct binding of adiponectin to 
ET-1 or adiponectin interfering with the interaction between ET-1 and its ETA 
receptor. Thus, it is possible that the hemodynamic effects of adiponectin described 
here may be due to a specific inhibitory action on the ET-1 signalling pathway in 
vascular smooth muscle cells.  
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Endothelin-1 binds to the G-protein coupled ETA receptor on vascular smooth muscle 
cells (VSMC), stimulating the production of inositol trisphosphate (IP3), which in turn 
stimulates the release of calcium (Ca2+) from the sarcoplasmic reticulum (SR), causing 
a transient peak in [Ca2+]i  (Pollock et al., 1995). ET-1 can sustain this increase in 
[Ca2+]i by stimulating extracellular Ca2+ entry via non-selective cation channels and 
store-operated Ca2+ channels (Furutani et al., 2002). Raised [Ca2+]i causes contraction 
of VSMC, resulting in vasoconstriction. NE elicits vasoconstriction via similar 
mechanisms, probably involving both IP3-dependent mobilisation of Ca2+ from SR 
and Ca2+ entry via L-type voltage-gated channels, followed by store-operated 
capacitative entry (Webb, 2003; Furutani et al., 2002). Therefore, the considerable 
overlap between the ET-1 and NE contractile pathways leaves few targets for the 
specific action of adiponectin, although differences in the ion channels activated for 
extracellular calcium entry, such as the L-type voltage-operated calcium channels 
reported to be activated by NE but not ET-1 (Furutani et al., 2002), may provide an 
avenue for investigation. Alternatively, the requirement for adiponectin to be present 
prior to ET-1 exposure suggests a mechanism early in the pathway; probably 
operating between the receptor and IP3 formation, before the signalling pathways of 
the two vasoconstrictors merge. It is tempting to hypothesise that by inhibiting the 
initial IP3-mediated Ca2+ release from SR, adiponectin may be able to prevent the 
sustained rise in [Ca2+]i and therefore block ET-1-mediated vasoconstriction.  
However, conflicting reports concerning whether blocking the peak [Ca2+]i response 
to ET-1 actually prevents the sustained increase in [Ca2+]i casts doubt on this theory 
(Thai et al., 2009; Wagner-Mann & Sturek, 1991). Bergdahl et al. (2003) found that 
cholesterol depletion in endothelium-denuded caudal arteries reduced contractility to 
ET-1 by disrupting the association between the ETA receptor and transient receptor 
potential channel 1 (TRPC1) within caveolae. The ET-1 response was affected 
following a 20 min pre-treatment with the cholesterol acceptor methyl-β-cyclodextrin 
(mβcd), but not when ET-1 and mβcd were added simultaneously (Bergdahl et al., 
2003). In addition, cholesterol depletion had no such effect on α1-receptor stimulation 
(Dreja et al., 2002), such as that elicited by NE. This profile closely matches the 
action of adiponectin described here and there is some evidence that adiponectin 
interferes with other aspects of cholesterol processing (Furukawa et al., 2004; 
Matsuura et al., 2007). This raises the possibility of cholesterol depletion as a 
mechanism for the adiponectin-mediated inhibition of ET-1 vasoconstriction. This 
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type of adiponectin action would be unlikely to fully block ET-1 action, as 
capacitative calcium entry may still occur, but this is also consistent with the 
observation of an approximate halving of the ET-1 response under the current 
conditions. However, such a proposal is highly speculative and further studies are 
needed to determine the mechanism via which adiponectin is able to modulate ET-1 
action.  
 
Several groups have proposed that the hemodynamic effects of insulin are regulated 
by the balance between the vasodilator and vasoconstrictor effects of NO and ET-1 
respectively (Cardillo et al., 1999b; Eringa et al., 2002; Verma et al., 2001). Thus, the 
ability of adiponectin to oppose ET-1-mediated vasoconstriction may be an important 
aspect of its insulin sensitising actions, leading to enhanced insulin action in muscle 
due to improved glucose and insulin supply to myocytes (Clark et al., 2003). In 
addition, the actions of ET-1 and NO have been reported to be mutually antagonistic, 
allowing any imbalance, such as those seen in obesity or insulin resistance, to be 
amplified (Mather et al., 2002). Mather et al. (2004) demonstrated that ETA receptor 
blockade increased the amount of bioavailable NO in obese, but not diabetic or lean, 
individuals. They explained this as being due to a dysregulation of the feedback 
system between ET-1 and NO and proposed that the increased activity of ET-1 in 
obesity is due to some feature of obesity itself, as it was not seen in the other subject 
groups (Mather et al., 2004). The hypoadiponectinemia present in obesity, and 
consequent reduction in the limiting effects of adiponectin on ET-1-mediated 
vasoconstriction, is a potential activator of this positive-feedback cycle. Progressive 
dysregulation of the relationship between ET-1 and NO may then contribute to the 
endothelial dysfunction observed in hypertension and type 2 diabetes (Mather et al., 
2004). Therefore, in the absence of adiponectin resistance, therapeutic targeting of 
adiponectin may redress the imbalance between ET-1 and NO in insulin resistance and 
hypertension, and improve disease outcomes in these states.  
 
In summary, this study has identified a specific activity of adiponectin to oppose the 
vasoconstrictor effects of ET-1 and its associated metabolic effects. The lack of such 
an effect once vasoconstriction is established or against NE indicates that adiponectin 
is unlikely to be acting via a NO-dependent mechanism. These findings suggest that 
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an interaction between adiponectin and ET-1 may contribute to the maintenance of 
normal vascular tone. Imbalance in this relationship in obesity may contribute to the 
development of insulin resistance and cardiovascular disease. 
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CHAPTER 4 – MODULATION OF ADIPONECTIN AND 
ENDOTHELIN-1 ACTION IN INSULIN 
RESISTANCE 
 
 
4.1 Introduction 
 
The preceding work demonstrated a novel action of adiponectin in an intact vascular 
system.  However, the actions of adiponectin may potentially be of more importance 
as insulin effects diminish. Intact adiponectin action in insulin resistance may provide 
a therapeutic target for improving insulin sensitivity. Conversely, impairments in 
adiponectin action may contribute to the pathological development of insulin 
resistance. 
 
Numerous studies have reported adiponectin-mediated insulin sensitisation, including 
alleviation of insulin resistance and diabetes by adiponectin replenishment (Yamauchi 
et al., 2001; Yamauchi et al., 2003). Similarly, Satoh et al. (2005) demonstrated 
adiponectin-mediated improvements in insulin-stimulated glucose infusion rate and 
glucose uptake in insulin resistant rats. Therefore, therapeutic targeting of adiponectin 
activity may be beneficial, particularly if these pathways remain functional in insulin 
resistance.  
 
Conversely, there have been reports that insulin resistant subjects also show resistance 
to the actions of adiponectin. Plasma adiponectin concentration increases with age, 
despite impaired insulin sensitivity and increasing hypertension, suggesting the 
adiponectin may be less effective (Iwashima et al., 2004). Attenuation of adiponectin 
action on glucose homeostasis, fatty acid oxidation and insulin sensitivity has been 
demonstrated in obese subjects, and genetic and diet-induced animal models of insulin 
resistance (Bruce et al., 2005; Lin et al., 2007; Mullen et al., 2007; Mullen et al., 
2009). This occurs independently of insulin resistance, as adiponectin resistance was 
observed in rats fed a high-unsaturated fat diet, which did not affect insulin sensitivity 
(Mullen et al., 2007). In a later study, Mullen et al. (2009) found that resistance to the 
effects of globular adiponectin on fatty acid oxidation occurred within 3 days of 
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feeding rats a high-fat diet. The adiponectin resistance preceded the development of 
increased lipid accumulation after 2 weeks of the diet, and impairments in insulin-
mediated glucose uptake, which were not recorded until 4 weeks of high-fat feeding 
(Mullen et al., 2009). In addition, based on their findings in a genetic model of insulin 
resistance, Lin et al. (2007) suggested that deterioration in adiponectin activity may 
contribute to the progression from insulin resistance to diabetes. These data suggest 
that adiponectin resistance may be a primary event independent of insulin resistance.  
 
Previous studies have investigated adiponectin action in high-fat fed animals. 
Yamauchi et al. (2001) showed that adiponectin is decreased following high-fat 
feeding in mice, and that chronic adiponectin administration improved insulin 
sensitivity and reduced the increase in adipose mass associated with high-fat feeding, 
despite a higher food intake. Meanwhile, adenoviral overexpression of adiponectin 
prevented high-fat feeding induced insulin resistance (Satoh et al., 2005). However, 
these studies have not examined adiponectin action acutely in insulin resistance, nor 
the effects of adiponectin in the vasculature. 
 
High-fat feeding may provide a better model of human insulin resistance than models 
based on genetic manipulation, as it more closely represents the events leading to 
insulin resistance in humans eating a westernised diet. Additionally, the high-fat fed 
rat is a model of insulin resistance early in the pathological progression, a stage which 
is thought to provide the best opportunity to improve insulin sensitivity and prevent 
the development of type 2 diabetes. Reports are mixed as to whether high-fat feeding 
increases body weight, possibly explained by variations between mice and rats and in 
the length of intervention, but consistently describe increased adiposity. High-fat 
feeding causes increased blood pressure, reduced endothelium-dependent vasodilation 
and insulin resistance, and these effects often occur in the absence of differences in 
food intake (Bourgoin et al., 2008; Guang-Yao et al., 2006; Henriksen et al., 2008; 
Noronha et al., 2005). In addition, high-fat fed rats exhibit impaired insulin-mediated 
microvascular perfusion (St-Pierre et al., 2010).  
 
The primary aim of this study was to determine whether the acute inhibitory action of 
adiponectin on ET-1-mediated vasoconstriction was retained in insulin resistant 
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animals. However, the vasoconstrictor response to ET-1 was found to be attenuated 
following high-fat feeding, leading to an examination of the interaction between ET-1 
and inducible nitric oxide synthase (iNOS) in insulin resistance. 
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4.2 Materials and Methods 
 
4.2.1 Animals 
All experiments were approved by the University of Tasmania Animal Ethics 
Committee and were performed in accordance with the guidelines set out under the 
NHMRC Code of Practice for the care and use of animals for scientific purposes 
seventh edition (2004). Male Sprague-Dawley Rats (n=74) were housed at 21±1°C 
under a 12h light/dark cycle, and provided with food and water ad libitum. Rats were 
obtained at 3-4 weeks of age and fed a high-fat diet (19.4% protein, 36% lipid, 35.2% 
carbohydrate, 9.4% crude fibre by weight; Specialty Feeds, Glen Forrest, WA, Aus) 
for 4 weeks. An age-matched control group was fed normal chow (22% protein, 9% 
lipid, 61.4% carbohydrate and 7.6% crude fibre by weight; Barastoc Stockfeed, 
Pakenham, VIC, Aus). The enriched fat content of this high-fat diet, with energy 
contribution from fat increased from 19% to 60%, is compensated for largely by a 
reduction in calories provided as carbohydrate (Table 4.1). 
 
4.2.2 Perfused rat hindlimb 
The constant flow, pump-perfused rat hindlimb procedure was conducted as described 
in Sections 3.2.2 and 3.2.3, with minor adjustments. Before removal of the testes, the 
epididymal fat pads were separated above the deferential artery and the combined wet 
weight was recorded. Immediately before the cannulas were inserted, 0.5mL of blood 
was collected intracardially and centrifuged to separate the erthrocytes from the 
plasma, which was stored at -20°C for later use in biochemical assays. 
Table 4.1: Relative energy contribution of macronutrients in the 
normal and high-fat diets. 
  Control Diet High-Fat Diet 
  % Calories % Calories 
Protein 21 14 
Total Fat 19 60 
Carbohydrate 60 26 
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N-(3-(Aminomethyl)benzyl)acetamidine (1400W) is a potent and selective inhibitor of 
the inducible isoform of NOS (iNOS), inhibiting 99% of iNOS activity (Garvey et al., 
1997). Garvey et al. (1997) showed that 1400W is 5000-fold more potent against 
iNOS than either eNOS or nNOS in vitro, and greater than 1000-fold more potent 
against rat iNOS than eNOS in isolated rat aortic rings. Additionally, inhibition of 
eNOS or nNOS by 1400W is rapidly reversible, compared to effectively irreversible 
iNOS inhibition (Garvey et al., 1997). In NOS inhibition experiments, 1400W or the 
general NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) (both from Sigma, 
St Louis, MO, USA) was added to the buffer reservoir to a final concentration of 
10μM. Thus, the hindlimb was exposed to the inhibitors throughout the equilibration 
period and for the duration of the experiment. ET-1 (Calbiochem, San Diego, CA, 
USA) was infused at 1/200th of the pump flow rate, providing final concentrations of 
1nM or 3nM to the hindlimb. All other details are as described in Section 3.2.3. 
Individual protocols are shown in Figure 4.1.  
 
 
Figure 4.1: Experimental protocols.  Horizontal bars represent infusion of test substances; 
 designates collection of venous effluent samples for determination of glucose and lactate; 
ET-1: endothelin-1. 
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4.2.3 Biochemical Measurements 
Glucose and lactate determinations were made using a glucose analyser (Model 2300 
Stat Plus, Yellow Springs Instruments), and hindlimb uptake or release data 
respectively were derived from the product of flow, arterio-venous (A-V) 
concentration difference and perfused muscle mass. Plasma concentrations of insulin 
(Mercodia AB, Sweden), ET-1 (Biomedica, Austria) and adiponectin (Phoenix 
Pharmaceuticals, Burlingame, CA, USA) were determined by ELISA. 
4.2.4 Statistics 
SigmaStat (SPSS Science, Chicago, IL, USA) was used to conduct all statistical 
analyses. Single point data sets were compared via Students t-test or one way 
ANOVA as appropriate. Time course data were analysed using two-way repeated 
measures ANOVA. Differences between conditions were assessed using the Student-
Neuman-Keuls post hoc test. Significance was assumed at the level of p<0.05. Data 
are presented as means ± standard error; if error bars are not visible, they are within 
the symbol. 
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4.3 Results 
 
4.3.1 Four week high-fat feeding causes insulin resistance 
4.3.1.1 High-fat feeding increases adiposity 
Four week high-fat feeding resulted in a small but statistically significant increase in 
body weight (242±5g vs. 230±3g with the normal diet; p<0.001; Figure 4.2A). This 
was accompanied by a large increase in abdominal adiposity, as measured via wet 
weight of the epididymal fat pads (2.9±0.1g vs. 1.6±0.1g with the normal diet; 
p<0.001; Figure 4.2B). The relative increase in epididymal fat was much greater than 
the increase in body weight, and the significant increase persisted when epididymal fat 
weight was expressed as a percentage of total body weight (1.17±0.04% vs. 
0.71±0.02% with the normal diet; p<0.001). Therefore, the 4 week high-fat fed rat is 
primarily a model of increased adiposity, and not obesity. This finding is in agreement 
with another recent study, although in that case no change in body weight was 
observed (St-Pierre et al., 2010). The discrepancy between these two studies may be 
due to minor differences in the response between rat strains or the age at which high-
fat feeding was initiated, as the rats may have commenced dietary intervention at a 
slightly earlier age in the present study. Although statistically significant, the increase 
in body weight was modest and so may not actually be biologically significant. Thus 
for most purposes these models are considered comparable. 
 
Figure 4.2: High-fat feeding increases body weight and adiposity. Changes in (A) body 
weight and (B) epididymal fat pad weight following 4 week high-fat feeding. NF: normal 
chow-fed rats (n=41); HFF: high-fat fed rats (n=46). * p<0.05, *** p<0.001, significantly 
different from normal diet.  
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4.3.1.2 High-fat feeding reduces insulin sensitivity 
Fasting plasma glucose was unchanged following 4 week high-fat feeding (Figure 
4.3A). However, there was a trend for increased fasting plasma insulin concentrations 
in high-fat fed rats (172±33pM vs. 113±15pM with the normal diet; p=0.084; Figure 
4.3B), suggesting increased insulin levels were required to maintain normoglycemia. 
Additionally, significant hyperglycemia was exposed in the fed state (Figure 4.3C), 
indicating a possible reduction in beta cell function. Together, these data suggest that 
4 week high-fat feeding altered insulin sensitivity. 
 
4.3.1.3 Plasma levels of ET-1 and adiponectin following high-fat feeding  
High-fat feeding did not significantly alter plasma concentrations of adiponectin 
(6.8±0.5μg.mL-1 vs. 7.5±0.55μg.mL-1 with the normal diet; n=10; p=0.359; Figure 
4.4A), or ET-1 (3.4±1.2pM vs. 2.0±0.5pM with the normal diet; n=4; p=0.323; Figure 
4.4B). However, adiponectin and ET-1 levels were slightly reduced and increased 
respectively. Additionally, ET-1 concentrations may be locally elevated in vascular 
tissue of high-fat fed rats, which may not be reflected in plasma concentrations 
Figure 4.3: High-fat feeding induces insulin resistance. Fasting plasma concentrations of 
(A) glucose and (B) insulin, and (C) fed plasma glucose. NF: normal chow-fed rats; HFF: 
high-fat fed rats. *** p<0.001, significantly different from normal diet (n=4-12).  
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(Bourgoin et al., 2008). Alternatively, this model may represent a stage in the 
pathological process prior to changes in these plasma peptide concentrations 
occurring.  
 
4.3.2 Adiponectin is ineffective against ET-1 in insulin resistance 
Under basal conditions at a flow rate of 5mL.min-1, average measurements in high-fat 
fed rats were perfusion pressure: 28.6±0.5mmHg, oxygen uptake: 10.3±0.3μmol.g-1.h-
1, glucose uptake: 5.6±0.5μmol.g-1.h-1, and lactate release: 18.3±0.7μmol.g-1.h-1 
(n=47). These parameters were not significantly different from basal measurements in 
normal animals. As in the normal-chow fed animals shown in Chapter 3, adiponectin 
alone did not alter perfusion pressure in rats fed a high-fat diet (Figure 4.5A). 
Adiponectin-mediated glucose uptake was lower in high-fat fed animals than those fed 
normal chow, potentially indicating a loss of adiponectin action. However, the change 
in glucose uptake was not different between adiponectin and vehicle infused 
hindlimbs, suggesting that the increased glucose uptake with adiponectin alone was an 
artefact of the vehicle (Figure 4.5C). 
 
Adiponectin had no effect on ET-1-induced vasoconstriction in high-fat fed rats, in 
contrast to the previous findings in normal animals. This result was consistent whether 
adiponectin was tested against the original 1nM ET-1 dose or at a similar perfusion 
pressure using 3nM ET-1 (Figure 4.5 A and B). Glucose uptake was higher in high-fat 
fed rat hindlimbs infused with adiponectin plus 1nM ET-1, compared to vehicle plus 
Figure 4.4: Adiponectin and Endothelin-1 levels in insulin resistance. (A) Plasma 
concentrations of adiponectin (n=10). (B) Plasma Endothelin-1 levels (n=4). NF: normal 
chow-fed rats; HFF: high-fat fed rats. 
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1nM ET-1 (Figure 4.5C). This contrasts with the findings in normal animals shown in 
Chapter 3, where adiponectin co-treatment reduced ET-1-mediated glucose uptake. 
 
It is possible that this indicates an unmasking of the effect of adiponectin alone in the 
presence of diminished ET-1 constriction following high-fat feeding. As it is proposed 
that the metabolic effects of ET-1 are entirely dependent on the vasoconstriction 
(Kolka et al., 2005), greater dilation in the presence of a reduced ET-1 response may 
allow greater access for adiponectin. Indeed, the small effect of ET-1 may be 
enhancing adiponectin action by limiting flow to the non-nutritive route and thereby 
increasing exposure of myocytes to adiponectin. No difference in glucose uptake in 
response to 3nM ET-1 was observed between rats treated with adiponectin or vehicle. 
Adiponectin also had no effect on 3nM ET-1-mediated oxygen uptake 
(1.5±0.3μmol.g-1.h-1 vs. 1.1±0.4μmol.g-1.h-1 with vehicle + ET-1; NS) or lactate 
release (17.2±1.4μmol.g-1.h-1 vs. 17.5±5.2μmol.g-1.h-1 with vehicle + ET-1; NS) in 
high-fat fed rats. 
Figure 4.5: Effects of adiponectin in high-fat fed animals. Effect of adiponectin on basal 
and 1nM ET-1-mediated changes (left) or 3nM ET-1-mediated changes (right) in (A-B) 
perfusion pressure, and (C-D) glucose uptake. Substances were infused at the times indicated 
according to Figure 4.1A. Data are normalised to t=0min. * Significantly different from 
vehicle and # significantly different from vehicle + ET-1 (p<0.05; n=4-8).  
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4.3.3 The response to ET-1 is reduced following high-fat feeding 
Perfusion pressure development in response to ET-1 was significantly reduced in 
high-fat fed animals compared to rats fed normal chow. The diminished ET-1 effect 
was apparent at both the 1nM and 3nM ET-1 doses (Figure 4.6A). These differences 
were not due to physical modifications or other basal variation between the animals, 
as no significant differences were observed prior to ET-1 infusion (Figure 4.6). The 
metabolic effects of ET-1 were similarly attenuated, with the effect of a given ET-1 
dose lower in the high-fat than the normal-chow fed animals on each measure, 
although the differences were not significant in all cases (Figure 4.6). Glucose uptake 
induced by 1nM ET-1 was significantly reduced in high-fat fed rats, while the effect 
of 3nM ET-1 approached significance (4.6±1.1μmol.g-1.h-1 vs. 8.7±0.9μmol.g-1.h-1 
with the normal diet at 50min; p=0.064). 
 
Figure 4.6: Response to endothelin-1 is reduced following high-fat feeding. Effect of 
1nM or 3nM ET-1 in normal chow-fed (NF) and high-fat fed (HFF) rats on (A) perfusion 
pressure, (B) oxygen uptake, (C) glucose uptake and (D) lactate release. Substances were 
infused at the times indicated according to Figure 4.1A. Data are provided raw or normalised 
to t=0min as indicated.NF: normal diet; HFF: high-fat fed * Significantly different from 
corresponding dose of ET-1 in normal chow-fed animals (p<0.05; n=6-8, except NF Vehicle 
+ 3nM ET-1, n=2).
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4.3.4 Inhibition of nitric oxide synthase restores normal ET-1 response in high-fat 
fed rats 
4.3.4.1 Nitric oxide synthase inhibition with L-NAME 
Suppression of all NOS isoforms by L-NAME did not alter basal perfusion pressure, 
which is consistent with the perfused rat hindlimb being dilated basally. However, L-
NAME treatment resulted in a significantly increased response to 1nM ET-1 in 
animals fed both diets (Figure 4.7B). These altered responses were accompanied by a 
significant increase in ET-1-stimulated oxygen uptake in normal animals and lactate 
release following high-fat feeding, but no other significant metabolic changes (Figure 
4.7 D - F). ET-1-mediated perfusion pressure was significantly increased in the 
normal animals treated with L-NAME and ET-1, compared to ET-1 alone. This 
suggests that a small amount of NO, which partially restricts ET-1 vasoconstriction, is 
produced under normal conditions. The vasoconstrictor response to ET-1 in high-fat 
fed animals was restored in the presence of L-NAME, so that the perfusion pressure 
was no longer different to that of the normal-chow fed animals (Figure 4.7B). These 
experiments indicate that the discrepancy in the ET-1 response between normal-chow 
and high-fat fed animals is due to dysregulation of NO production. 
 
4.3.4.2 Specific inhibition of inducible nitric oxide synthase  
The finding of increased NOS activity in insulin resistance was contrary to numerous 
literature reports of reduced NO bioavailability (see Section 1.5). However, there have 
been reports that the inducible NOS (iNOS) isoform is upregulated in insulin 
resistance (Dallaire et al., 2008; Fujimoto et al., 2005; Noronha et al., 2005; Perrault 
& Marette, 2001). Therefore, iNOS was specifically targeted using the iNOS inhibitor 
1400W, which is at least 1000-fold more selective for iNOS than either eNOS or 
nNOS (Garvey et al., 1997). When this inhibitor was present before and during ET-1 
infusion, ET-1-mediated perfusion pressure was significantly increased in the high-fat 
fed rats (Figure 4.7C). Once again, this was not due to basal variations in perfusion 
pressure between the dietary cohorts (Figure 4.7C). Meanwhile, there was no change 
in perfusion pressure in normal-chow fed animals. Therefore, specific iNOS inhibition 
restored the ET-1 vasoconstrictor response following high-fat feeding to a level that 
was not significantly different from the same treatment in normal-chow fed rats, or 
from the effect of ET-1 alone in normal animals. No significant metabolic effect of 
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iNOS inhibition was apparent in either dietary group (Figure 4.6 D-F). The significant 
effect of iNOS inhibition in high-fat fed, but not control animals, indicates that 
increased iNOS activity is responsible for the diminished ET-1 response in insulin 
resistance. Additionally, the difference in the effects of the two inhibitors on ET-1 
action in normal-chow fed animals (perfusion pressure 66.0±5.9mmHg with L-NAME 
vs. 52.2±7.9mmHg with 1400W at 40min; p=0.045) indicates that the low level NO 
produced under normal conditions is most likely derived from eNOS or nNOS. 
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4.4 Discussion 
 
Adiponectin has been widely described as an insulin sensitiser, but whether these 
actions are maintained in the insulin resistant state remains unclear. A common animal 
model of insulin resistance, the high-fat fed rat, was used to address this question. 
Four weeks of high-fat feeding induced insulin resistance with increased adiposity, in 
the absence of overt obesity. In these animals, adiponectin was unable to oppose ET-
1-mediated vasoconstriction, in the manner previously demonstrated in normal-chow 
fed rats. The lack of effect suggests that the vascular actions of adiponectin are 
restricted in insulin resistance, possibly implicating this loss of action in the 
development of insulin resistance. However, interpretation of this data is impeded by 
the finding that ET-1 vasoconstriction was also modulated by high-fat feeding. Using 
pharmacological inhibitors, I was able to attribute this variation to an increase in 
iNOS-derived NO in the model of insulin resistance. 
 
Studies have consistently shown that endogenous ET-1 activity is increased in obesity, 
insulin resistance, diabetes and hypertension (Cardillo et al., 2004; Miller et al., 2002; 
Cardillo et al., 2002; Elgebaly et al., 2008; Cardillo et al., 1999a). Similarly, a shift 
towards insulin-stimulated constriction, indicating increased ET-1 activity, has been 
described in rats fed a high-fat, high-sucrose diet (Bourgoin et al., 2008). Enhanced 
ET-1 action is most likely due to the increased ET-1 production observed in these 
states (Campia et al., 2004; Cardillo et al., 2002; Miller et al., 2002). The exception to 
these studies is a report of impaired vasodilation in response to ETA receptor blockade 
in type 2 diabetics, although that may be accounted for by the normal plasma ET-1 
levels in those subjects (McAuley et al., 2000b). However, there are conflicting 
reports of both enhanced and impaired constrictor responses to exogenous ET-1 under 
conditions of metabolic stress. Increased responses to exogenous ET-1 have been 
described in hypertension in both rats and humans (Cardillo et al., 1999a; Juan et al., 
1998) and in animal models of type 1 diabetes (Alabadí et al., 2004; Lloréns et al., 
2004). ET-1-mediated constriction is also enhanced in genetic and fructose-fed rat 
models of insulin resistance (Katakam et al., 2001; Romanko et al., 2009; Hopfner et 
al., 1998; Lesniewski et al., 2008), although Simandle et al. (2005) found that 
contractile responses to ET-1 were unchanged following fructose-feeding. The 
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majority of authors have proposed that the augmented ET-1 action is attributable to 
either an increase in the number or activity of the ETA receptor or a reduction in NO 
bioavailability, particularly in response to ETB activation (Juan et al., 1998; Alabadí et 
al., 2004; Lloréns et al., 2004; Katakam et al., 2001). Conversely, a number of studies 
have demonstrated a decreased response to ET-1, in agreement with the present work. 
Reduced ET-1 constrictor responses were observed in hypertensive patients and rats 
(Ferro et al., 2002; Amiri et al., 2010). Similarly, ET-1 action was diminished in 
obese Zucker rats (Katakam et al., 2006; Romanko & Stepp, 2005) and in type 2 
diabetic subjects (Cardillo et al., 2002; McAuley et al., 2000a; Nugent et al., 1996). It 
has been widely suggested that these changes are due to downregulation of the ETA 
receptor or constrictor pathways (Cardillo et al., 2002; Romanko & Stepp, 2005; 
Amiri et al., 2010), in contrast to the previous studies suggesting upregulation. Such 
an adaptation may occur as a compensatory response to chronically elevated ET-1, 
and indeed Hirata et al. (1988) showed that 24h treatment of vascular smooth muscle 
cells with ET-1 decreased ET-1 binding capacity without affecting binding affinity, 
indicating a decrease in total ET receptor number. However, ETA receptor expression 
was normal in obese Zucker rats (Katakam et al., 2006) and unaffected by ET-1 
overexpression (Hocher et al., 2004), indicating this may not be occurring in vivo. 
Katakham et al. (2006) alternatively suggested that ET-1 receptor activation and 
calcium elevation are uncoupled in obese Zucker rats, as ET-1-stimulated increases in 
intracellular calcium were lower despite full receptor activation. 
 
Variation in ET-1 constrictor responses may be due to differences in the precise 
pathologies being examined. It has been suggested that hyperinsulinemia may be 
responsible for altered ET-1 action (Cardillo et al., 2002; Hopfner et al., 1998). 
Insulin increases circulating ET-1 levels, ET-1 activity, ETA receptor expression and, 
as a result, blood pressure (Frank et al., 1993; Hopfner et al., 1998; Juan et al., 2004). 
However, Lteif et al. (2008) conducted differentially dosed hyperinsulinemic clamps 
in lean and obese subjects, in order to elicit the same insulin-mediated NO release in 
both groups. Under these conditions, there was no difference in insulin-mediated 
dilation in the presence of ETA receptor inhibition, despite insulin concentrations 
being 3-fold higher in obese patients. Therefore, the authors concluded that 
augmented ET-1 responses in obesity are not due to elevated insulin levels (Lteif et 
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al., 2008). Additionally, the association of enhanced ET-1 activity with hypertension 
and type 1 diabetes where insulin is presumably low, while ET-1 effects are reduced 
in type 2 diabetes, suggests that hyperinsulinemia does not account for increased ET-1 
constrictor responses. McAuley et al. (2000b) suggested that hyperglycemia may lead 
to ETA downregulation in type 2 diabetes, but the discrepant ET-1 responses in type 1 
and 2 diabetes, which both exhibit hyperglycemia, would similarly counter this 
argument. Cardillo et al. (2004) reported increased endogenous ET-1 activity in obese 
but not lean hypertensive subjects, suggesting an association with obesity and not 
hypertension. In other studies, elevated ET-1 responses were observed in animal 
models of both insulin resistance and type 2 diabetes in the absence of obesity, 
indicating that obesity is not the causal factor (Romanko et al., 2009; Elgebaly et al., 
2008). In a telling investigation by Lesniewski et al. (2008), an amplified ET-1 
response was demonstrated in pre- and short-term type 2 diabetes in the Zucker 
diabetic fat rat. The enhanced ET-1 activity preceded the development of overt 
diabetes and obesity, and was lost in long-term diabetes (Lesniewski et al., 2008). 
This data complements that of Romanko & Stepp (2005), where reduced 
vasoconstriction was observed in obese Zucker rats but not in the fructose-fed insulin 
resistant model. Based on all of the data discussed, it appears that ET-1 reactivity is 
increased is type 1 diabetes, hypertension and in the early stages of insulin resistance, 
possibly due to increased ET-1 concentrations and ETA receptor activity. However, 
more severe insulin resistance and type 2 diabetes, particularly in the presence of 
obesity, leads to a diminution of ET-1 reactivity. This theory is consistent with the 
data of the current study, whereby ET-1 vasoconstrictor responses were impaired in 
high-fat fed rats; a model of insulin resistance with increased adiposity. Given that this 
was attributed to increased iNOS activity, it is proposed that the reduced ET-1 
response is primarily associated with the inflammation present in these states. 
 
I have identified increased iNOS activity as the cause of the reduced ET-1 response in 
the high-fat fed rat. Noronha et al. (2005) showed a very similar effect, with iNOS 
inhibition eliciting an increase in the constrictor response to phenylephrine in high-fat 
fed, but not lean, mice. Diminished ET-1-mediated constriction in Zucker obese rats 
has also been related to elevated basal NO, as the response was normalised in the 
presence of L-NAME (Katakam et al., 2006). Furthermore, augmented iNOS activity 
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resulting in decreased vasoconstrictor responses has been associated with the 
development of hypotension (reviewed in Nathan, 1997). Although increased iNOS 
expression was not established in the current study, a number of previous 
investigations have demonstrated enrichment of iNOS in conditions of metabolic 
stress. iNOS mRNA was increased in aortas of high-fat fed mice, without a change in 
eNOS or nNOS expression (Noronha et al., 2005). Elevated iNOS has also been 
described in liver, skeletal muscle and adipose tissue of genetic and diet-induced 
models of obesity and insulin resistance (Dallaire et al., 2008; Fujimoto et al., 2005; 
Perreault & Marette, 2001). High-fat fed mice had increased iNOS expression 
particularly in muscle, with some increase also in adipose tissue, but there was no rise 
in liver iNOS mRNA following high-fat feeding (Perreault & Marette, 2001). This is 
in contrast to the effects of an acute intralipid infusion, which predominantly 
augmented iNOS in liver (Charbonneau & Marette, 2010). A number of studies have 
shown that iNOS is induced by pro-inflammatory cytokines, particularly in 
combination (Kapur et al., 1999; Bédard et al., 1997). Therefore, it has been 
suggested that increased pro-inflammatory cytokines in adiposity, possibly derived 
from adipocytes within skeletal muscle, may trigger iNOS expression (Perreault & 
Marette, 2001). Additionally, transgenic overexpression of ET-1 caused increased 
iNOS expression, and this was also linked to inflammation (Hocher et al., 2004). This 
suggests an alternate mechanism of iNOS upregulation, whereby elevated ET-1 levels 
may promote inflammation, leading to iNOS induction.  
 
Activation of iNOS under normal conditions has a range of beneficial functions, most 
notably in immune responses to infection and inflammation (reviewed in Nathan, 
1997). However, iNOS also affects a range of other processes, and so can be 
detrimental in excess. Enhanced iNOS activity impairs vascular function, reducing 
endothelium-dependent vasorelaxation (Kessler et al., 1997; Gunnett et al., 2001) and 
causing apoptosis of vascular smooth muscle cells (Iwashina et al., 1998). Excess NO 
has been reported to decrease insulin-mediated glucose uptake in isolated muscle, 
indicating it also has direct effects on muscle metabolism (Kapur et al., 1997). 
Upregulation of iNOS is associated with diminished insulin sensitivity, depressed 
hepatic insulin signalling, enhancement of the hepatic gluconeogenesis pathway and 
nitration of tyrosine residues (Bédard et al., 1997; Charbonneau & Marette, 2010; 
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Fujimoto et al., 2005). Inhibition of iNOS improved insulin sensitivity and signalling 
in ob/ob mice (Fujimoto et al., 2005); while rosiglitazone improved insulin sensitivity 
in high-fat fed mice in conjunction with completely normalised iNOS levels (Dallaire 
et al., 2008). Disruption of the iNOS gene protects mice from insulin resistance 
induced by both high-fat feeding and acute lipid infusion, without affecting insulin 
sensitivity and glucose homeostasis in normal animals (Perreault & Marette, 2001; 
Noronha et al., 2005; Charbonneau & Marette, 2010). Thus, increased iNOS activity 
is likely to contribute to the pathology of insulin resistance. 
 
Although excess ET-1 also has a range of detrimental effects, it too is beneficial when 
tightly regulated. ET-1 is increased in internal organs and non-working muscles 
during exercise, reducing blood flow to these areas, and ETA receptor inhibition 
reduces flow in working muscle while preventing normal flow decreases in other 
tissues (Maeda et al., 1997; Maeda et al., 2002b). Thus, ET-1 plays an important role 
in redistributing blood flow to high demand areas during exercise. Additionally, ET-1 
is produced in response to insulin (Yang & Li, 2008; Ferri et al., 1995; Ferri et al., 
1996) and its localised effects are thought to improve insulin action, by redirecting 
blood flow away from the non-nutritive route (Kolka et al., 2005). Thus, insulin 
stimulates both NO and ET-1 production, and it has been shown that it is the balance 
between the two that is important for insulin’s hemodynamic action (Eringa et al., 
2002; Verma et al., 2001). Meanwhile, iNOS produces markedly higher levels of NO 
than the constitutive NOS isoforms, and iNOS-induced dilation is likely to 
indiscriminately increase both nutritive and non-nutritive blood flow. Therefore, iNOS 
upregulation would be expected to interfere with the highly coordinated hemodynamic 
regulation, reducing muscle insulin sensitivity. This further implies that the benefits of 
vasodilation must be considered in context, and general dilators may not be 
particularly useful for the treatment of insulin resistance. Elevated activation of both 
ET-1 and iNOS in metabolic stress would maintain the balance between ET-1 and 
NO, but at a fundamentally increased level. This is supported by findings that 
endogenous ET-1 activity was not augmented in rats chronically fed a high-fat diet for 
12 months (da Silva et al., 2004), nor in patients with essential hypertension, despite 
an impaired response to exogenous ET-1 (Ferro et al., 2002).  Additionally, Hocher et 
al. (2004) demonstrated that ET-1 overexpression upregulates iNOS, causing blood 
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pressure to be unchanged. In the presence of increases in both vasoconstrictor and 
vasodilator signals, a relatively small stimulation of NO production through eNOS is 
unlikely to have any great additional effect. Thus, an increased state of balance 
between ET-1 and NO may contribute to the development of endothelial dysfunction 
and the loss of insulin’s vascular actions. 
 
The present work tends to suggest that insulin resistance is accompanied by resistance 
to adiponectin action. Specifically, the ability of adiponectin to acutely oppose ET-1 
action was absent in high-fat fed rats. However, these results are inconclusive, as 
identical dose and pressure conditions of ET-1 in both dietary cohorts, against which 
to test adiponectin, could not be achieved. In addition, adiponectin inhibits iNOS 
induction and the concomitant NO production (Tao et al., 2007). Activating AMPK, a 
kinase known to be involved in adiponectin signalling, reduces iNOS activity and 
protein expression, resulting in improved insulin sensitivity (Pilon et al., 2004). 
Rosiglitazone-mediated normalisation of iNOS levels and improvements in insulin 
sensitivity in high-fat fed mice have been associated with markedly increased 
adiponectin concentrations, which are a hallmark of the PPARγ agonist insulin 
sensitising drugs (Dallaire et al., 2008). These data suggest that adiponectin may have 
an inhibitory effect on iNOS activity. Therefore, the absence of adiponectin-mediated 
changes in perfusion pressure in high-fat fed rats demonstrated here may be 
complicated by conflicting effects of adiponectin to inhibit both ET-1 and iNOS. 
However, the above studies largely described chronic changes in iNOS gene 
expression, so an interaction between adiponectin and iNOS may not affect the acute 
adiponectin treatment of the current study. Furthermore, as discussed above, the 
vasodilatory effects of adiponectin are likely to be relatively modest, and thus any 
action is likely to be inconsequential in the presence of increased levels of both ET-1 
and NO. Therefore, the primary aim of this study, to determine whether the inhibitory 
action of adiponectin on ET-1-mediated vasoconstriction was retained in insulin 
resistant animals, was unable to be properly addressed due to the modulation of the 
ET-1 response in insulin resistance. 
 
This work has identified an attenuation of ET-1 action in insulin resistance, which is 
attributable to increased iNOS activity. Increases in both vasodilator and 
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vasoconstrictor stimuli may reduce responsiveness to NO-dependent vasodilators, and 
thus contribute to endothelial dysfunction and vascular defects associated with the 
metabolic syndrome.  
 
80 
CHAPTER 5 – THE HEMODYNAMIC AND METABOLIC 
ACTIONS OF ADIPONECTIN IN VIVO. 
 
 
5.1 Introduction 
 
Having examined the direct effects of adiponectin on skeletal muscle vasculature in 
the perfused rat hindlimb, the next aim was to investigate acute adiponectin action in 
vivo. As the perfused rat hindlimb includes mainly muscle, potential contributions to 
the metabolic and vascular actions of adiponectin from the liver and central nervous 
system are not able to be assessed using that technique. Non-recirculating perfusion of 
the hindlimb also washes out any endogenous circulating factors that may contribute 
to vascular tone, including adiponectin. Thus, perfused hindlimb experiments can not 
indicate whether exogenous adiponectin has any added effect above endogenous 
concentrations, a question particularly important when considering therapeutically 
increasing adiponectin levels. Furthermore, the perfused rat hindlimb does not allow 
for examination of microvascular redistribution under physiological conditions, due to 
the highly dilated basal state. In addition, the constricted perfused rat hindlimb 
technique used in previous investigations of this thesis was not particularly suitable 
for the evaluation of adiponectin-mediated insulin sensitisation. As insulin was able to 
completely abolish ET-1-mediated vasoconstriction (Kolka et al., 2005), submaximal 
insulin doses would be required to observe an adiponectin effect, preventing the 
question of additivity or synergism from being addressed. Thus, whilst the perfused 
rat hindlimb provides a valuable system for the examination of vascular changes 
specifically in muscle, whole animal studies provide a more physiologically relevant 
system to investigate hemodynamic and metabolic influences. 
 
The hyperinsulinemic euglycemic clamp is the current gold standard measure of 
insulin sensitivity. Insulin is infused systemically, stimulating glucose disposal and 
inhibiting hepatic glucose output, leading to reduced blood glucose. However, 
changes in glucose levels independent of insulin have biological effects including 
sympathetic nervous system activation (Donovan et al., 1994), as well as affecting NO 
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release and insulin-stimulated vasodilation (Taubert et al., 2004). To avoid these 
confounding effects glucose is continually infused in concert with the insulin, and the 
rate at which glucose infusion is required to maintain stable glycemia is a powerful 
indicator of whole body insulin sensitivity. This technique has been used widely for 
the examination of insulin sensitivity in conjunction with measures of both total blood 
flow and microvascular perfusion, in anaesthetised rats (Zhang et al., 2004; Wheatley 
et al., 2004; St-Pierre et al., 2010; and reviewed in Clark et al., 2003). Although 
anaesthetics have a range of biological effects, studies in conscious animals do not 
readily lend themselves to measures of blood flow, especially microvascular flow, 
which are subject to movement artefacts. Given that the hemodynamic actions of 
adiponectin were the primary focus of the current study, accurate blood flow 
measurements were crucial. Additionally, insulin has comparable effects on 
microvascular perfusion in anaesthetised animals and conscious human subjects 
(reviewed in Clark, 2008), indicating that the anaesthetic should not substantially 
affect the results of the current experiments. 
 
Previous investigations of adiponectin action in vivo have demonstrated increased 
insulin sensitivity, in particular suppression of endogenous glucose production. 
These studies have predominantly been conducted using chronic elevations in 
adiponectin, via either adenoviral or transgenic overexpression (Combs et al., 2004; 
Kim et al., 2007; Satoh et al., 2005; Yamauchi et al., 2003). Similarly, continuous 
infusion of adiponectin reduced body weight and restored insulin sensitivity in high-
fat fed animals over a two week treatment period (Freubis et al., 2001; Yamauchi et 
al., 2001). In one study concerning the vasculature, angiogenesis was increased in 
rabbit corneas 14 days after adiponectin injection (Ouchi et al., 2004). A few studies 
have also reported acute effects of adiponectin in vivo. Yamauchi et al. (2002) 
reported phosphorylation of AMPK and ACC in isolated myocytes within five 
minutes of adiponectin treatment. Globular adiponectin reduced the postprandial 
increase in free fatty acids within one hour of treatment and improved in vivo glucose 
homeostasis within two hours (Fruebis et al., 2001); while a single injection of 
adiponectin was sufficient to abolish hyperglycemia in diabetic mice (Berg et al., 
2001). Meanwhile, acute infusion of adiponectin in the presence of physiological 
hyperinsulinemia improved insulin sensitivity via a significant suppression of hepatic 
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glucose production (Combs et al., 2001). However, the acute effects of adiponectin on 
in vivo vasoactivity have not been described. 
 
The aim of the current experiments was to determine if adiponectin acutely affects 
hemodynamics or metabolism in vivo. Given that the previously described vascular 
action of adiponectin in the perfused rat hindlimb was relatively modest and specific, 
it was of interest to see if it translates into a significant effect in the setting of complex 
hemodynamic regulatory mechanisms in vivo. The response to adiponectin was 
investigated, both alone and in the presence of a hyperinsulinemic clamp, to assess 
adiponectin-mediated insulin sensitisation. Additionally, the anaesthetised rat largely 
avoids the issue of altered ET-1 vasoconstriction in insulin resistance associated with 
the pre-constricted hindlimb, thus providing an alternate platform to examine the 
actions of adiponectin in insulin resistance. 
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5.2 Methods 
 
5.2.1 Animals 
All experiments were approved by the University of Tasmania Animal Ethics 
Committee and were performed in accordance with the guidelines set out under the 
NHMRC Code of Practice for the care and use of animals for scientific purposes 
seventh edition (2004). The majority of experiments were conducted on Hooded 
Wistar Rats (n=71), with Sprague-Dawley rats used for the low-dose adiponectin 
experiments when Hooded Wistars were no longer available. Male rats were housed at 
21±1°C under a 12h light/dark cycle. Rats were provided with rat chow (Barastoc 
Stockfeed, Pakenham, VIC, Aus), containing 21.4% protein, 4.6% lipid, 68% 
carbohydrate and 6% crude fibre by weight, with added vitamins and minerals, and 
water ad libitum.  
 
Rats for high-fat feeding studies were obtained at approximately 4 weeks of age and 
fed a high-fat diet (19.4% protein, 36% lipid, 35.2% carbohydrate, 9.4% crude fibre 
by weight; Specialty Feeds, Glen Forrest, WA, Aus) for 4 weeks. This protocol was 
designed so that the rats were age-matched to the control group at the time of 
experiment. The enriched fat content of this high-fat diet, with energy contribution 
from fat increased from 10% to 60%, is compensated for largely by a reduction in 
calories provided as carbohydrate (Table 5.1). 
 
Table 5.1: Relative energy contribution of macronutrients in the 
normal and high-fat diets. 
  Control Diet High-Fat Diet 
  % Calories % Calories 
Protein 19 14 
Total Fat 10 60 
Carbohydrate 71 26 
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5.2.2 In vivo experiments 
5.2.2.1 Surgery 
Surgery was conducted on male rats weighing 240.5±2.3g (n=92) following an 
overnight fast. Animals were anaesthetised with an intraperitoneal injection of 
pentobarbital sodium (50mg.kg-1 body weight; Ilium Veterinary Laboratories, 
Smithfield, NSW, Australia). The rats were positioned on a heat pad at 37C under a 
heat lamp to maintain body temperature. A ventral incision was made in the neck, and 
a tracheotomy was performed to allow the rat to freely breathe room air throughout 
the procedure. Both jugular veins were cannulated using polyethylene cannulas (PE-
60, Intramedic®), which was secured in place with silk ligatures, to allow continuous 
infusion of anaesthetic and test substances. The carotid artery on one side was 
cannulated in the same way for arterial blood sampling. The arterial cannula was 
connected to a pressure transducer (Transpac IV, Abbott Critical Systems, Morgan 
Hill, CA, USA) to provide continuous blood pressure and heart rate measurements. A 
small area of skin (approximately 1cm2) was removed from the medial side of each 
rear leg, to expose the femoral vessels. The superficial epigastric vessels of each leg 
were ligated to restrict blood flow to the femoral artery and allow accurate assessment 
of total limb blood flow via this vessel. The femoral artery of one leg was separated 
from the saphenous nerve and femoral vein, and an ultrasonic flow probe 
(TransonicTM Systems, VB series 0.5mm, Ithaca, NY, USA) was positioned around 
the artery between the junction of the rectus muscle and the epigastric artery branch 
point. The leg cavity was filled with lubricating gel (H-R, Mohawk Medical Supply, 
Utica, NY, USA) to provide good sound conductance. The flow probe was then 
attached to a flow meter (Model T106 ultrasonic volume flow meter, TransonicTM 
Systems, Ithaca, NY, USA). 
 
5.2.2.2 Experimental procedures 
Rats were maintained under anaesthesia using a variable rate, continuous infusion of 
pentobarbital sodium into the jugular vein. An equilibration period of 60min was 
allowed after completion of the surgery, to ensure stable anaesthesia. Following this, 
an arterial sample was collected for the determination of fasting blood and plasma  
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Figure 5.1: Experimental protocols. The in vivo actions of adiponectin or vehicle were examined 
alone (A) or during a hyperinsulinemic euglycemic clamp (B). The effects of pre-treatment and co-
infusion of adiponectin or vehicle with insulin was also examined (C). 3-[3H]-D-glucose was infused 
throughout all experiments to determine glucose turnover. An i.v. bolus of 2-deoxy-D-[1-14C]-glucose 
(2-DG) was administered at 108min for the determination of muscle glucose uptake and arterial blood 
was continuously sampled over the last 10min of the protocol to provide a measure of circulating 
radioactivity. 1-MX was continuously infused for the last hour of experiments for the determination of 
microvascular perfusion. The muscles of the calf were excised and freeze-clamped in liquid nitrogen at 
the conclusion of the experiment. 
 
Horizontal bars represent venous infusions,  designates collection of arterial blood samples for 
determination of blood glucose and lactate,  represents venous blood sample to determine of arterio-
venous differences, — denotes continuous sampling of arterial blood to determine circulating 2-DG 
levels, and arrows indicate bolus injections of allopurinol (ALP) or radioactive 2-DG as indicated.
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glucose. The effect of a 1hr adiponectin infusion (24 or 96μg.min-1.kg-1), alone or in 
the presence of insulin, was examined using the protocols shown in Figure 5.1. The 
effect of adiponectin was compared to the effect of the vehicle preparation extracted 
from non-transfected bacteria. The hyperinsulinemic euglycemic clamp technique was 
used to examine the effects of adiponectin on insulin action, in which insulin 
(Humulin R, Eli Lilly®, USA) was infused at a rate of 3mU.min-1.kg-1 for 2hr. Insulin 
was diluted in heparinised saline containing 0.4% w/v bovine serum albumin. 
Physiological hyperinsulinemia was selected for these experiments to allow detection 
of adiponectin-mediated improvements in insulin sensitivity. During insulin infusion a 
variable rate infusion of 30% w/v glucose was used to maintain euglycemia. Blood 
glucose was measured every 10min during the first hour of the insulin infusion, and 
every 15min in the second hour when the effects of insulin reach a steady state. The 
rate of glucose infusion was used as a measure of whole body insulin sensitivity. 
 
All infused substances were diluted in heparinised saline. Throughout the experiment, 
pressure, flow and heart rate data were continuously recorded using WINDAQ data 
acquisition software (DATAQ instruments, Akron, OH, USA). At the conclusion of 
the experimental protocol, the epididymal fat pads were excised and the wet weight 
recorded. Arterial and venous plasma samples collected throughout the experiment 
were stored at -20°C. 
 
5.2.2.3 1-methylxanthine metabolism 
Microvascular perfusion was assessed via a previously established method using the 
metabolism of exogenous 1-methylxanthine (1-MX; Sigma Aldrich, St. Louis, MO, 
USA) by the enzyme xanthine oxidase (Rattigan et al., 1997b). Xanthine oxidase is 
located in the endothelium of capillaries and small arterioles in skeletal muscle 
(Jarasch et al., 1986). As the number of perfused capillaries increases, so does the 
endothelial surface area exposed to the circulating 1-MX. Therefore the rate of 1-MX 
metabolism reflects changes in capillary perfusion. 
 
1-MX is rapidly metabolised by xanthine oxidase, thus allopurinol, a specific inhibitor 
of xanthine oxidase, is used to partially inhibit its activity, particularly in non-muscle 
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tissue (Asp et al., 1997; Emmerson et al., 1987). Allopurinol (10μmol.kg-1; Sigma 
Aldrich, St. Louis, MO, USA) was administered as a bolus via the carotid artery 5min 
prior to commencement of 1-MX infusion (0.1mg.min-1.kg-1), maintaining a constant 
arterial concentration of 1-MX throughout the experiment. 1-MX and allopurinol were 
both dissolved in 0.03% v/v 1M NaOH in heparinised saline and stored at -20°C. 
 
Arterial and venous blood samples were collected in chilled tubes rapidly upon 
completion of the protocol. Plasma was obtained by immediate centrifugation, and 
20μL was mixed with 80μL of 2M perchloric acid to deproteinate the sample. 
Concentrations of 1-MX were determined by reverse-phase high performance liquid 
chromatography as previously described (Rattigan et al., 1997a). 1-MX metabolism 
was calculated by multiplying the arterial-venous 1-MX difference by femoral blood 
flow, and corrected for the volume accessible to 1-MX (0.871), which was determined 
from plasma concentrations after addition of 1-MX to whole rat blood. 
 
5.2.2.4 Muscle glucose uptake 
To assess the uptake of glucose into skeletal muscle, a 100μL bolus of 2-deoxy-D-[1-
14C]-glucose (2-DG; specific activity 56.0mCi.mmol-1, Amersham Pharmacia Biotech, 
IL, USA) was administered via the jugular vein, 12min prior to completion of the 
experiment. The circulating concentration of radioactive glucose was determined from 
a sample of arterial blood constantly withdrawn at a rate of 50μL.min-1 for the final 
10min of the protocol. Samples were centrifuged and radioactivity was assessed from 
25μL of plasma. 
 
At the conclusion of the experiment, whole calf muscle samples, consisting of the 
soleus, plantaris and gastrocnemius muscles were excised, freeze-clamped in liquid 
nitrogen and stored at -80°C. Frozen muscle samples were powdered under liquid 
nitrogen and 100mg of tissue was homogenised with 1mL water using a HeidolphTM 
silent crusher M (27000rpm.min-1). Free and phosphorylated [14C] 2-DG were 
separated by ion exchange chromatography using an anion exchange resin (AG® 1-
X8, Bio-Rad Laboratories, CA). 
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Samples were combined with Biodegradable Counting Scintillant (Amersham 
Pharmacia Biotech, IL) and [14C] radioactivity was determined using a scintillation 
counter (Tri-Carb 2800TR, Perkin Elmer Inc., IL, USA). Muscle 2-DG uptake (R’g), 
which reflects glucose uptake into the muscle, was calculated using the counts from 
the muscle and arterial samples, as previously described by others (Kraegen et al., 
1985; James et al., 1985). 
 
5.2.2.5 Rate of glucose turnover 
The rate of glucose appearance and disappearance, or glucose turnover, was 
determined using a continuous infusion of 3-[3H]-D-glucose (0.1μCi.min-1; specific 
activity 16.6Ci.mmol-1; Amersham Pharmacia Biotech, IL, USA). This was 
administered over the 2hr of the insulin, or corresponding saline, infusion. Arterial 
plasma samples were collected 15min prior to, and on completion of the experiment, 
and deproteinised using 2M perchloric acid. Samples were evaporated to dryness, in 
order to remove 3H2O, and resuspended in distilled water. Biodegradable Counting 
Scintillant (Amersham Pharmacia Biotech, IL) was added to each sample and [3H] 
radioactivity was determined using a scintillation counter (Tri-Carb 2800TR, Perkin 
Elmer Inc., IL, USA). The rates of appearance (Ra) and disappearance (Rd) of glucose 
calculated using the isotope dilution equation: 
 
Ra = Rd = F / SA 
 
* Where: F = the rate of tracer infusion 
     SA = the specific activity of glucose (calculated by dividing the plasma  
radioactivity by the glucose concentration). 
 
5.2.3 Biochemical measurements 
Glucose and lactate determinations were made using a glucose analyser (Model 2300 
Stat Plus, Yellow Springs Instruments). Plasma concentrations of insulin (Mercodia 
AB, Sweden), ET-1 (Biomedica, Austria) and adiponectin (Phoenix Pharmaceuticals, 
Burlingame, CA, USA) were determined by ELISA.  
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5.2.4 Data analysis 
Mean arterial blood pressure (MAP), mean heart rate (HR) and mean femoral blood 
flow (FBF) were calculated from 5sec sub-samples of data, representing 
approximately 300 measurements for each data point. Vascular resistance (VR) in the 
hindleg was calculated by dividing mean arterial pressure in mmHg by femoral blood 
flow in mL.min-1 for each time point. Hindleg glucose uptake (HGU) was derived 
from the product of the arterio-venous (A-V) concentration difference and plasma 
flow.  
 
5.2.5 Statistical analysis 
SigmaStat (SPSS Science, Chicago, IL, USA) was used to conduct all statistical 
analyses. Single point data sets were compared via Students t-test or one way 
ANOVA as appropriate. Time course data were analysed using two-way repeated 
measures ANOVA. Differences between conditions were assessed using the Student-
Neuman-Keuls post hoc test. Significance was assumed at the level of p<0.05. Data 
are presented as means ± standard error; if error bars are not visible, they are within 
the symbol. 
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5.3 Results 
 
5.3.1 Effect of high-dose adiponectin on in vivo hemodynamics and glucose 
homeostasis 
Preliminary experiments were conducted using adiponectin dosing based on the 
murine study by Combs et al. (2001), using a constant adiponectin infusion of 
20μg.min-1.kg-1 for 10min, reduced to 2μg.min-1.kg-1 for the remainder of the 90min 
experiment. However, this dose of adiponectin, in the presence or absence of insulin, 
did not affect any measure of in vivo hemodynamics or glucose homeostasis (data not 
shown). Therefore, experiments were conducted using a high rate of adiponectin 
infusion, at 96μg.min-1.kg-1. These experiments were designed to produce supra-
physiological circulating adiponectin concentrations, to determine whether 
adiponectin has any vascular activity at what were likely to be saturating levels. 
 
5.3.1.1 Infusion of recombinant adiponectin raised circulating adiponectin 
Adiponectin plasma levels did not vary over the course of a saline infusion 
(2.6±0.2μg.mL-1 fasting vs. 2.3±0.1μg.mL-1 after 120min saline infusion). Infusion of 
96μg.min-1.kg-1 adiponectin for 60min increased circulating adiponectin levels 
 
Figure 5.2: Plasma adiponectin concentrations. Samples were collected at t=120min; + 
designates infusion of indicated substance; insulin 3mU.min-1.kg-1, adiponectin 96µg.min-
1.kg-1.  *** Significantly different from saline (p<0.001; n=3-6). 
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approximately 40-fold (Figure 5.2). Neither 3mU.min-1.kg-1 insulin nor vehicle 
infusion affected fasting plasma adiponectin. Insulin co-infusion slightly reduced the 
final plasma adiponectin concentration (77.8±6.4μg.mL-1 vs. 86.4±5.4μg.mL-1 with 
adiponectin alone; p<0.05), although it is unclear whether this difference would be 
biologically significant given the supra-physiological levels reached in both cases. 
 
5.3.1.2 Effect of high-dose adiponectin on in vivo hemodynamics 
Sampling procedures for the measurement of 2-deoxyglucose uptake required the 
arterial pressure monitor to be detached for the final 10min of the experiment, so no 
MAP or HR data were recorded after this time. Similarly, vascular resistance 
estimates after this point were excluded due to the reliance on MAP for their 
calculation. There were no relevant significant differences in MAP or HR between 
saline and insulin treatments. Adiponectin did not affect MAP or HR, either alone or 
in the presence of insulin (Figure 5.3). 
Figure 5.3: Adiponectin does not affect mean arterial pressure or heart rate. Upper: 
Time course of mean arterial pressure during vehicle or adiponectin infusion in the absence 
(A) or presence or 3mU.min-1.kg-1 insulin (B). Lower: Time course of heart rate during 
vehicle or adiponectin infusion in the absence (C) or presence or 3mU.min-1.kg-1 insulin (D). 
Mean arterial pressure and heart rate were monitored via a cannula placed in the carotid 
artery. * Significantly different from saline (p<0.05; n=5-7). 
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There was a trend for FBF to be reduced during adiponectin infusion, although this 
did not reach significance (0.7±0.1mL.min-1 vs. 1.1±0.1mL.min-1 after 90min saline 
infusion; p=0.069; Figure 5.4A). Consequently, there was a significant increase in VR 
after 45min of adiponectin infusion (Figure 5.4C). However, this cannot be solely 
attributed to adiponectin, as the same effect was demonstrated during vehicle infusion, 
with FBF significantly reduced and VR significantly increased by the vehicle within 
30min (Figure 5.4A and C). The vehicle-induced changes were not apparent in the 
presence of insulin (Figure 5.4B and D). Whilst infusion of this relatively low dose of 
insulin was not found to significantly increase FBF, it is possible that a small, 
moderating effect of insulin is able to counteract the vehicle effects in these combined 
treatments. 
 
Figure 5.4: Femoral blood flow and vascular resistance. Upper: Time course of femoral 
blood flow during vehicle or adiponectin infusion in the absence (A) or presence or 
3mU.min-1.kg-1 insulin (B). Blood flow was measured by a transonic flow probe positioned 
around the femoral artery. Lower: Time course of vascular resistance during vehicle or 
adiponectin infusion in the absence (C) or presence or 3mU.min-1.kg-1 insulin (D). Vascular 
resistance was calculated by dividing mean arterial pressure by femoral blood flow for each 
time point.  * Significantly different from saline (p<0.05; n=5-7). 
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Microvascular perfusion was assessed using the 1-MX metabolism technique 
(Rattigan et al., 1997b). There was no significant difference in 1-MX metabolism 
between any of the groups, although it tended to be lower in rats treated with vehicle 
(Figure 5.5). Adiponectin appeared to counteract the effect of the vehicle, but further 
experiments would be required to confirm this.  
 
5.3.1.3 Effect of adiponectin on glucose homeostasis 
In contrast to expectations, adiponectin infusion in the absence of insulin increased 
blood glucose levels above that seen with saline (p<0.01 at 120min; Figure 5.6A). The 
same effect was apparent with vehicle infusion, suggesting that a bacterial 
contaminant rather than adiponectin was responsible. Thus, no glucose infusion was 
required during either treatment (Figure 5.6 A and C). However, in the presence of 
insulin, maintenance of constant blood glucose concentrations required infusion of 
exogenous glucose (Figure 5.6B and D). However, co-infusion of insulin with vehicle, 
but not adiponectin, required a significant reduction in the glucose infusion rate (GIR) 
to maintain stable blood glucose levels (Figure 5.6D).  
 
To assess which tissues contributed to the change in GIR, hindleg glucose uptake 
(HGU), 2-deoxyglucose uptake (2-DG), rate of glucose appearance (Ra) and whole   
 
Figure 5.5: Microvascular perfusion. Effect of vehicle or adiponectin infusion in the 
presence or absence of 3mU.min-1.kg-1 insulin on 1-methyxanthine metabolism. Plasma 
samples for analysis were collected at the completion of the experiment, t=120min (n=5-6). 
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Figure 5.6: Blood glucose and glucose infusion rate. Upper: Time course of blood glucose 
concentrations during vehicle or adiponectin infusion in the absence (A) or presence or 
3mU.min-1.kg-1 insulin (B). Lower: Time course of glucose infusion rate during vehicle or 
adiponectin infusion in the absence (C) or presence or insulin (D). * Significantly different 
from saline and # significantly different from insulin (p<0.05; n=5-7). 
 
Figure 5.7: Glucose homeostasis. Effect of vehicle or adiponectin infusion in the presence 
or absence of 3mU.min-1.kg-1 insulin on (A) hindleg glucose uptake, (B) radioactive 2-deoxy 
glucose uptake (R’g) into whole calf muscle, (C) the rate of glucose appearance (hepatic 
glucose output), and (D) the rate of glucose disappearance (whole body glucose uptake). All 
samples were collected at the completion of the experiment, t=120min. * Significantly 
different from saline (p<0.05; n=5-6). 
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body rate of glucose disposal (Rd) were measured during infusion of adiponectin or 
vehicle, alone or in the presence of insulin (Figure 5.7). Few of the changes reached 
significance, although adiponectin prevented the significant insulin-mediated 
reduction in Ra and vehicle treatment tended to increase HGU. 
 
5.3.2 Effect of high-dose adiponectin in vivo in insulin resistance 
The previous set of experiments did not show significant hemodynamic or metabolic 
actions of adiponectin. The interpretation of this data is inhibited by interference from 
effects of the bacterial vehicle preparation. However, the effect of the vehicle on 1-
MX metabolism and GIR were not apparent in animals infused with the recombinant 
adiponectin preparation. This suggested that adiponectin may be augmenting 
microvascular perfusion and insulin sensitivity, and in this way counteracting the 
detrimental effects of the vehicle. As these adiponectin actions were small, it was 
hypothesised that vascular adiponectin action may be more apparent in insulin 
resistance, where the effects of insulin and endogenous adiponectin are likely to be 
diminished. 
 
Table 5.2: Basal characteristics of normal chow and high-fat fed rats. 
  Normal chow High-fat p value 
Body weight (g) 232.6 ± 2.5 240.4 ± 3.0 0.051 
Epididymal fat (g) 1.4 ± 0.1 3.0 ± 0.1 <0.001 
Plasma glucose (mM) 6.0 ± 0.2 6.7 ± 0.2 0.011 
Plasma insulin (pM) 108.4 ± 20.4 207.0 ± 22.2 0.004 
Plasma adiponectin (μg.mL-1) 2.1 ± 0.1 2.4 ± 0.1 0.140 
Mean arterial pressure (mmHg) 100.1 ± 1.4 104.4 ± 1.3 0.029 
Heart rate (beats.min-1) 340.7 ± 4.8 366.4 ± 6.7 0.002 
Femoral blood flow (mL.min-1) 0.9 ± 0.0 0.7 ± 0.0 0.008 
Vascular resistance (VR units) 123.5 ± 5.8 156.8 ± 7.9 <0.001 
All measures taken at the commencement of the experiment, t=0min, except epididymal fat pads 
which were extracted upon experimental completion. Values are mean ± SE. p values as 
determined by Students t test (n=12-39). 
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5.3.2.1 High-fat feeding induces insulin resistance 
Rats were fed a high-fat diet for four weeks to induce insulin resistance. Body weight 
of the high-fat fed rats was borderline significantly increased compared to normal-
chow fed rats (Table 5.2). Epididymal fat pad weight was doubled following high-fat 
feeding, indicating a marked increase in adiposity. These data are consistent with 
previous findings from this thesis (Section 4.3.1.1) and other studies (St-Pierre et al., 
2010), demonstrating that the four week high-fat fed rat is a model of increased 
adiposity in the absence of overt obesity. 
 
Fasting plasma concentrations of both glucose and insulin were significantly increased 
in high-fat fed rats (Table 5.2), in agreement with a previous study (St-Pierre et al., 
2010). In addition, glucose infusion rate (4.7±0.0mg.min-1.kg-1 vs. 8.6±0.6mg.min-
1.kg-1 in normal animals; p<0.01) and insulin-mediated suppression of hepatic glucose 
output (4.9±0.9mg.min-1.kg-1 vs. 0.9±0.8mg.min-1.kg-1 in normal animals; p<0.01) 
were both markedly attenuated following high-fat feeding. These data demonstrate 
that rats fed a high-fat diet for four weeks develop insulin resistance. There was no 
significant change in fasting plasma adiponectin in response to the high-fat diet (Table 
5.2). In conjunction with reduced insulin sensitivity, measures of macrovascular 
function were all significantly altered in high-fat fed rats (Table 5.2). However, the 
magnitudes of the hemodynamic changes were modest, and similar changes were not 
reported in a previous study (St-Pierre et al., 2010), so it is unclear if they are 
biologically significant. 
 
5.3.2.2 Effect of adiponectin on basal and insulin-mediated hemodynamics and 
metabolism in high-fat fed rats 
Neither 96μg.min-1.kg-1 adiponectin nor vehicle infusion significantly altered any 
vascular parameter in high-fat fed rats, alone or in the presence of insulin (Table 5.3). 
However, there was a tendency for increased 1-MX metabolism in response to vehicle 
treatment (Table 5.3), in contrast to the effect of the vehicle in normal-chow fed 
animals (Figure 5.5). Muscle 2-deoxy glucose uptake was also not significantly 
affected by adiponectin or vehicle treatment, although there was a tendency for 
increased 2-DG uptake in vehicle treated rats (Table 5.3). Significant insulin-mediated 
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2-DG uptake was only apparent in the presence of vehicle or adiponectin (p<0.05 vs. 
saline). 
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As in the normal animals, blood glucose was significantly increased by vehicle 
infusion alone, in the absence of exogenous glucose infusion (Figure 5.8 A and C). A 
trend for increased blood glucose was also apparent in rats treated with adiponectin 
(4.6±0.3mM vs. saline 3.6±0.0mM; p=0.068; Figure 5.8A). However, adiponectin 
significantly blunted the vehicle-induced increase in blood glucose in high-fat fed rats 
Figure 5.8: Adiponectin did not affect glucose metabolism in high-fat fed rats. Upper: 
Time course of blood glucose during vehicle or adiponectin infusion in the absence (A) or 
presence or 3mU.min-1.kg-1 insulin (B). Middle: Time course of glucose infusion rate during 
vehicle or adiponectin infusion in the absence (C) or presence or insulin (D). Lower: Effect 
of vehicle or adiponectin infusion in the presence or absence of insulin on (E) the rate of 
glucose appearance (hepatic glucose output), and (F) the rate of glucose disappearance 
(whole body glucose uptake). Samples were collected at t=120min. * Significantly different 
from saline, # significantly different from insulin and § significantly different from vehicle 
(p<0.05; n=4-7). 
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(4.6±0.3mM vs. vehicle 5.7±0.5mM at 120min; p<0.05). During insulin infusion, the 
glucose infusion rate was markedly reduced by co-infusion of either adiponectin or 
vehicle (Figure 5.8D). Over this time, blood glucose increased in both treatment 
groups, becoming significant in the case of insulin plus vehicle infusion (Figure 5.8B), 
suggesting that the glucose infusion rate should actually have been further reduced. 
There was no significant difference in the rates of glucose appearance and 
disappearance between any of the treatments following high-fat feeding (Figure 5.8 E 
and F). Despite this, the rate of hepatic glucose production appeared to be slightly 
higher in rats treated with adiponectin or vehicle than corresponding controls, possibly 
accounting for the increase in blood glucose. However, the Ra and Rd determinations 
of glucose turnover are based on the assumption that blood glucose concentrations are 
at steady-state. Therefore, these measurements may not be accurate under the current 
conditions of changing blood glucose. 
 
Plasma adiponectin levels were not reduced following high-fat feeding, in contrast to 
previous reports (Yamauchi et al., 2001; Mullen et al., 2009). However, circulating 
adiponectin concentrations in the normal chow-fed Hooded Wistar rats used in this 
experiment were at the low end of the described range for adiponectin (Table 5.2). 
This, in conjunction with the lack of significant effect of insulin in these animals 
suggested that the insulin sensitivity may have already been reduced. Fasting plasma 
adiponectin was significantly higher in normal-chow fed Sprague-Dawley (Figure 4.4) 
than Hooded Wistar rats (7.5±0.5μg.mL-1 vs. 2.1±0.1μg.mL-1, p<0.001). While both 
the hemodynamic and metabolic responses of the two strains are qualitatively similar, 
Sprague-Dawley rats may have a slightly higher muscle mass and be slightly more 
insulin sensitive than this population of Hooded Wistar rats (unpublished 
observation). Lowered sensitivity to insulin, and potentially also adiponectin (see 
section 4.1), may affect the results of the current studies. Therefore, further 
experiments were undertaken using Sprague-Dawley rats. 
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5.3.3 Pre-treatment and co-infusion of adiponectin during an insulin clamp 
revealed marked vehicle effects 
In addition to indications in the normal-chow fed animals that adiponectin may 
counter the effects of the vehicle to improve 1-MX metabolism and GIR, I have 
shown significant adiponectin-mediated blunting of the vehicle-induced increase in 
basal blood glucose in high-fat fed rats. These data are suggestive that adiponectin 
may have beneficial vascular and metabolic actions, although this could not be 
confirmed. However, the results are confounded by substantial vehicle effects, in the 
presence of which the actions of adiponectin cannot be accurately assessed. Therefore, 
even with further experiments, definitive conclusions about the actions of adiponectin 
could not be drawn while the vehicle effects remained. Blood glucose levels did not 
rise significantly until after the vehicle was infused for at least 45min, suggesting the 
vehicle effects may be due to accumulation of a bacterial contaminant. To investigate 
whether this was the case, the protein preparations were infused earlier in the 
experiment. Additionally, it was previously shown that adiponectin opposes 
endothelin-1 action in the perfused rat hindlimb (Section 3.3.2.1). Based on reports 
that insulin stimulates production of ET-1 (Ferri et al., 1995; Ferri et al., 1996), it was 
hypothesised that adiponectin may be more effective at improving insulin sensitivity 
when present before insulin, and thus the increased ET-1. Therefore, adiponectin 
action was investigated using an adjusted experimental protocol to examine this 
hypothesis (Figure 5.1C).  
 
Initial experiments exposed a dramatic drop in mean arterial pressure when 96μg.min-
1.kg-1 adiponectin was infused prior to and during insulin infusion (Figure 5.9A). The 
same response was apparent towards the end of a 60min infusion of the vehicle 
preparation (Figure 5.9B), indicating that this is a side-effect of the bacterial vehicle. 
Blood pressure recovered after the vehicle or adiponectin infusion ceased. These 
severe side effects of the vehicle were not apparent in the previous set of experiments, 
although the same dose was used in both cases. It is likely that these effects are the 
result of vehicle contaminants accumulating in the blood stream, as they were only 
apparent towards the end of the infusion. Therefore, it is probable that they were not 
apparent in the previous experiments because they occurred in the final minutes of the 
protocol, when mean arterial pressure and heart rate data were not available due to 
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procedural requirements. Alternatively, these side effects may have been limited by 
the increased presence of insulin due to prior infusion. Such side effects of the vehicle 
preparation affect the ability to assess adiponectin action, and may possibly counteract 
any effects of adiponectin. Thus it was considered vital to reduce the effects of the 
vehicle in order to accurately assess adiponectin action. 
 
As the side effects of the vehicle appeared to be due to accumulation of contaminants, 
it was hypothesised that they may be sufficiently reduced by lowering the dose of 
infused adiponectin. Although adiponectin infusion was stopped 90min prior to the 
end of the experiment, plasma concentrations remained significantly elevated until 
completion of the protocol (Figure 5.10A). Plasma adiponectin was raised much 
higher than initially calculated for, as it has been recently been reported that 
adiponectin has a relatively long half-life (Halberg et al., 2009). The approximately 
40-fold increase in circulating adiponectin achieved with this infusion regime is 
clearly supra-physiological. Indeed, as the adiponectin assay used to produce these 
figures measures both LMW and HMW adiponectin multimers, and the highest 
proportion of endogenous adiponectin circulates as HMW (Waki et al., 2003), the fold 
increase in the LMW adiponectin would actually be even higher. Therefore, it was 
concluded that plasma adiponectin would still be adequately increased using a 
significantly lower dose. This was shown; when the adiponectin dose was reduced by 
75%, plasma adiponectin was increased approximately 4-fold (Figure 5.10B). 
Figure 5.9: Early adiponectin infusion exposes marked vehicle effects. Representative 
trace of mean arterial pressure during (A) adiponectin or (B) vehicle pre-treatment and co-
infusion with 3mU.min-1.kg-1 insulin according to Figure 5.1C. Mean arterial pressure was 
monitored via a cannula placed in the carotid artery. Sampling artifacts have been excluded. 
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5.3.4 Eliminating the vascular vehicle effects using a reduced dose did not expose 
adiponectin action 
5.3.4.1 Adiponectin does not alter hemodynamics in vivo 
Insulin significantly increased all measures of glucose uptake in Sprague-Dawley rats 
(glucose infusion rate: 6.7±0.5mg.min-1.kg-1 vs. saline 0.0±0.0mg.min-1.kg-1; rate of 
glucose disappearance: 8.8±0.7mg.min-1.kg-1 vs. saline 6.3±0.4mg.min-1.kg-1; hindleg 
glucose uptake: 0.32±0.03μmol.min-1 vs. saline 0.2±0.02μmol.min-1; and 2-deoxy 
glucose uptake: 10.5±2.2μg.g-1.min-1 vs. saline 2.2±0.2μg.g-1.min-1; p<0.05). Insulin 
also significantly decreased the rate of glucose appearance (1.7±0.4mg.min-1.kg-1 vs. 
saline 6.3±0.4mg.min-1.kg-1; p<0.001). 1-MX metabolism tended to be higher in the 
presence of insulin compared to saline, although this did not reach significance 
(6.48±1.08nmol.min-1 vs. saline 4.6±0.6nmol.min-1, n=7, p=0.28). 
 
At the lower dose vehicle infusion, the effects on mean arterial pressure and heart rate 
seen at the higher dose were eliminated. Heart rate was significantly higher at all time 
points in the vehicle + insulin group than in rats treated with insulin alone, but neither 
group changed significantly from basal. There was also no change from insulin in 
femoral blood flow and vascular resistance with vehicle co-infusion (Figure 5.11). 
Figure 5.10: (A) Plasma adiponectin concentrations prior to and upon cessation of 
adiponectin infusion, and at completion of experiments conducted according to Figure 5.1C. 
(n=1). (B) Plasma adiponectin concentrations in response to varying adiponectin doses. 
Samples were collected at experimental completion, t=120min according to Figure 5.1C. * 
p<0.05, ** p<0.01, significantly different from 0μg.min-1.kg-1 adiponectin (n=1-4). 
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Figure 5.11: Adiponectin does not alter macrovascular parameters. Time course of (A) 
mean arterial pressure, (B) heart rate, (C) femoral blood flow, and (D) vascular resistance 
during vehicle or adiponectin pre-treatment and co-infusion with 3mU.min-1.kg-1 insulin 
according to Figure 5.1C. Mean arterial pressure and heart rate were monitored via a cannula 
placed in the carotid artery. Blood flow was measured by a transonic flow probe positioned 
around the femoral artery. Vascular resistance was calculated by dividing mean arterial 
pressure by femoral blood flow for each time point. (n=6-8). 
 
Figure 5.12: Adiponectin does not affect microvascular perfusion. Effect of vehicle or 
adiponectin pre-treatment and co-infusion with 3mU.min-1.kg-1 insulin, on 1-methyxanthine 
metabolism. Plasma samples for analysis were collected at t=120min according to Figure 
5.1C (n=6-7). 
104 
This further suggests that using a lower dose may avoid the effects of the vehicle on 
these measures, seen in the initial set of experiments using protocol A (Figure 5.2A). 
However, in the absence of hemodynamic vehicle effects, no action of adiponectin 
was revealed, with no significant difference from control treatment in any of the 
macrovascular measures. Insulin-stimulated microvascular perfusion was similarly 
unaffected by either vehicle or adiponectin infusion (Figure 5.12). 
Figure 5.13: Adiponectin does not alter glucose homeostasis. Upper: Time course of (A) 
blood glucose, and (B) glucose infusion rate during vehicle or adiponectin pre-treatment and 
co-infusion with 3mU.min-1.kg-1 insulin. Lower: Effect of vehicle or adiponectin pre-
treatment and co-infusion with 3mU.min-1.kg-1 insulin on (C) hindleg glucose uptake, (D) 
radioactive 2-deoxy glucose uptake (R’g) into whole calf muscle, (E) the rate of glucose 
appearance (hepatic glucose output), and (F) the rate of glucose disappearance (whole body 
glucose uptake). All samples were collected at the completion of the experiment, t=120min 
according to Figure 5.1C. * Significantly different from insulin (p<0.05; n=6-8). 
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5.3.4.2 Adiponectin does not alter insulin sensitivity 
GIR was significantly reduced by infusion of vehicle between 30min and 90min, and 
tended to remain lowered until the end of the experiment (5.1±0.8mg.min-1.kg-1 vs. 
insulin 6.7±0.5mg.min-1.kg-1 at t=120min; p=0.077; Figure 5.13B). This may be 
attributable to a persistent effect of the vehicle to diminish insulin-mediated 
suppression of hepatic glucose output (Figure 5.13E). An increased rate of glucose 
appearance is also likely to be the cause of increased blood glucose and reduced GIR 
seen with the earlier protocols. However, reducing the dose of adiponectin, and thus 
vehicle, appears to have avoided the vehicle effects on 2-DG uptake, Rd and HGU 
(Figure 5.13). Adiponectin did not alter insulin-mediated 2-DG uptake or HGU, nor 
did it oppose the effects of the vehicle on Ra and GIR (Figure 5.13). Therefore, there 
was no indication that adiponectin improves insulin sensitivity in vivo acutely. 
 
5.3.4.3 Adiponectin did not affect circulating levels of insulin or endothelin-1 
Infusion of physiological insulin significantly increased fasting plasma insulin 
concentrations (Figure 5.14). Adiponectin infusion did not affect the circulating level 
of insulin achieved at completion of insulin infusion (Figure 5.14). This finding was 
consistent in the initial protocol using a higher adiponectin dose (Insulin: 361±65pM, 
Insulin + vehicle: 298±19pM, and Insulin + Adiponectin: 330±84pM; NS). Therefore, 
the absence of differences between groups in vascular and insulin sensitivity measures 
 
Figure 5.14: Adiponectin does not affect plasma insulin concentration. Effect of vehicle 
or adiponectin pre-treatment and co-infusion with 3mU.min-1.kg-1 insulin on plasma insulin. 
Plasma samples for ELISA analysis were collected at t=120min according to Figure 5.1C. * 
Significantly different from fasting (p<0.05; n=6-19). 
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was not due to an altered effective dose of insulin. 
 
The latter experimental protocol was designed on the premise that adiponectin may 
oppose the effects of insulin-stimulated ET-1 production. Neither adiponectin 
(4.2±0.6pM vs. 2.9±0.2pM with insulin alone after 120min; NS) nor vehicle 
(4.9±0.9pM vs. 2.9±0.2pM with insulin alone after 120min; NS) significantly altered 
plasma ET-1 levels at any dose. However, there was also no change in circulating ET-
1 levels with insulin infusion (2.9±0.2pM vs. 2.0±0.5pM basally; NS), although 
changes in local ET-1 levels cannot be excluded. A previous study from our 
laboratory has described increased plasma ET-1 during a supra-physiological 
10mU.min-1.kg-1 insulin infusion (Ross et al., 2007). Thus it seems likely that the 
physiological hyperinsulinemia used in the present study is not sufficient to stimulate 
endothelin-1 secretion at a detectable level. The hypothesis that adiponectin may 
improve insulin sensitivity by opposing endothelin-1 action in vivo, in a similar way to 
that shown in the perfused rat hindlimb, may be better investigated using a higher 
insulin dose. However, with increased insulin action, the likelihood of detecting an 
additional significant effect of adiponectin is reduced, making higher insulin dosage 
incompatible with the primary study aims. 
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5.4 Discussion 
 
The acute hemodynamic and metabolic actions of adiponectin were examined in 
anaesthetised rats. No significant difference between adiponectin and vehicle groups 
was observed in any of the parameters measured, despite multiple protocols and doses 
being assessed. Specifically, adiponectin did not stimulate glucose uptake or 
microvascular perfusion, alone or in conjunction with insulin. Furthermore, there was 
no indication that acute adiponectin treatment attenuates insulin resistance. 
 
The interpretation of this data is limited by confounding effects of a vehicle 
preparation purified from bacterial lysates. It is possible that the effects of the vehicle 
are counteracting, and thus masking, adiponectin action. A high dose infusion of 
vehicle alone reduced femoral blood flow, leading to increased vascular resistance, 
and increased blood glucose concentrations. In the presence of insulin, the vehicle 
blunted insulin-mediated suppression of hepatic glucose output causing a reduction in 
glucose infusion rate. At high doses, vehicle infusion also caused a dramatic drop in 
mean arterial pressure. Although endotoxin was not measured in the vehicle solutions, 
the effects observed are consistent endotoxic shock. The bacterial endotoxin 
lipopolysaccharide (LPS) stimulates the sympathetic nervous system causing blood 
pressure to drop (Vayssettes-Courchay et al., 2005), which is consistent with the 
macrovascular vehicle effects observed at high doses. Endotoxins, alone and in 
conjunction with pro-inflammatory cytokines, reduce insulin-stimulated glucose 
uptake (Ling et al., 1994). Similar combined treatment also leads to induction of iNOS 
(Kapur et al., 1999; Bédard et al., 1997), which has been shown to reduce insulin 
sensitivity, most notably by increasing hepatic glucose production basally and 
following insulin stimulation (Charbonneau & Marette, 2010). Furthermore, it has 
been directly demonstrated that LPS raises hepatic glucose output (Sugita et al., 
2002). Sugita et al. (2002) also showed increased blood glucose and dramatically 
impaired insulin-stimulated GIR within 60min of LPS treatment, indicating that such 
endotoxin effects are highly relevant to the current acute study. These data 
complement the present observations of a persistent effect of the bacterial vehicle 
preparation on the rate of glucose appearance. In addition, increased iNOS activity in 
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conjunction with augmented iNOS in insulin resistance, may explain the apparent 
tendency of the vehicle to increase glucose uptake and microvascular perfusion in 
high-fat fed rats. Such effects may also be more apparent following high-fat feeding as 
the compensatory actions of insulin are diminished. Globular adiponectin has been 
shown to reduce the inflammatory effects of bacterially-derived LPS (Noriaki et al., 
2009), possibly accounting for blunted vehicle effects on glucose homeostasis in some 
of the adiponectin treated groups. However, that study looked at changes in mRNA 
expression and protein levels after 12h of adiponectin exposure, and so may not be 
relevant to the 60min treatment used here (Noriaki et al., 2009). Alternatively, the 
small but significant effect of adiponectin on blood glucose in the high-fat fed rats 
may be due a minor but independent action of adiponectin on glucose homeostasis 
counteracting the vehicle effects. Overall, these data demonstrate that experimental 
results obtained using bacterially produced proteins should be interpreted with 
caution, and in particular, emphasise the importance of an appropriate vehicle control. 
 
The vehicle preparation used in the present studies may not accurately represent the 
contaminants in the adiponectin preparation. Comparison of the measured adiponectin 
and total protein concentrations of the recombinant adiponectin and vehicle 
preparations suggests that the vehicle may actually contain more contaminants than 
the adiponectin preparation, although the potential inaccuracy of these measures has 
been discussed in Chapter 2. It is possible that the large amounts of recombinant 
protein present in the adiponectin solution compete with bacterial contaminants to 
bind to the affinity purification column, resulting in higher levels of contaminants in 
the vehicle preparation. This may explain the apparent adiponectin-mediated 
improvements in some of the vehicle side-effects. Use of bacteria expressing an 
inactive scramble protein sequence for production of a vehicle preparation would 
better control for the possibility of this occurring. However, the nature of the vehicle 
effects are consistent with the presence of an endotoxin such as LPS, which is unlikely 
to be affected by competitive protein binding. Products are available for the detection 
and removal of these endotoxins from solutions, although for the purposes of in vivo 
studies it is important to consider any effects that the added purification procedure 
may have on protein yield. Further consideration of the preparation of infusion 
solutions may improve interpretation of future physiological studies using bacterially 
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expressed recombinant proteins. The current study cannot definitively conclude a lack 
of adiponectin effects in the absence of complete elimination of vehicle effects. 
 
A number of studies have previously described reduced endogenous glucose 
production in response to adiponectin. However, vehicle effects aside, this finding was 
not replicated in the present analysis. Plasma adiponectin concentrations in humans 
are negatively correlated with basal and insulin-suppressed endogenous glucose 
production, independent of glucose tolerance (Stefan et al., 2003). Combs et al. 
(2001) found that constant infusion of mammalian full-length adiponectin in the 
presence of insulin in fasted, conscious mice elicited a 73% increase in glucose 
infusion rate. There was no difference in whole body glucose disposal; rather the 
improved insulin sensitivity was solely attributable to a significant suppression of 
hepatic glucose production (Combs et al., 2001). In another report from the same 
laboratory using an identical adiponectin preparation, Berg et al. (2001) observed an 
acute effect of mammalian adiponectin to reduce basal blood glucose that was not 
apparent using bacterial globular adiponectin. Post-translationally modified, 
mammalian adiponectin is also dramatically more effective at enhancing insulin-
mediated inhibition of glucose production from isolated hepatocytes than preparations 
limited to LMW multimers (Wang et al., 2002). Thus, the lack of adiponectin-
mediated suppression of hepatic glucose output in the current study can be attributed 
to the LMW adiponectin preparation used, as all the above described studies 
demonstrated effects using HMW adiponectin. This is not entirely surprising, since it 
has previously been established that HMW adiponectin multimers preferentially act in 
the liver, as discussed in Chapter 2. However, the predominantly LMW bacterial 
adiponectin preparation was specifically chosen for the present work to evaluate 
adiponectin action in skeletal muscle and its associated vasculature. Therefore, these 
discrepant results do not detract from the conclusions of the current study, but rather 
support the finding that LMW adiponectin does not display significant hepatic 
activity. 
 
The results of the various experiments comprising this work indicate that adiponectin 
does not have significant acute hemodynamic or metabolic effects in vivo, within the 
limits of the measurement system. It is possible that beneficial actions of adiponectin 
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may have become apparent in the absence of confounding vehicle effects. However, 
the broad-scale absence of significant differences between adiponectin and vehicle 
treated groups, in both normal and insulin resistant animals, tends to indicate that 
adiponectin is genuinely not having any effect. The lack of response is unlikely to 
result from insufficient adiponectin dosage, as the plasma concentrations achieved are 
substantially higher than physiological levels, with up to 40-fold elevations. The 
adiponectin dose was reduced in order to eliminate the majority of vehicle effects, but 
even under these conditions adiponectin action was not apparent. Using a lower dose 
again raises the possibility that effects may be being missed. However, even the 
lowest dose evaluated elicited a four-fold increase in plasma adiponectin. Significant 
improvements in in vivo insulin sensitivity have been demonstrated with only an 
approximate doubling of plasma adiponectin (Liu et al., 2009a; Combs et al., 2001). 
The primary aim of this work was to examine the acute effect of adiponectin in the in 
vivo vasculature, and even with adiponectin increased four-fold and all vascular 
vehicle effects abolished, there was no detectable adiponectin-mediated change in any 
vascular measure. Therefore, it is unlikely that bacterial contaminants are preventing 
an adiponectin effect from being observed. In addition, the finding of Combs et al. 
(2001) that the insulin-sensitising effect of HMW adiponectin is entirely attributable 
to hepatic actions suggests it does not have contributing hemodynamic effects, and 
thus such effects have not been missed in the present study due to the choice of 
adiponectin preparation.  This study was not able to address the question of whether 
adiponectin resistance occurs in insulin resistance due to the lack of adiponectin 
activity in both normal-chow and high-fat fed animals, although I have shown that this 
model of mild insulin resistance is not adiponectin-deficient. The limited vascular 
effects of adiponectin previously observed in isolated vessels and my experiments in 
the perfused rat hindlimb did not translate into detectable augmentation of vascular 
parameters in vivo. It has previously been reported that adiponectin-mediated 
activation of eNOS plateaus after around an hour and at a dose of approximately 
10ug.mL-1 (Hattori et al., 2008). Therefore, in vivo, vascular adiponectin signalling 
pathways may already be maximally activated by endogenous adiponectin. 
Additionally, there are a wide range of vascular influences in vivo, and a moderate 
effect of adiponectin may not be distinguishable in this setting. Therefore, 
contributions to hemodynamic regulation do not appear to be a major aspect of 
adiponectin action in vivo. 
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Hemodynamic and metabolic responses to adiponectin were assessed in the 
anaesthetised rat under a range of different conditions. There were no substantial 
differences between adiponectin and vehicle treatments in any measure, whether alone 
or in the presence of insulin. The absence of adiponectin action was demonstrated in 
both normal and insulin resistant animals. Therefore, I conclude that low molecular 
weight adiponectin does not acutely alter vascular action or muscle metabolism in 
vivo. 
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CHAPTER 6 – DISCUSSION 
 
This thesis has examined the acute hemodynamic and metabolic actions of 
adiponectin. Full-length recombinant adiponectin was produced in bacteria, and was 
shown to consist predominantly of trimeric adiponectin. This adiponectin stimulated 
eNOS phosphorylation in vitro, suggesting it has similar biological activity to 
preparations described in the literature. The acute physiological response to this 
adiponectin preparation was examined in the perfused rat hindlimb, where it was 
observed to oppose the vasoconstrictor effects of ET-1. This finding suggests that 
vascular actions of adiponectin may make important contributions to its beneficial 
effects on both insulin sensitivity and cardiovascular health. In addition, the 
specificity of this acute action suggested that this effect was NO-independent, 
indicating a novel mechanism of adiponectin action. The acute adiponectin-mediated 
inhibition of ET-1 action was not apparent in rats fed a high-fat diet to induce insulin 
resistance, possibly pointing to concurrent adiponectin resistance. However, the 
vasoconstrictor response to ET-1 was also diminished following high-fat feeding, due 
to enhanced activity of iNOS. This suggests that interaction between increased levels 
of both ET-1 and iNOS under conditions of metabolic stress may contribute to the 
associated vascular dysfunction. The systemic, acute actions of adiponectin were then 
investigated in anaesthetised rats. Adiponectin had no significant effect on basal or 
insulin-stimulated measures of glucose homeostasis and hemodynamic variables in 
normal animals, within the limits of detection. Similarly, there was no significant 
improvement in glucose homeostasis or vascular measures in insulin resistant high-fat 
fed rats acutely treated with adiponectin. Therefore, it appears that acute vascular 
actions do not substantially contribute to adiponectin action in vivo. 
 
The data included in this thesis was all acquired using bacterially produced 
adiponectin, which is limited to forming low molecular weight (LMW) multimers. 
However, different forms of adiponectin exhibit variable properties, which affect 
experimental findings. It is primarily high molecular weight (HMW) adiponectin 
levels that correlate to increased insulin sensitivity (Lara-Castro et al., 2006; Pajvani 
et al., 2004). HMW, but not LMW, adiponectin multimers are downregulated in 
diabetic individuals (Basu et al., 2007), and HMW adiponectin is selectively increased 
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following weight loss (Kobayashi et al., 2004). As described in Chapter 5, HMW 
adiponectin has action to inhibit endogenous glucose production that is not seen with 
the LMW form (Wang et al., 2002; Berg et al., 2001). In addition, chronic infusion of 
adiponectin purified from foetal bovine serum, but not protein that was bacterially 
expressed, improved insulin sensitivity in high-fat fed mice (Wang et al., 2004). 
Therefore, it appears that the effects of adiponectin on whole-body insulin sensitivity 
are primarily attributable to HMW multimers.  
 
It was hypothesised that LMW adiponectin may have beneficial effects on insulin 
sensitivity via acute muscle or vascular actions. However, the findings of this thesis 
suggest that such effects are not an important part of adiponectin action, a conclusion 
supported by previous studies. Improved insulin sensitivity following rosiglitazone 
treatment is associated with increases in AdipoR1 expression in adipose tissue, while 
levels in skeletal muscle are decreased (Tan et al., 2005). Similarly, insulin signalling 
was impaired in the liver, but not skeletal muscle, of adiponectin knockout mice 
(Yano et al., 2008). Furthermore, Halperin et al. (2005) reported that neither total nor 
HMW adiponectin concentrations correlated with endothelium-dependent vasodilation 
in individuals at risk of developing type 2 diabetes and cardiovascular disease. 
 
This raises the question of whether LMW adiponectin has physiologically significant 
actions. Adiponectin has been reported in cerebrospinal fluid (CSF) at concentrations 
of approximately 1-4% of circulating levels (Qi et al., 2004), and CSF adiponectin 
concentration correlates with serum adiponectin (Kusminski et al., 2007). Intravenous 
injection of adiponectin increased both serum and CSF measures of adiponectin, and 
caused decreased body weight through increased energy expenditure in both normal 
and obese mice (Qi et al., 2004). Full-length and globular adiponectin, and a mutated 
form of adiponectin unable to form HMW structures, were equally effective at 
eliciting these effects (Qi et al., 2004). Additionally, trimeric adiponectin 
preferentially accumulates in CSF, while HMW adiponectin multimers are 
undetectable (Kusminski et al., 2007). Adiponectin has also been found to act in the 
brain via AMPK to stimulate food intake (Kubota et al., 2007). However, Spranger et 
al. (2006) were unable to detect adiponectin in CSF and found that adiponectin was 
unable to cross the blood-brain barrier. The authors alternatively suggested that 
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adiponectin may act via its receptors on brain endothelial cells (Spranger et al., 2006). 
These data suggest that LMW adiponectin may be of primary importance in eliciting 
central effects. 
  
Emerging evidence suggests that the primary role of adiponectin may actually be 
involved in lipid processing. While PPAR is the most referenced promoter of 
adiponectin, the gene has a number of other transcriptional controls, including sterol 
regulatory element-binding protein (SREBP), which is associated with fatty acid 
metabolism, cholesterol homeostasis and adipogenesis (Schäffler et al., 1998; Kim et 
al., 2006). Adiponectin in turn suppresses expression of SREBP, leading to decreased 
fatty acid synthesis in the liver (Awazawa et al., 2009). Adiponectin knockout mice 
have increased serum triglyceride concentrations (Kubota et al., 2002), as well as less 
ability to clear fat from the blood stream following a challenge (Maeda et al., 2002a).  
Meanwhile, clearance of plasma free fatty acids (FFAs) is accelerated by both acute 
adiponectin treatment and adiponectin overexpression (Combs et al., 2004; Fruebis et 
al., 2001; Wang et al., 2004). In one study, lipid clearance was shown to be markedly 
improved by globular adiponectin, while the full-length protein was significantly less 
effective (Fruebis et al., 2001). It has previously been shown that adiponectin-
mediated improvements in insulin sensitivity are associated with decreased circulating 
FFA and triglyceride levels, and decreased triglyceride content in both muscle and 
liver (Fruebis et al., 2001; Yamauchi et al., 2001; Wang et al., 2004). Therefore, it has 
been suggested that adiponectin may improve insulin sensitivity indirectly, via a 
reduction in intramuscular lipid accumulation (reviewed in Dyck et al., 2006). 
Speculation that adiponectin opposes ET-1 vasoconstriction by affecting cholesterol 
handling, also supports a primary role of adiponectin in lipid processing. 
 
Resistance to the vascular actions of insulin has been widely associated with increases 
in circulating lipids. Feeding animals a high-fat diet raises plasma FFA (Henriksen et 
al., 2008; Bourgoin et al., 2008). Isolated endothelial cells treated for three hours with 
FFA demonstrated impaired insulin signalling via Akt and eNOS, leading to decreased 
NO production (Kim et al., 2005). Results from Symons et al. (2009) indicate that 
vascular dysfunction and hypertension following high-fat feeding may be due to FFA-
mediated impairment of eNOS phosphorylation. Consistent with this is the proposal 
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that FFAs activate protein kinase C  in endothelium, which inhibits insulin-mediated 
Akt activation and stimulates insulin-mediated ERK1/2 activation, resulting in a shift 
towards insulin-mediated, ET-1-dependent vasoconstriction (Bakker et al., 2008). 
Infusion of intralipid into humans was found to impair basal NO release, as well as 
insulin-stimulated leg blood flow and whole body glucose disposal (Steinberg et al., 
2000). The change in glucose disposal rate with insulin was strongly correlated with 
insulin-stimulated leg blood flow, indicating that FFAs primarily affect vascular 
insulin sensitivity (Steinberg et al., 2000). It has been suggested that local 
accumulation of perivascular adipose tissue may impair nutritive blood flow 
(reviewed in Eringa et al., 2007). Acute elevations in plasma FFA impair insulin-
mediated glucose uptake and microvascular perfusion in both rats and humans (Clerk 
et al., 2002; Liu et al., 2009b; de Jongh, 2004). The FFA-induced effects on insulin-
stimulated glucose metabolism were time-dependent, occurring approximately 1.5 
hours after FFA elevation (Clerk et al., 2002). Therefore, if adiponectin improves 
insulin sensitivity largely by reducing FFA concentrations, a significant change would 
not be apparent during the 1 hour adiponectin infusion used in the current in vivo 
study. 
 
In one of the most dramatic studies into adiponectin action, Kim et al. (2007) have 
shown that leptin knockout and adiponectin overexpressing crossover mice show no 
signs of insulin resistance, despite severe obesity. Adiponectin overexpression also 
prevented the development of further insulin resistance when these mice were 
challenged with a high-fat diet, despite an even greater weight gain. Although overall 
fat mass was increased, improved insulin sensitivity was associated with reductions in 
visceral fat. These mice also displayed decreased circulating triglycerides, improved 
triglyceride clearance after lipid challenge and an increased number of smaller 
adipocytes. The authors suggested that adiponectin promotes storage of triglycerides 
preferentially in adipose tissues, reducing the levels in liver and muscle and thus 
improving insulin sensitivity (Kim et al., 2007). Conversely, the work by Mullen et al. 
(2009) describing adiponectin resistance preceding lipid accumulation and impaired 
insulin action in muscle, lead to the proposal that rapid loss of adiponectin-mediated 
fat oxidation leaves the muscle less able to respond to the excess lipid exposure during 
high-fat feeding. Visceral adipose tissue is especially detrimental to insulin sensitivity, 
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and adipocytes isolated from visceral fat are less sensitive to the antilipolytic effects 
of insulin, leading to increased FFA release (van Harmelen et al., 2008). 
Rosiglitazone-mediated improvements in insulin sensitivity are associated with both 
increased adiponectin and adipose tissue remodelling, producing smaller adipocytes in 
which adiponectin secretion is greater (Dallaire et al., 2008). In addition, this tissue 
remodelling means that treatment with thiazoledinediones is usually correlated with 
increased body weight gain, partially due to differentiation of fat cells (Dallaire et al., 
2008; Combs et al., 2002). Furthermore, it has been proposed that adipose tissue is 
hypoxic in obesity, causing inflammation and leading to diabetes. Adiponectin 
promotes angiogenesis and development of more, smaller adipocytes, decreasing the 
diffusion distance, thus potentially improving oxygen availability in adipose tissue 
(Trayhurn et al., 2008). Overall, these findings indicate that the most significant 
actions of adiponectin may be in lipid processing, by encouraging appropriate fat 
deposition and lowering circulating FFAs, thereby indirectly improving insulin 
sensitivity. Adiponectin-mediated modulation of lipid storage would require chronic 
exposure, and is thus consistent with the present findings that LMW adiponectin does 
not acutely alter metabolism or hemodynamic regulation in vivo. The conclusions of 
this thesis are in agreement with a recent proposal by Kadowaki et al. (2008) that 
adiponectin may act as a starvation signal, with HMW multimers redirecting fuel 
utilisation in peripheral tissue from glucose to fatty acids, and LMW multimers acting 
in the brain to increase food intake, decrease energy expenditure and encourage fat 
storage. 
 
The aim of this thesis was to investigate whether adiponectin has acute vascular 
actions that contribute to its role as an insulin sensitiser. I have identified a novel 
effect of adiponectin to oppose ET-1-mediated vasoconstriction in an isolated vascular 
system. However, it appears that vascular effects of adiponectin may be of minor 
physiological significance, as adiponectin had no effect on acute hemodynamic or 
metabolic parameters in vivo. The long-term effects of adiponectin have not been 
examined here, and it is possible that adiponectin acts in the vasculature to improve 
insulin sensitivity chronically. It is proposed that the primary function of low 
molecular weight adiponectin is in lipid processing, which may in turn chronically 
modulate hemodynamic regulation.  
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